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Abstract
The continuous growth of fungal infections, coupled with the increased resistance
of many microorganisms towards antifungal compounds, is an alarming health
problem and the discovery of new antifungal agents has become a particularly
important area of research. Jerangolid D is a potential antifungal agent of
major interest. Recently, the first total synthesis of this natural product has
been reported by our group. Its structure can be divided into three subunits: a
substituted dihydropyran, an unsaturated lactone and a skipped 1,4-diene middle
fragment. Our purpose is to operate a series of chemical modifications on these
three subunits in order to create a set of new compounds, similar to Jerangolid D,
but possessing hopefully enhanced stability, increased activity and lower toxicity.
In this thesis, we shall initially describe our efforts towards the synthesis of
the substituted dihydropyran. In order to do so, two methodologies have been
developed, based upon previous work in our ...
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 ABSTRACT 
The continuous growth of fungal infections, coupled with the increased 
resistance of many microorganisms towards antifungal compounds, is an 
alarming health problem and the discovery of new antifungal agents has 
become a particularly important area of research. Jerangolid D is a potential 
antifungal agent of major interest. Recently, the first total synthesis of this 
natural product has been reported by our group. 
 
Its structure can be divided into three subunits: a substituted dihydropyran, 
an unsaturated lactone and a skipped 1,4-diene middle fragment. Our 
purpose is to operate a series of chemical modifications on these three 
subunits in order to create a set of new compounds, similar to Jerangolid D, 
but possessing hopefully enhanced stability, increased activity and lower 
toxicity. 
Initially, we shall describe our efforts towards the synthesis of the 
substituted dihydropyran. In order to do so, two methodologies have been 
developed, based upon previous work in our laboratory. The second one 
gave the best results and enabled access to the desired dihydropyran in 6 
operations using an intramolecular silyl modified Sakurai cyclisation (ISMS) 
as the key step. 
 
The same pathway was used to construct new dihydropyrans by modifying 
the C-C triple bond. 
 
With the natural DHP in hand, different modifications were applied to the 
double bond in order to reach the right-hand fragment of jerangolid B, E and 
H in which the stereochemistry at C14 was still unknown. 
 
Subsequently, we will describe our efforts towards the preparation of the 
left-hand lactone of jerangolid D as well as a set of new analogues. 
Finally, we will present some preliminary investigations on the synthesis of 
new analogues of the central part of these natural products. 
 
 RÉSUMÉ 
L’augmentation continuelle des infections fongiques, de paire avec 
l’augmentation de la résistance des microorganismes vis-à-vis des 
antifongiques, est un problème de santé alarmant et la découverte de 
nouveaux composés antifongiques est devenue un domaine de recherche 
particulièrement important. Le jérangolide D est un composé dont l’activité 
antifongique potentielle est d’intérêt majeur. Récemment, la première 
synthèse totale de ce produit naturel a été décrite par notre groupe. 
 
Sa structure peut être divisée en 3 sous-unités : un dihydropyrane substitué, 
une lactone insaturée et un fragment central bioléfinique. Notre but est 
d’opérer une série de modifications chimiques sur ces trois fragments pour 
créer un set de nouveaux composés, similaires au jérangolide D, mais 
possédant éventuellement une stabilité accrue, une meilleure activité et une 
toxicité plus faible.  
Dans un premier temps, nous allons décrire les efforts déployés pour la 
synthèse du dihydropyrane substitué. Pour ce faire, deux méthodologies, 
basées sur des travaux antérieurs du laboratoire, ont été développées. La 
seconde a donné les meilleurs résultats et nous a permis d’accéder au 
dihydropyrane désiré en six opérations, avec comme étape-clé une 
cyclisation ISMS. 
 
Le même schéma réactionnel a été utilisé pour construire des nouveaux 
dihydropyranes en fonctionnalisant la triple liaison carbone-carbone. 
 
Une fois le DHP naturel obtenu, différentes modifications ont été apportées à 
la double liaison afin d’accéder à la partie droite des jérangolides B, E et H, 
dans lesquels la stéréochimie du carbone 14 était encore inconnue. 
 
D’autre part, nous décrirons ensuite nos efforts dirigés vers la synthèse de la 
lactone du jérangolide D ainsi que de nouveaux analogues de cette sous-
unité. 
Finalement, la synthèse de nouveaux analogues de la partie centrale des 
jérangolides et leurs tentatives d'union aux autres fragments seront 
présentées. 
 
 ABREVIATIONS 
Å : Angström 
AcOEt : Ethyl acetate 
AcOH : Acetic acid 
AmB : Amphotericin B 
AmdeB : Amphoteronolide B 
Aq. : Aqueous 
Ar : Aryl 
Bn : Benzyl 
n-Bu : Butyl 
t-Bu : Tert-butyl 
Bz : Benzoate 
CBS : Corey-Bakshi-Shibata reagent 
cm : Centimeter 
Cp : Cyclopentadienyl 
CSA : Camphorsulfonic acid 
Cy : cyclohexyl 
CYP : Cytochrome P450 
DCM : Dichloromethane 
DCC : Dicyclohexyl carbodiimide 
DDQ : 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DHP : Dihydropyran 
DIAD : Diisopropyl azodicarboxylate 
DIBAL-H : Diisobutylaluminium hydride 
DMAP : 4-dimethylamino pyridine 
DMF : N,N-dimethylformamide 
DMP : Dess-Martin periodane 
DMSO : Dimethylsulfoxide 
DNA : Deoxyribonucleic acid 
d.e. : Diastereomeric excess 
e.e. : Enantiomeric excess 
EF2 : Elongation Factor 2 
Eq. : Equivalent 
Et : Ethyl 
5-FC : 5-fluorocytosine 
FDA : Food and Drugs Administration 
FdUMP : 5-fluorodeoxyuridine monophosphate 
FUTP : 5-fluorouridine triphosphate 
5-FU : 5-fluorouracil 
GC : Gas chromatography 
GC-I : Grubbs catalyst-I 
h : Hour 
HIV : Human Immunodeficiency Virus 
HMPA : Hexamethylphosphoramide 
HRMS : High resolution mass spectroscopy 
HOG : High Osmolarity Glycerol 
Hz : Hertz 
IFIs : Invasive Fungal Infections 
 i-Pr : Isopropyl 
IR : Infra-red 
LA : Lewis Acid 
Me : Methyl 
MeOH : Methanol 
MS : Mass Spectrometry 
mmol : Millimole 
N : Normal 
n-BuLi : n-butyllithium 
n.d. : Non determined 
NMR : Nuclear Magnetic Resonance 
o.n. : overnight 
PCC : Pyridinium chlorochromate 
PDC : Pyridinium dichromate 
PE : Petroleum Ether 
Ph : Phenyl 
PMB : p-methoxy benzyl 
PPTS : Pyridinium p-toluenesulfonate 
n-Pr : n-Propyl 
ppm : Part par million 
RCM : Ring-closing metathesis 
RNA : Ribonucleic acid 
r.t. : Room temperature 
TBAF : Tetrabutylammonium fluoride 
TBS : Tert-butyl dimethyl silyl 
TBDPS : Tert-butyl diphenyl silyl 
Tf : CF3SO2 
TfOH : Triflic acid 
TFA : Trifluoroacetatic acid 
THF : Tetrahydrofuran 
TLC : Thin layer chromatography 
TMS : Trimethylsilyl 
TMEDA : Tetramethylethylenediamine 
Tol. : Toluene 
   
   
   
   
 
  
 
 
 
 
 
“If you keep on believing, 
The dreams that you wish will come true.” 
    Cinderella 
 
 
 
“Things dont always work out the first time, 
But keep trying.”  
    Donald Duck
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I. Fungal Infections 
In recent years, there has been an increase of fungal infections all around the 
world. These infections pose a continuous and serious threat to human 
health1. In humans, fungal diseases can be classified into (1) allergic 
reactions to fungal proteins, (2) toxic reactions to toxins present in some 
fungi, (3) infections also called mycoses. The latest are by far the most 
serious, hard to diagnose and eventually treat, as they exist in various forms. 
Healthy individuals can develop superficial, cutaneous, subcutaneous, and in 
some instances, systemic infections that cause a wide range of conditions 
from athletes foot and nail infections to severe life-threatening diseases such 
as histoplasmosis2. Many fungal infections are caused by opportunistic 
pathogens that may be endogenous (Candida infections) or caught from the 
environment (Cryptococcus, Aspergillus infections) 3.  
Immuno-compromised individuals are susceptible to a large number of 
opportunistic systemic mycoses, resulting from the inability of the host 
immune system to fight off attacks from normally benign fungal pathogens2.  
These infections, commonly called invasive fungal infections (IFIs), have 
increased steadily due to the rise of immunocompromised patients and those 
                                                     
1 F. M. Garibotto, A. D. Garro, M. F. Masman, A. M. Rodríguez, P. G. M. Luiten, 
M. Raimondi, S. A. Zacchino, C. Somlai, B. Penke, R. D. Enriz, Bioorg. Med. 
Chem. 2010, 18, 158-167. 
2 D. Barrett, Biochim. Biophys. Acta - Molecular Basis of Disease 2002, 1587, 224-
233. 
3 a. M. K. Kathiravan, A. B. Salake, A. S. Chothe, P. B. Dudhe, R. P. Watode, M. S. 
Mukta, S. Gadhwe, Bioorg. Med. Chem. 2012, 20, 5678-5698 b. T. Lorand, B. 
Kocsis, Mini Rev. Med. Chem. 2007, 7, 900-911. 
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with critical illnesses4. The reasons are numerous: the emergence of 
aggressive cancer chemotherapy, highly efficient immunosuppressants for 
organ transplantation, widespread use of powerful broad spectrum 
antibacterial agents and the explosion of HIV infection cases have all 
contributed to the increase of life-threatening fungal diseases2.  
Most IFIs are caused by Candida and Aspergillus fumigatus. Clinically, 
candidiasis5 and aspergillosis6 account for 80% to 90% of systemic fungal 
infections in immunocompromised patients3. However, the number of 
previously uncommon or new pathogens, many of which are resistant to 
antifungal agents is increasing; these include non-fumigatus Aspergillus spp, 
Zygomycetes, Scedosporium and Fusarium4. 
Although the panel of antifungal drugs has expanded, currently available 
antifungal agents for effective treatments of these emerging infections are in 
short supply, thereby contributing to a high mortality rate. Moreover, the 
increasing antifungal resistance is particularly problematic as initial 
diagnosis of systemic fungal infection can be delayed and there are few 
antifungal drugs available7. Thus, the development of new antifungal drugs 
has been a constant requirement in clinical therapy3.  
                                                     
4 a. S. C. A. Chen, E. G. Playford, T. C. Sorrell, Current Opinion in Pharmacology 
2010, 10, 522-530 b. T. J. Walsh, A. Groll, J. Hiemenz, R. Fleming, E. Roilides, E. 
Anaissie, Clin. Microbiol. Infect. 2004, 10, 48-66  
5 M. A. Pfaller, R. N. Jones, S. A. Messer, M. B. Edmond, R. P. Wenzel, Diagn. 
Microbiol. Infect. Dis. 1998, 31, 327-332. 
6 W. W. Hope, D. W. Denning, Clin. Microbiol. Infect. 2004, 10, 2-4. 
7 R. D. Cannon, E. Lamping, A. R. Holmes, K. Niimi, K. Tanabe, M. Niimi, B. C. 
Monk, Microbiology 2007, 153, 3211-3217. 
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II. Commercially available antifungal drugs 
During the second half of the 20th century, especially during the last two 
decades, several classes of antifungal agents have been discovered8.  
There are four main classes of antifungal compounds with different targets in 
fungi cells7 (Figure 1). They will be described in this section. 
 
Figure 1 : targets of current antifungal drugs 
II.1. 5-Fluorocytosine 
5-Fluorocytosine 1.001 (5-FC), a fluorinated pyrimidine analogue, is one of 
the oldest antifungal agents. It was first synthesized in 1957 as a potential 
anti-tumour agent but failed in this role. Four years later, it was proved to be 
                                                     
8 V. T. Andriole, J. Ant. Chemother. 1999, 44, 151-162. 
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active in treating candidosis in mice and, in 1968, it was used for the first 
time to treat human candidosis9.  
5-FC itself shows no antifungal activity. It is only after entering the fungal 
cell that it is converted to 5-fluorouracil 1.002 (5-FU) by cytosine deaminase 
(scheme 1). After this conversion, two mechanisms for the antifungal 
activity of 5-FU can be distinguished. The first one involves the conversion 
of 5-FU to 5-fluorouridine triphosphate (FUTP) which is further 
incorporated in fungal RNA. It results in the inhibition of protein synthesis 
by altering the aminoacylation of tRNA. The second mechanism is the 
transformation of 5-FU to 5-fluorodeoxyuridine monophosphate (FdUMP) 
which is a potent inhibitor of thymidylate synthetase. This results in the 
inhibition of fungal DNA synthesis10. It is still unclear whether one 
mechanism is more important than the other for the total antifungal effect of 
5-FC.  
 
Scheme 1 : conversion of 5-FC to 5-FU in fungal cells 
5-Fluorocytosine is available in oral form and as intravenous preparation. Its 
spectrum is restricted to Candida species and Cryptococcus neoformans9. 
                                                     
9 a. A. Vermes, H.-J. Guchelaar, J. Dankert, J. Ant. Chemother. 2000, 46, 171-179 b. 
R. Herbrecht, Y. Nivoix, C. Fohrer, S. Natarajan-Amé, V. Letscher-Bru, J. Ant. 
Chemother. 2005, 56, i39-i48. 
10 A. R. Waldorf, A. Polak, Antimicrob. Agents Chemother. 1983, 23, 79-85. 
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Unfortunately, a significant proportion of C. albicans isolates are resistant to 
5-FC, thus limiting its utility7.  
II.2. Polyenes 
Amphotericin B (AmB) and nystatin are the currently available and 
employed polyenes, although nystatin has been limited to topical use due to 
differing safety profiles11.  
AmB 1.003 was first isolated from a soil bacterium Streptomyces nodosus 
obtained from the bed of the Orinoco River in Venezuela in 195512.  
 
Figure 2 : structure of amphotericin B 
It is a macrocyclic polyene with in vitro antifungal activity that covers most 
of the fungal pathogens involved in human diseases9. Moreover, resistance to 
AmB has remained exceptionally rare despite its extended use worldwide to 
treat life-threatening IFIs for more than half a century7.  
The usual formulation of AmB is a micellar deoxycholate complex 
(Fungizone) that has been on the market for over 40 years. Unfortunately, it 
is highly toxic to patients, often causing decreased renal function, chills, 
high fever, nausea, phlebitis, anorexia and many other unpleasant side-
                                                     
11 G. R. Thompson, J. Cadena, T. F. Patterson, Clin. chest med. 2009, 30, 203-215. 
12 C. M. McNamara, S. Box, J. M. Crawforth, B. S. Hickman, T. J. Norwood, B. J. 
Rawlings, J. Chem. Soc. Perkin Trans. 1 1998, 83-88. 
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effects. Coupled with long therapeutic uses, these negative effects restrict its 
usefulness to all but the most life-threatening systemic fungal infections13. 
However, to avoid the high nephrotoxicity, several other formulations have 
been developed such as lipid preparations. This solution has drastically 
reduced the toxicity of this drug without diminishing its powerful antifungal 
action14.  
Despite five decades of investigations, the mode of action of AmB remains 
unclear. In the now widely accepted leading model, AmB kills yeast by self-
assembly of several molecules to form barrel-stave-like trans-membrane 
pores. This channel mode has also been extended to rationalize the lack of 
resistance to AmB. The number of molecules involved in forming the pores 
is not known but 4 to 12 units have been proposed15. In 2011, the group of 
Ide proposed a rectification and claims that AmB channel consists of 6 
monomeric units16.  
However, in a recent paper, the group of Burke determined that AmB binds 
directly to membrane-embedded ergosterol (the main sterol found in yeast 
cell), in a way that requires the mycosamine fragment present in AmB. 
Indeed, when this fragment was removed to yield a derivative called 
                                                     
13 S. Hartsel, J. Bolard, Trends Pharmacol. Sci. 1996, 17, 445-449. 
14 a. J. P. Barrett, K. A. Vardulaki, C. Conlon, J. Cooke, P. Daza-Ramirez, E. G. V. 
Evans, P. M. Hawkey, R. Herbrecht, D. I. Marks, J. M. Moraleda, G. R. Park, S. J. 
Senn, C. Viscoli, Clin. Ther.  2003, 25, 1295-1320 b. A. Antoniadou, B. Dupont, J. 
Med. Mycol. 2005, 15, 230-238  
15 a. R. W. Holz, Ann. N. Y. Acad. Sci. 1974, 235, 469-479 b. T. E. Andreoli, ibid., 
448-468 c. A. A. Volmer, A. M. Szpilman, E. M. Carreira, Nat. Prod. Rep. 2010, 27, 
1329-1349. 
16 M. Hirano, Y. Takeuchi, N. Matsumori, M. Murata, T. Ide, J. Membrane Biol. 
2011, 240, 159-164 
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amphoteronolide B (AmdeB), which can not bind to ergosterol but can still 
form pores, no fungal activity was observed (figure 3).  
 
 
Figure 3 : Structures of AmB and AmdeB 
These findings, along with other observations, led them to the conclusion 
that ergosterol binding alone is the primary mechanism of action of Amb; 
channel formation represents a second complementary mode of action17.  
II.3. Azoles 
The azoles are a family of synthetic compounds that were discovered in the 
1960s.  They are the largest class of antifungal agents in clinical use18. The 
                                                     
17 a. K. C. Gray, D. S. Palacios, I. Dailey, M. M. Endo, B. E. Uno, B. C. Wilcock, 
M. D. Burke, Proc. Natl. Acad. Sci. 2012, 109, 2234-2239 b. Y. Umegawa, T. 
Adachi, N. Matsumori, M. Murata, Bioorg. Med. Chem. 2012, 20, 5699-5704. 
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family of azoles can be divided into two subclasses: the imidazoles and the 
triazoles. 
Miconazole 1.004, the very first member of the imidazole family, was 
discovered in 1969 by Janssen Pharmaceutica when they initiated a research 
program on imidazole chemistry (figure 4). 
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Figure 4 : structures of miconazole and clotrimazole 
Unfortunately, miconazole shows poor oral bioavailability. However, it is a 
useful topical drug for the treatment of superficial mycoses19. The same year, 
some researchers at Bayer discovered clotrimazole 1.005 which cannot be 
given parenterally and showed poor oral absorption, but is used for the 
treatment of oral and vaginal candidosis and athlete’s foot infection8,20.  
Many synthetic explorations and modifications on miconazole at Jansen 
Pharmaceutica led to the discovery of ketoconazole 1.006 in 1977 as the first 
orally active broad-spectrum antifungal agent that can be used to treat 
superficial and deep mycoses19,21 (figure 5).  
                                                                                                                            
18 F. C. Odds, A. J. P. Brown, N. A. R. Gow, Trends Microbiol. 2003, 11, 272-279. 
19 J. Heeres, L. Meerpoel, P. Lewi, Molecules 2010, 15, 4129-4188 
20 R. A. Fromtling, Clin. Microbiol. Rev. 1988, 1, 187-217. 
21 J. Heeres, L. J. J. Backx, J. H. Mostmans, J. Van Cutsem, J. Med. Chem. 1979, 22, 
1003-1005. 
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Figure 5 : structure of ketoconazole 
Oral ketoconazole is effective in patients with candidosis, 
coccidioidomycosis, blastomycosis, histoplasmosis, paracoccidioidomycosis 
and cutaneous dermatophyte infections. It has nowadays been replaced by 
newer azoles for the treatment of many of these infections8. 
In 1986, a new antifungal agent with broad-spectrum antifungal activity was 
discovered at Janssen Pharmaceutica by replacing the imidazole moiety by a 
triazole and by functionalizing the structure even more. It was named 
itraconazole 1.00722 (figure 6).  
 
Figure 6 : structure of itraconazole 
Further structure modifications of the itraconazole family led to the 
discovery of posaconazole 1.008 by Schering-Plough (Figure 7). It was 
                                                     
22 J. Heeres, L. J. J. Backx, J. Van Cutsem, J. Med. Chem. 1984, 27, 894-900 
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approved by the FDA in 2006 for the prophylaxis of invasive Aspergillus 
and Candida infections23.  
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Figure 7 : structure of Posaconazole 
At the same time as itraconazole was born, another important series of 
antifungal agents was developed by Pfizer by shifting the benzyl moiety in 
miconazole from the oxygen to the α-carbon (figure 8) and replacing the 
imidazole ring by a triazole19.  
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Figure 8 
                                                     
23 a. C. A. Kauffman, A. N. Malani, C. Easley, P. Kirkpatrick, Nat. Rev. Drug 
Discov. 2007, 6, 183-184 b. V. Nagappan, S. Deresinski, Clin. Infect. Dis. 2007, 45, 
1610-1617. 
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These modifications gave rise to fluconazole 1.009, which is one of the most 
frequently prescribed triazoles due to its excellent bioavailability, tolerability 
and side-effect profile11,24 (figure 9).  
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Figure 9 : structure of fluconazole 
More recently, further modifications provided voriconazole 1.010 which has 
been marketed in several countries since 2002 (figure 10). The spectrum of 
activity of this new triazole covers most pathogenic yeasts9.  
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Figure 10 : structure of voriconazole 
Concerning their mode of action, the family of azoles blocks the synthesis of 
ergosterol, an important component of fungal cytoplasmic membranes. They 
inhibit the 14-α-demethylation of lanosterol into ergosterol in the 
                                                     
24 D. J. Sheehan, C. A. Hitchcock, C. M. Sibley, Clin. Microbiol. Rev. 1999, 12, 40-
79.  
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biosynthetic pathway (scheme 2). This mechanism leads to the depletion of 
ergosterol and the increase of 14-α-methylated sterols thus disturbing the 
structure, permeability and fluidity of the fungal membrane. The azole 
antifungals target a cytochrome P450-Erg11P enzyme possessing a 
monooxygenase activity. This enzyme contains an iron protoporphyrin unit 
at its active site. The azoles bind to iron via a nitrogen atom of the imidazole 
or triazole ring. The rest of the molecule binds to the apoprotein18,25. A 
stereoview of active site of lanosterol 14α-demethylase (heme iron in 
yellow) of Candida albicans with bound fluconazole (in green) is shown in 
figure 1126.   
 
                                                     
25 H. V. Bossche, L. Koymans, H. Moereels, Pharmacol. Ther. 1995, 67, 79-100.  
26 H. Ji, W. Zhang, Y. Zhou, M. Zhang, J. Zhu, Y. Song, J. Lü, J. Zhu, J. Med. 
Chem. 2000, 43, 2493-2505. 
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Figure 11 
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Scheme 2: Inhibtion of ergosterol synthesis by azole antifungals 
As a class, the azoles are safe, have a broad spectrum of activity and can be 
administered intraveinously or orally. However, their mechanism of action 
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leads to some drug-drug interactions that need to be taken into account when 
administered to patients27. 
It should be noted that there is an increasing drug resistance to these drugs. 
This resistance can occur either by mutations, that modify the target 
molecule, or by overexpression of membrane efflux pumps that export the 
antifungals from the cell18,28. 
II.4. Echinocandins 
Echinocandins form the newest family of antifungal agents that act by a 
different pathway9. They are fungal secondary metabolites, composed of a 
cyclic hexapeptide core bearing a lipid side-chain. Random screening in the 
1970s led to the discovery of two prototypes with interesting antifungal 
activities: echinocandin B and aculeacin A. A modified version of 
echinocandin B, cilofungin, was developed to phase 2 in clinical trials but 
was abandoned because its formulation was toxic to patients. 
In the late 1990s, three synthetically modified echinocandin derivatives 
entered clinical developments18.  In 2001, the first of them, caspofungin 
(Merck), was approved by the FDA, followed by anidulafungin and 
micafungin2. The molecular weight of all three of them is large, and this 
presumably explains their poor oral absorption. Therefore, they are all for 
intravenous use only29. 
                                                     
27 P. O. Gubbins, S. Heldenbrand, Mycoses 2010, 53, 95-113.  
28 M. M. Canuto, F. G. Rodero, Lancet Infect. Dis. 2002, 2, 550-563.  
29 a. D. Cappelletty, K. Eiselstein-McKitrick, Pharmacotherapy 2007, 27, 369-388 
b. D. W. Denning, J. Antimicrob. Chemother. 2002, 49, 889-891.  
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Caspofungin 1.011 is a semi-synthetic water-soluble aminoderivative of 
pneumochandin B0 30(figure 12). 
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Figure 12 : Structure of caspofungin 
Echinocandins possess antifungal activities mainly against Candida spp. and 
Aspergillus spp31. Their mode of action is different from the other antifungal 
agents as they block the synthesis of β(1,3)-D-glucan of the fungal cell wall, 
by a non-competitive inhibition of the enzyme β(1,3)-D-glucan synthase. 
β(1,3)-D-glucan is a component of the cell wall, giving it its shape and 
mechanical strength. This inhibition has a double effect: fungistatic, which 
results from blockade of the cell wall synthesis, reducing fungal growth and 
fungicidal, which originates from a change in the integrity of the cell wall 
resulting in the loss of its mechanical strength. The cell is thus unable to 
resist the intracellular osmotic pressure and lysis occurs29. 
                                                     
30 V. Letscher-Bru, R. Herbrecht, J. Antimicrob. Chemother. 2003, 51, 513-521.  
31 P.-L. Shao, L.-M. Huang, P.-R. Hsueh, Int. J. Antimicrob. Agents 2007, 30, 487-
495.  
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Since there is no counterpart of fungal cell walls in mammalian cells, the 
echinocandins are usually well tolerated with few adverse effects. 
Furthermore, unlike triazoles, the CYP450-independent metabolism and 
degradation reduces concern about drug-drug interaction30.  
Clinical resistance is rare, despite case reports of caspofungin resistance in 
several Candida spp32. 
Due to their clinical efficacy and safety, echinocandins are today among the 
first-line therapies recommended for treatment of candidemia and invasive 
candidiasis. However, they are expensive33.  
III. Emerging antifungal compounds 
III.1. The sordarins 
Sordarin 1.012 is a fungal metabolite isolated in 1969 from the fungus 
Sordaria araneosa by scientists at the Sandoz Co. Its degradation with 
concentrated HCl releases a diterpenoid aglycone called sordaricin 1.013 
(figure 13)34. 
 
                                                     
32 S. A. Chen, M. Slavin, T. Sorrell, Drugs 2011, 71, 11-41.  
33 C. F. Neoh, M. Slavin, S. C. A. Chen, K. Stewart, D. C. M. Kong, Int. J. 
Antimicrob. Agents 2014, 43, 207-214.  
34 H. Liang, Beilstein J. Org. Chem. 2008, 4, 31.  
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Figure 13 : structures of sordarin and sordaricin 
These products were shown to have antifungal activities in the 1970s but 
they generated considerable interest only 2 decades later, when several types 
of novel sordarins derivatives were developed preclinically by Glaxo-
Wellcome and Merck35.  
The sordarins are interesting because they inhibit a novel target for 
antifungal agents: elongation factor 2 (EF2) in protein biosynthesis. This 
enzyme catalyzes the translocation of the ribosome along the mRNA during 
elongation of the emerging polypeptide chain. Sordarin inhibits this 
translocation by stabilizing the EF2/ribosome complex36.  
A number of molecules based on the sordarin pharmacophore were shown to 
have therapeutic efficacy in various animal models but no obvious candidate 
for clinical development has emerged yet3,34. Recently, Astellas pharma 
reported a novel sordarin derivative, FR290581 1.014, modified at the 
                                                     
35 L. Ostrosky-Zeichner, A. Casadevall, J. N. Galgiani, F. C. Odds, J. H. Rex, Nat. 
Rev. Drug Discov. 2010, 9, 719-727.  
36 G. R. Andersen, P. Nissen, J. Nyborg, Trends Biochem. Sci. 2003, 28, 434-441.  
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aglycone part, which shows good in vivo activities against Candida 
albicans37 (figure 14). 
 
Figure 14 
III.2. Isavuconazole 
Isavuconazole 1.015 is a triazole in phase III clinical development for 
treatment of invasive candidemia and candidiasis (figure 15). It is active in 
vitro and in vivo against Aspergillus spp. and Candida spp.38. 
                                                     
37 T. Hanadate, M. Tomishima, N. Shiraishi, D. Tanabe, H. Morikawa, D. Barrett, S. 
Matsumoto, K. Ohtomo, K. Maki, Bioorg. Med. Chem. Lett. 2009, 19, 1465-1468.  
38 a. S. Perkhofer, V. Lechner, C. Lass-Flörl, Antimicrob. Agents Chemother. 2009, 
53, 1645-1647 b. A. C. Pasqualotto, D. W. Denning, J. Antimicrob. Chemother. 
2008, 61, i19-i30.  
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Figure 15 : structure of isavuconazole 
III.3. Nikkomycin Z 
Nikkomycin Z 1.016 is a peptide-nucleoside isolated from Streptomyces 
tendae that was initially identified by Bayer Pharmaceutical Company in the 
1970s as a potential antifungal agent (figure 16).  
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Figure 16 : structure of nikkomycin Z 
Nikkomycin Z inhibits chitin synthase and thereby interferes with cell wall 
construction. While chitin is essential for fungi, it is absent in human 
organisms.  
Shaman Pharmaceuticals started the phase I study for the development of 
nikkomycin Z. However, after they closed down, the trial was acquired by 
the Valley Fever Center for Excellence at the University of Arizona34.  
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Nikkomycin Z is currently under development as a first in class orphan 
product for treatment of coccidioidomycoses. Phase II of the clinical trials 
will begin in the near future39. 
 
Over the last 50 years during which antifungal agents have been discovered, 
the clinical needs have evolved constantly. Superficial mycoses remain easy 
to treat with a wide range of over-the-counter antimycotic products. 
However, whilst the availibilty of the extended-spectrum triazoles and the 
echinocandins represents remarkable advances in the treatment of IFIs, the 
mortality rate remains high. Moreover, due to the growth of susceptible 
populations, limitations of the activity spectrum or tolerability of current 
antifungals and the development of antifungal resistance, there is a constant 
need for new solutions with novel antifungal agents3,30,34. 
IV. Ambruticin and Jerangolids 
Natural compounds among myxobacterial metabolites often show interesting 
antifungal bioactivities. Amongst the wide list of these compounds are two 
families of polyketides with similar structures and related mode of actions: 
ambruticins and jerangolids40.  
                                                     
39 a. D. E. Nix, R. R. Swezey, R. Hector, J. N. Galgiani, Antimicrob. Agents 
Chemother. 2009, 53, 2517-2521 b. L. F. Shubitz, H. T. Trinh, R. H. Perrill, C. M. 
Thompson, N. J. Hanan, J. N. Galgiani, D. E. Nix, J. Infect. Dis. 2014.  
40 K. J. Weissman, R. Muller, Nat. Prod. Rep. 2010, 27, 1276-1295.  
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IV.1. Ambruticins 
Ambruticin S 1.017 was isolated in the 1970s, in the laboratories of Warner-
Lambert, from an isolate of Polyangium cellulosum var. fulvum41 (figure 17).  
 
Figure 17 : structure of ambruticin S 
The exact structure was elucidated by systematic degradative studies coupled 
with spectroscopic analysis. Derivatization of ambruticin afforded a 
crystalline product on which a single-crystal X-ray diffraction analysis could 
be performed unambiguously establishing the relative stereochemistry of the 
natural product42. Shortly afterwards, the same group isolated a less polar 
molecule from the same fermentation broth as ambruticin and determined its 
structure as being 5-epi ambruticin, named ambruticin F43.  
Later, ambruticin variants containing a free or methyl substituted amino 
group instead of an –OH function were discovered by the group of 
Reichenbach. They were labeled ambruticin VS44 (figure 18). 
                                                     
41 S. M. Ringel, R. C. Greenough, S. Roemer, D. Connor, A. L. Gutt, B. Blair, G. 
Kanter, S. von, J. Antibiot. 1977, 30, 371-375.  
42 D. T. Connor, R. C. Greenough, M. Von Strandtmann, J. Org. Chem. 1977, 42, 
3664-3669.  
43 D. T. Connor, M. Von Strandtmann, J. Org. Chem. 1978, 43, 4606-4607.  
44 G. Höfle, H. Steinmetz, K. Gerth, H. Reichenbach, Liebigs Ann. Chem. 1991, 
1991, 941-945.  
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R1 R2 ambruticin 
CH3 +NMe3 VS-1 
H +NHMe2 VS-2 
H +NOMe2 VS-3 
H +NH2Me VS-4 
H +NH3 VS-5 
Figure 18 : structures of ambruticin VS 
Ambruticins are of interest because of their antifungal effect which is quite 
impressive.  
The antibiotic is highly active in vitro against systemic pathogens such as 
Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatidis as 
well as the dermatophytic filamentous fungi40. Moreover, ambruticin 
compared favorably with amphotericin B and miconazole when tested 
against the dimorphic pathogens Histoplasma capsulatum, Coccidioides 
immitis, Blastomyces dermatidis and against Aspergillus fumigatus45.  
                                                     
45 S. Shadomy, D. M. Dixon, A. Espinel-Ingroff, G. E. Wagner, H. P. Yu, H. J. 
Shadomy, Antimicrob. Agents Chemother. 1978, 14, 99-104.  
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Furthermore, it has been disclosed that ambruticin S has a low animal 
toxicity (LD50 > 1000 mg/kg for an oral dose)46. 
Various studies on mice revealed its oral activity for the treatment of 
histoplasmosis even though the day dose was higher for ambruticin (150 
mg/kg) than for amphotericin B (25 mg/kg)47.  
Ambruticin S showed curative effects against murine coccidioidal infection. 
When mice were infected with lethal doses of Coccidioides spp. and treated 
with ambruticin S from 17 to 56 days, 73% to 100% of them survived and 
were found to be free of the fungus48. More recently, based on these results, 
two analogs of ambruticin S with greater in vitro potency were developed 
and tested against lethal murine Coccidioides infection. Both improved the 
survival rate of treated mice over that of control mice49.  
In another study, a derivative of ambruticin VS4, designated KOSN-2079 
1.019, was tested in the mouse model of invasive apergillosis (figure 19).  
 
Figure 19 : structure of Ambruticin VS4 analogue 
                                                     
46 S. M. Ringel, Antimicrob. Agents Chemother. 1978, 13, 762-769.  
47 S. Shadomy, C. J. Utz, S. White, Antimicrob. Agents Chemother. 1978, 14, 95-98. 
48 H. B. Levine, S. M. Ringel, J. M. Cobb, CHEST Journal 1978, 73, 202-206.   
49 L. F. Shubitz, J. N. Galgiani, Z.-Q. Tian, Z. Zhong, P. Timmermans, L. Katz, 
Antimicrob. Agents Chemother. 2006, 50, 3467-3469.  
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It significantly reduced pulmonary fungal burdens and increased survival 
compared to mice that received the vehicle alone. This study suggests that 
additional ambruticin analogues should be explored for the treatment of this 
disease in human50. 
IV.2. Jerangolids 
Jerangolids were isolated in 1992 from the myxobacteria Sorangium 
cellulosum So ce 307, which was isolated at the GBF in 1987 from a soil 
sample collected in Jerusalem. Jerangolids are rare metabolites of Sorangium 
cellulosum strains (4 in 1000). Five compounds from this family are known 
and their structures are depicted in figure 20. 
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Figure 20 : structures of jerangolids 
For jerangolid B, E and H, the stereochemistry at C14 is still unknown.  
In vitro tests on jerangolid A show that it possesses potent antifungal activity 
against a wide range of pathogenic fungi such as Hansenula anomala and 
                                                     
50 L. Y. Chiang, D. E. Ejzykowicz, Z. Q. Tian, L. Katz, S. G. Filler, Antimicrob. 
Agents Chemother. 2006, 50, 3464-3466.  
GENERAL INTRODUCTION  49 
Mucor hiemalis (MIC 0.7μg/mL), Debaryomyces hansenii and Trisporo 
terrestre (0.1-0.4 μg/mL) and Candida albicans (4.2 μg/mL)51. 
IV.3. Mode of action 
Jerangolids and ambruticins possess a similar mode of action. They are 
believed to induce the high-osmolarity glycerol (HOG) signaling pathway, 
resulting in the accumulation of triacylglycerols and free fatty acids. In the 
absence of high external osmolarity, intracellular accumulation of glycerol 
causes leakage of cellular content which presumably results in cell death52.  
It was shown recently that ambruticin targets Hik1, a histidine kinase, and 
that binding of the drug results in an inappropriate cellular response, 
including intracellular accumulation of glycerol and, ultimately, cell death. 
Binding of ambruticin would result in the production of dephosphorylated 
Ssk1 (active form), the phosphate signal is carried downstream to Hog1, 
resulting in overstimulation of the HOG pathway53. The proposed 
mechanism of the HOG pathway without the effect of a drug in Candida 
albicans is represented in figure 21. The left side shows unstressed 
conditions while the right side illustrates stressed conditions54. The exact 
mechanism of binding of the drug is still unknown. 
 
                                                     
51 K. Gerth, P. Washausen, G. Hofle, H. Irschik, H. Reichenbach, J. Antibiot. 1996, 
49, 71-75.  
52 P. Knauth, H. Reichenbach, J. Antibiot. 2000, 53, 1182-1190.  
53 a. L. Vetcher, H. G. Menzella, T. Kudo, T. Motoyama, L. Katz, Antimicrob. 
Agents Chemother. 2007, 51, 3734-3736 b. A. Dongo, N. Bataillé-Simoneau, C. 
Campion, T. Guillemette, B. Hamon, B. Iacomi-Vasilescu, L. Katz, P. Simoneau, 
Appl. Environ. Microbiol. 2009, 75, 127-134.  
54 Y. Bahn, Eukaryotic cell 2008, 7, 2017-2036. 
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Figure 21 
Despite the recently extended armamentarium of antifungal agents to treat 
the continuously increasing infections with invasive mycoses, there is a 
constant need for new solutions. Indeed, the increase of immunosuppressed 
patients as well as the rising resistance of fungi makes the discovery of new 
antifungal agents an important area of research. In this context, we are 
interested in the two families of natural products presented above, which 
have shown interesting potential antifungal activities. In this thesis, we will 
specifically direct our efforts towards the synthesis of jerangolids and some 
new analogues. 
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As shown in the general introduction, jerangolids are a family of natural 
products with interesting potential antifungal activities. 
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Figure 1: structures of jerangolids 
Despite their promising activity, there have only been two total syntheses 
and two partial syntheses of jerangolid A and D reported so far. Syntheses of 
jerangolid A were published by the groups of Donaldson and Hanessian 
whilst work about jerangolid D was described in our group. These syntheses 
will be described in this chapter. 
I. Syntheses of jerangolid A 
I.1. A short synthesis of the dihydropyran  
In 2005, the group of Donaldson reported the first enantioselective 
preparation of the common dihydropyranyl segment 2.001 present in 
jerangolid A and D as well as in ambruticin S1. 
                                                     
1 J. M. Lukesh, W. A. Donaldson, Tetrahedron Lett. 2005, 46, 5529-5531.  
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Figure 2 : structure of dihydropyran 2.001 
They envisioned the construction of this oxane ring by a Lewis acid 
catalyzed hetero Diels-Alder reaction followed by a C-glycosidation of the 
derived pseudoglycal2.  
To this end, reaction of optically pure aldehyde3 2.002 with butadiene4 
2.003, in the presence of BF3-etherate, followed by work-up with TFA, gave 
a mixture of two inseparable diastereomers 2.004 and 2.005 (scheme 1). 
O
OBn
OMe
OTMS
1) Lewis
acid
2) TFA
O O
O O
BnO BnOH H
BF3.OEt2/CH2Cl2/-78 °C to 23 °C 1:1.6 (71 %)
MgBr2/THF/0 °C to 23 °C
2.002
2.003 (+)-2.004 2.005
1:0 (86 %)
+
 
Scheme 1 : hetero Diels-Alder reaction   
                                                     
2 a .S. J. Danishefsky, M. T. Bilodeau, Angew. Chem. Int. Ed. 1996, 35, 1380-1419 
b. J. M. Lukesh, W. A. Donaldson, Tetrahedron: Asymm. 2003, 14, 757-762.  
3 D. Enders, S. von Berg, B. Jendeleit, Org. Synth. 2002, 78, 177-188. 
4 S. Danishefsky, C.-F. Yan, R. K. Singh, R. B. Gammill, P. M. McCurry, N. 
Fritsch, J. Clardy, J. Am. Chem. Soc. 1979, 101, 7001-7008.  
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To solve this problem, they switched to MgBr2 as a Lewis acid which 
allowed them to reach dihydropyranone (+)-2.004 as a single diastereomer 
after work-up with TFA.  
Reduction of 2.004 with DIBAL-H gave the pseudoglycal (+)-2.006 as a 
single diastereomer (scheme 2).  
 
Scheme 2 
Subsequent treatment of pseudoglycal (+)-2.006 with triethylaluminium in 
the presence of BF3-etherate gave a mixture of trans- and cis-dihydropyrans 
(8:1 ratio). Purification by silica gel column chromatography separated the 
isomers and afforded the pure trans-isomer (-)-2.007 in good yield. An axial 
attack of the weak nucleophile on the cyclic oxonium generated by 
ionization of 2.006 explains the formation of the major trans-product (figure 
3). 
O
H
OBn
Half-chair
Nu-
Half-boat
 
Figure 3 
Deprotection of the benzyl-group with sodium in ammonia followed by 
oxidation of the alcohol to the corresponding ketone gave (-)-2.009 (scheme 
3). 
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Scheme 3 
Base-catalyzed epimerization of the trans-ketone afforded the desired right-
hand part of jerangolid A 2.001, after two equilibration/separation cycles in 
83 % combined yield (scheme 4). 
 
Scheme 4  
In summary, the dihydropyranyl segment 2.001 was synthetized in six steps 
from optically active aldehyde 2.002 in 31.7 % overall yield. 
I.2. Total synthesis of jerangolid A 
The group of Hanessian reported the first total synthesis of jerangolid A 
2.010 in 20105.  
                                                     
5 S. Hanessian, T. Focken, R. Oza, Org. Lett. 2010, 12, 3172-3175.  
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Figure 4 : structure of jerangolid A 2.010 
They envisioned a late-stage assembly of two ring segments through a 
phosphonamide anion-based olefination methodology developed in their 
group6 and a Julia-Kociensky reaction (scheme 5). 
 
Scheme 5 
I.2.1. Synthesis of lactone 2.011 
They began building the lactone from PMB protected (R)-glycidol. Opening 
of this epoxide 2.014 with the anion derived from ethyl propiolate, in the 
presence of BF3-etherate, afforded quantitatively previously known alkyne7 
2.015. Further treatment of the latter with NaOMe in MeOH furnished 
lactone 2.016 in good yield (scheme 6).  
                                                     
6 Y. L. Bennani, S. Hanessian, Chem. Rev. 1997, 97, 3161-3196.  
7 A. Ahmed, E. K. Hoegenauer, V. S. Enev, M. Hanbauer, H. Kaehlig, E. Öhler, J. 
Mulzer, J. Org. Chem. 2003, 68, 3026-3042.  
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Scheme 6  
Two more steps were required to introduce the hydroxymethyl group. In 
order to do so, lactone 2.016 was iodinated and the resulting adduct 2.017 
was then treated with i-PrMgCl at -78°C. The resulting organomagnesium 
species reacted with a solution of formaldehyde to yield hydroxymethyl 
lactone 2.011 (scheme 7). 
Scheme 7 
Protection of the alcohol with TBS and removal of PMB with DDQ 
successfully delivered alcohol 2.018 in 75 % yield. Oxidation to the 
corresponding aldehyde was tricky due to the unstable nature of the latter. 
Swern conditions proved to be the best, affording aldehyde 2.019 in 
sufficient purity for subsequent transformation (scheme 8).  
Scheme 8  
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I.2.2. Synthesis of dihydropyran 2.012 
The synthesis of this subunit is based on a palladium-catalyzed cyclization of 
allylic diols developed by Uenishi and others. Upon treatment with 
Pd(CH3CN)2Cl2, tetrahydro- or dihydro-pyrans are formed via a 6-exo or 6-
endo-trig cyclization respectively. The selectivity is controlled by the 
relative configuration of the diol8. 
The allylic diols are reached by opening of (R)-benzylated glycidol with 
dithiane to yield 2.021 followed by unmasking of the enone system. 
Protection of the free alcohol was necessary in order for the smooth removal 
of the dithiane (scheme 9).  
Scheme 9  
Reduction of enone 2.022 with (R)- or (S)-Me-CBS and subsequent 
treatment with TBAF furnished the diastereomerically pure diols 2.023a and 
2.023b (scheme 10). 
 
Scheme 10 
                                                     
8 a. J. i. Uenishi, M. Ohmi, Angew. Chem. Int. Ed. 2005, 44, 2756-2760 b. N. Kawai, 
S. Mahadeo Hande, J. i. Uenishi, Tetrahedron 2007, 63, 9049-9056.  
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The following cyclization was conducted under Uenishi’s conditions. 
Unfortunately, with these particular substrates, treatment of diols 2.023a and 
2.023b with Pd(CH3CN)2Cl2 led to a 1.5:1 ratio of syn/anti dihydropyrans. 
After optimizations based on other studies9, they were able to obtain the 
desired syn-dihydropyran 2.024 using either the cationic complex 
Pd(CH3CN)2Cl2, BF3.OEt2 or TfOH, starting from either diols (table 1). This 
observation suggests that the stereochemistry of the allylic alcohol is of no 
importance in the final outcome of this cyclization process, indicating a 
cationic mechanism.  
 
entry Catalyst (equiv) solvent Yield (%) Syn/anti 
1 Pd(CH3CN)2Cl2 (1.0) THF 53 1.5:1 
2 Pd(CH3CN)2(BF4)2 (0.05) CH2Cl2 72 25:1 
3 BF3OEt2 (0.1) CH2Cl2 82 20:1 
4 TfOH (0.1) CH2Cl2 81 16:1 
Table 1 
The end of the sequence proceeds smoothly. The benzyl group was removed 
under Birch conditions. Swern oxidation, addition of methyl Grignard on the 
                                                     
9 a. M. Reiter, H. Turner, V. Gouverneur, Chemistry – A European Journal 2006, 
12, 7190-7203bA. Guérinot, A. Serra-Muns, C. Gnamm, C. l. Bensoussan, S. b. 
Reymond, J. Cossy, Org. Lett. 2010, 12, 1808-1811.  
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resulting aldehyde and a second Swern oxidation afforded the desired 
dihydropyran 2.001 in 72 % yield (scheme 11). 
Scheme 11 
I.2.3. Completion of the synthesis 
The two rings were connected using two olefination methods. The first one 
employs cyclic phosphonamides10. Deprotonation with n-BuLi was followed 
by the addition of ketone 2.001. After quenching with acetic acid, a 
separable mixture of E/Z isomers containing the desired one as the major 
product was obtained (table 2).  
                                                     
10 K. J. Koeller, C. D. Spilling, Tetrahedron Lett. 1991, 32, 6297-6300.  
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TBSO P N
N
R
R
O
n-BuLi, 2.001
THF, -78 °C
then AcOH
TBSO OH H
2.026a R=Me
2.026b R=i-Pr 2.027  
Entry phosphonamide Yielda E/Z 
1 2.026a 57 3:1 
2 2.026a 62 6:1b 
3 2.026b 20 13:1
    a Recovery of ketone 2.027 : 20-60 %. 
  bAddition of AcOH at r.t. 
Table 2 
As shown in table 2, changing the substituents from methyl to isopropyl led 
to increased selectivity, though at the expense of the yield.  
Removal of the TBS with TBAF afforded the corresponding alcohol in 90 % 
yield, which was then transformed into PT-sulfide under Mitsunobu 
conditions. Subsequent oxidation afforded compound 2.028 which is ready 
for coupling with aldehyde 2.019 under Julia-Kociensky conditions (scheme 
12). 
Scheme 12 
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After some optimizations11, the desired E-olefin was obtained almost 
exclusively in 46 % yield (E/Z > 25:1). Final removal of the TBS group 
under mild acidic conditions provided jerangolid A (scheme 13). 
Scheme 13  
In summary, the first total synthesis of jerangolid A was reported in 16 linear 
steps and 6 % overall yield from glycidol 2.020. 
II. Jerangolid D 
Jerangolid D is very similar to jerangolid A. The only difference between 
them occurs at C2 where the CH2-OH substituent is replaced by a methyl 
group (figure 5). 
 
Figure 5 : structure of jerangolid D 
II.1. Total synthesis 
The first total synthesis of jerangolid D was described by our group in 2007 
by Dr J. Pospísil12. The molecule was divided into three fragments: lactone 
                                                     
11 P. Liu, E. N. Jacobsen, J. Am. Chem. Soc. 2001, 123, 10772-10773.  
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A, sulfone B and dihydropyrane C that would ultimately be connected via 
two Julia olefinations (scheme 14).  
O
O
O
H3C
MeO HH
1
8 15
5
A
B
C O
O
H3C
MeO
1
OH
6
7
+
TBSO SO2Ph
+
O
O H H
A B
C
7 8
15
2.001
2.030
2.031
Scheme 14 
II.1.1. Synthesis of lactone 2.030 
The synthesis of lactone 2.030 began with (R)-benzylated glycidol 2.020 
which was opened using Nagata’s reagent13 to access β-hydroxynitrile 2.032 
in quantitative yield. The latter reacted with methyl 2-bromopropanoate in 
the presence of activated zinc dust under Blaise conditions14. The 
corresponding β-ketoester 2.033 was isolated in good yield. Surprisingly, the 
free hydroxyl group was tolerated under these conditions15 (scheme 15). 
                                                                                                                            
12 J. Pospíšil, I. E. Markó, J. Am. Chem. Soc. 2007, 129, 3516-3517.  
13 a. F. Benedetti, F. Berti, S. Norbedo, Tetrahedron Lett. 1999, 40, 1041-1044. b. 
W. Nagata, M. Yoshioka, T. Okumura, Tetrahedron Lett. 1966, 7, 847-852.  
14 For a review on Blaise reaction: H. S. Prakash Rao, S. Rafi, K. Padmavathy, 
Tetrahedron 2008, 64, 8037-8043. 
15 For similar observation : F.-D. Wang, J.-M. Yue, Synlett 2005, 2005, 2077-2079.  
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Scheme 15  
One-pot cyclisation/enol-ether formation, promoted by TMSCl in MeOH, 
furnished protected lactone 2.034 in 84 % yield. The benzyl group was 
removed using FeCl3 to complete the synthesis of the left-hand fragment 
2.030 (scheme 16). 
 
Scheme 16 
II.1.2. Synthesis of dihydropyran 2.001 
The dihydropyran moiety was assembled using a diastereoselective three-
component Sakurai condensation previously developed in our laboratory16 
(scheme 17).  
                                                     
16 J. Pospíšil, T. Kumamoto, I. E. Markó, Angew. Chem. Int. Ed. 2006, 45, 3357-
3360.  
66                                              JERANGOLIDS 
 
 
Scheme 17 
Aldehyde 2.035, silyl ether 2.036 and allylsilane 2.037 were mixed together 
at -78 °C and a catalytic amount of TMSOTf was added. The syn-syn adduct 
2.038 was obtained as a single diastereomer in 80 % yield.  
Ring-closing metathesis with Grubbs-I catalyst provided protected 
dihydropyran 2.039 in excellent yield. Deprotection of the TBS group with 
TBAF, followed by oxidation with Dess-Martin periodane, finished the 
synthesis of the right-hand fragment 2.001 (scheme 18).  
Scheme 18 
II.1.3.  Completion of the synthesis 
A Julia olefination between ketone 2.001 and sulfone 2.031 was selected to 
form the first olefin. Initially, a one-pot condensation and benzoylation was 
attempted (path 1). Surprisingly, this procedure proved to be irreproducible 
and therefore, a two-steps procedure had to be used (path 2)17. Reductive 
                                                     
17 R. Dumeunier, I. E. Markó, Tetrahedron Lett. 2004, 45, 825-829.  
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elimination with SmI2 provided the desired olefin 2.041 with good yield and 
excellent E/Z selectivity18 (scheme 19). 
SO2Ph
OTBS
1) n-BuLi, THF, -78 °C
2) 2.001, -78 °C, 2 h
3) BzCl, -78 °C to r.t.
4) Me2N(CH2)3OH
OTBSO H H
PhO2S
OBz
OTBSO H
SmI2HMPA
THF, -78 °C
0-61 % over 2 steps
E/Z: >95:1
H
1) n-BuLi, THF, -78 °C
2) 2.001, -78 °C, 2 h
OTBSO H H
PhO2S
OR SmI2HMPA
THF, -78 °C
2.031 2.040
2.041, R=H
2.040, R=Bz
2.041Bz2OSc(OTf)3CH3CN, r.t.
52-67 % over 3 steps
E/Z >95:1
Path 1
Path 2
Scheme 19 
The remaining TBS group was removed with TBAF and the corresponding 
alcohol was transformed into PT-sulfone 2.042 (scheme 20). 
Scheme 20  
                                                     
18 a. I. E. Markó, F. Murphy, S. Dolan, Tetrahedron Lett.1996, 37, 2089-2092 b. I. 
E. Markó, F. Murphy, L. Kumps, A. Ates, R. Touillaux, D. Craig, S. Carballares, S. 
Dolan, Tetrahedron 2001, 57, 2609-2619.  
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In parallel, alcohol 2.030 was oxidized into aldehyde 2.043 which, due to its 
lack of stability, was directly reacted with sulfone 2.042 under standard 
Julia-Kociensky olefination conditions. Jerangolid D 2.029 was isolated in 
54 % yield and >95:1 E/Z selectivity (scheme 21). 
 
Scheme 21 
In summary, the first total synthesis of jerangolid D was accomplished in 22 
steps (12 steps in the longest linear sequence) and 6.1 % overall yield 
starting from epoxide 2.020, Roche ester and ethyl lactate. 
II.2. Synthesis of lactone 2.030 
A second strategy for the synthesis of the left-hand lactone of jerangolid D 
was developed in our group a short time after the publication of the first total 
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synthesis19. This second approach is based upon a retrosynthesis using ring-
closing metathesis (RCM) as the key step (scheme 22). 
 
Scheme 22 
The synthesis began with the selective reduction of the C6 ester of dimethyl 
malate 2.045. The corresponding primary alcohol was then protected with a 
TBS group (scheme 23). 
 
Scheme 23 
The free alcohol was transformed into acetal 2.044 by PPTS-catalyzed trans-
acylation of methacrolein diethyl acetal20. A subsequent Takai-Utimoto 
olefination21 yielded the desired precursor for RCM in 85 % yield (scheme 
24). 
                                                     
19 J. Pospíšil, I. E. Markó, Tetrahedron Lett. 2008, 49, 1523-1526.  
20 J. A. VanAllan, Org. Synth. 1952, 32, 5-8 
21 T. Okazoe, K. Takai, K. Oshima, K. Utimoto, J. Org. Chem. 1987, 52, 4410-4412.  
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Scheme 24 
After numerous optimization studies, the ring was closed using Grubbs-II 
catalyst (GC-2) (10 mol %) at room temperature with excellent yield. The 
corresponding acetal was directly oxidized with PCC to afford the protected 
lactone 2.047 (scheme 25). 
 
Scheme 25 
Final removal of the TBS group furnished the left-hand part 2.030 of 
jerangolid D in 81 % yield (scheme 26). 
 
Scheme 26 
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In our project, we are interested in the synthesis of new analogues of 
jerangolid D. Based upon the synthesis described in our laboratory and 
detailed above (see II.1), our goal is to operate a series of chemical 
modifications on the three fragments in order to create a set of new 
compounds, similar to jerangolid D, but possessing enhanced stability and 
hopefully, increased activity and lower toxicity. 
The high convergence of our total synthesis enables us to modify at will each 
of these three subunits before connecting them to construct analogues of 
jerangolid D. 
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The main goals of this thesis are to synthesize jerangolid D, as a reference 
sample and to prepare some new analogues, based upon the synthesis 
described in our laboratory. 
As depicted before, jerangolid D can be divided into three fragments: a 
lactone A, an unsaturated central part B and a dihydropyran C (scheme 1). 
Scheme 1 
I. Synthesis of DHP C 
Initially, we shall focus our efforts on the synthesis of DHP 2.001, using the 
methodology previously developed in the lab (vide supra chapter 2).  
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Scheme 2 
Since this dihydropyran is present in ambruticin, as well as in jerangolids 
family, different esters of alcohol 3.001 will be prepared. To mimic both 
families, different vinylic, aromatic and polyenic side-chain esters have been 
chosen (figure 1). 
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Figure 1 
Moreover, it would be interesting to replace the ethyl and the methyl groups 
on the DHP cycle by other substituents. This should be easily accomplished 
by changing the substituents on silyl ether 3.002 (scheme 3).  
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Scheme 3 
Finally, we would like to work on the modifications of the double bond of 
cycle C in order to determine if these functionalities are of importance for its 
biological activity. Some of these structures will serve to assemble 
jerangolid B, E and H and we will try to establish their stereochemistry at 
C14 which is still unknown (see chapter 1, IV.2) (scheme 4). 
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Scheme 4 
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II. Synthesis of lactone A 
Secondly, we will focus on the synthesis of the left-hand lactone of 
jerangolid D, once again employing methodologies that have been developed 
in the group (scheme 5).  
Scheme 5 
The importance of the substituents on the lactone would also be determined. 
Lactones lacking the methyl group (3.010), the methoxy group (3.011) or 
both substituents (3.012) will therefore be synthesised (figure 2). 
 
Figure 2 
III. Central fragment B 
The central fragment could also be modified. We could remove the methyl 
group, inverse its stereochemistry, or add a second one. It could also be 
replaced by a 5-membered spiro cycle (figure 3).  
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Figure 3 
We could also remove one carbon, to form conjugated olefins. Moreover, 
some studies have demonstrated the importance of the cyclopropane ring 
present in ambruticin on the antifungal activity displayed by this natural 
product1. An analogue bearing that cyclopropane could be synthetized in our 
case (figure 4). 
 
Figure 4 
IV. Coupling  
At this stage, in order for our approach to be very powerful and versatile, it 
would be very useful to develop a one-pot methodology to couple the three 
fragments at once. A selective double Julia olefination has been imagined 
and is the object of another thesis currently ongoing in our group.
                                                     
1 V. Michelet, J.-P. Genet, Current Org. Chem. 2005, 9, 405-418.  
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In this chapter, we wish to report the results obtained for the synthesis of the 
dihydropyran moiety 2.001 C present in jerangolid D. However, before 
presenting them, we thought it would be interesting to give an overview of 
the different methodologies employed for the construction of such an 
heterocycle and illustrate it with selected examples from the literature. 
I. Dihyropyrans in the literature 
Substituted pyrans are a common structural motif found in a wide range of 
natural products. The dihydropyran (DHP) skeleton is an especially 
attractive scaffold present in many natural compounds and the olefin 
function is a useful platform for further functionalizations. It is often used as 
a key intermediate in the generation of substituted tetrahydropyrans (THP)1. 
Henceforth, there are many routes described in the literature to construct 
DHPs. In this chapter, we have selected a few approaches that we seemed 
interesting to form these particular cycles. It is important to point out that 
this list is not exhaustive.  
I.1. Hetero Diels-Alder 
The formal hetero-Diels-Alder (HDA) reaction between dienes and carbonyl 
compounds has been an important area of research in asymmetric catalysis. 
Pioneering work in this field was accomplished by Danishefsky who 
described Lewis acid catalyzed cyclocondensations of functionalized dienes 
with unactivated aldehydes in 1982 (scheme 1)2. 
                                                     
1 A. P. Dobbs, S. Martinović, Tetrahedron Lett. 2002, 43, 7055-7057 
2 S. Danishefsky, J. F. Kerwin, S. Kobayashi, J. Am. Chem. Soc. 1982, 104, 358-360 
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Scheme 1 
Since then, there have been many examples in the literature of asymmetric 
HDA reactions between electron rich dienes and/or electron-deficient 
dienophiles3.  
In 1999, the group of Jacobsen developed a new class of asymmetric HDA 
between less nucleophilic dienes bearing fewer than two oxygens and 
unactivated carbonyl compounds. These reactions provide a direct route to 
enantioenriched (2,6)-syn-dihydropyrans.  
Using a chiral chromium catalyst and depending on the counter-anion, they 
were able to access the desired dihydropyrans in high yields, 
diastereoselectivities and enantioselectivities4 (scheme 2). 
                                                     
3 a. M. Bednarski, S. Danishefsky, J. Am. Chem. Soc.1983, 105, 6968-6969. b. H. 
Waldmann, Synthesis 1994, 535-551. c. K. A. Jørgensen, Angew. Chem. Int. Ed. 
2000, 39, 3558-3588. 
4 A. G. Dossetter, T. F. Jamison, E. N. Jacobsen, Angew. Chem. Int. Ed. 1999, 38, 
2398-2400. 
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Scheme 2 
They further used this methodology as a key step in their synthesis of 
FR9014645 (scheme 3) and Ambruticin6 (scheme 4). 
 
Scheme 3 
                                                     
5 C. F. Thompson, T. F. Jamison, E. N. Jacobsen, J. Am. Chem. Soc. 2000, 122, 
10482-10483. 
6 P. Liu, E. N. Jacobsen, J. Am. Chem. Soc. 2001, 123, 10772-10773. 
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Scheme 4 
Removal of the triethylsilyloxy group in 4.014 by hydroboration and acid-
catalyzed elimination gave access to the right-hand part of ambruticin 1.017. 
This subunit is also present in jerangolid D 2.029. 
Other groups applied this methodology in their synthesis of natural products, 
such as the group of Paterson in their approach to (-)-Laulimalide7 (scheme 
5).  
                                                     
7 I. Paterson, C. De Savi, M. Tudge, Org. Lett. 2001, 3, 3149-3152. 
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Scheme 5 
I.2. Prins and Silyl-Prins cyclization 
The Prins cyclization provides a powerful access to tetrahydropyran 
derivatives. In its simplest case, it involves a homoallylic alcohol 4.018, an 
aldehyde 4.019 and a Lewis acid (scheme 6). There are many examples in 
the literature where a Prins cyclization is used for the synthesis of 
tetrahydropyrans8.  
 
Scheme 6 
In this work, we are more interested in dihydropyrans so we will focus on 
the variants of the Prins cyclisation that lead to DHP’s. 
If a vinylsilane, a vinylstannane or an allylsilane is used as a terminating 
group instead of a simple alkene, the transformation will lead to the 
formation of dihydropyrans. It has been called “silyl-Prins cyclisation”. 
                                                     
8 For a recent review, see: C. Olier, M. Kaafarani, S. Gastaldi, M. P. Bertrand, 
Tetrahedron 2010, 66, 413-445.  
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The group of Speckamp reported the cyclization of a vinylsilane onto an 
oxocarbenium ion in 1997. Depending upon the geometry of the vinylsilane, 
the cis/trans ratio varies. The Z-isomer gives the syn-dihydropyran with 
remarkably high diastereoselectivity (scheme 7)9. 
 
Scheme 7 
The group of Dobbs has extended this methodology to various aldehydes and 
epoxides. They have shown that using InCl3 as a Lewis acid allows the 
formation of dihydropyrans in good yields and excellent diastereoselectivity 
at room temperature (scheme 8). BF3-etherate or TMSOTf also lead to high 
yields but require lower temperatures10.  
 
Scheme 8 
In her synthesis of the spiro moiety of spirolides B and D, Brimble used the 
silyl-Prins cyclization to form the dihydropyran present in these natural 
                                                     
9 C. Semeyn, R. H. Blaauw, H. Hiemstra, W. N. Speckamp, J. Org. Chem. 1997, 62, 
3426-3427. 
 
10 A. P. Dobbs, S. Martinović, Tetrahedron Lett. 2002, 43, 7055-7057. 
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products. Alcohol 4.025 reacted with acetal 4.026 to give 4.027 as a mixture 
of cis and trans isomers in a ratio exceeding 4:1 (scheme 9)11.  
 
Scheme 9 
It has recently been shown that the use of vinylstannanes instead of 
vinylsilanes also leads to the formation of syn-dihydropyrans in high yields 
in the presence of TMSOTf. The use of optically pure starting material 
produced optically pure DHPs without racemization (scheme 10) 12. 
 
Scheme 10 
Allylsilanes have also been used to form dihydropyrans. For example, the 
group of Roush wanted to synthesise trans-DHP by reacting allylsilane 
4.030 with different aldehydes (scheme 11).  
                                                     
11 K. Meilert, M. A. Brimble, Org. Lett. 2005, 7, 3497-3500. 
 
12 M. Dziedzic, B. Furman, Tetrahedron Lett. 2008, 49, 678-681 
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Scheme 11 
Despite their predictions based on the stereoelectronic effects of the TMS 
group, only cis-dihydropyrans were isolated (scheme 12). Based on their 
results, they explain that all of the intramolecular allylation reactions leading 
to the preferential formation of the 2,6-cis-dihydropyrans proceed with high 
stereochemical fidelity via boat-like transition states13. 
 
Scheme 12 
Most recently, Saikia’s group developed a methodology using the Prins 
cyclisation that doesn’t need the presence of a vinyl- or an allyl-silane. The 
use of acrylyl enol ethers in the presence of TMSOTf in DCM allows the 
formation of syn-dihydropyrans stereo- and regioselectively in good yields14 
(scheme 13). 
                                                     
13 W. R. Roush, G. J. Dilley, Synlett 2001, 955-959. 
14 S. Sultana, K. Indukuri, M. J. Deka, A. K. Saikia, J. Org. Chem. 2013, 78, 12182-
12188. 
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Scheme 13 
Another interesting example comes from the group of Li who developed a 
tandem allylation-Prins cyclization to form symmetrical syn-dihydropyrans 
(scheme 14). The reaction is promoted by InCl3 and works only with 
aliphatic aldehydes15. 
 
Scheme 14 
I.3. ISMS 
When the alcohol moiety present on the allyl- or vinyl-silane is protected 
with a silyl group, the reaction is called intramolecular silyl-modified 
Sakurai cyclisation (ISMS). This reaction was developed in our group in the 
early 1990s. It enables the formation of exo-methylene cis-tetrahydropyrans 
or syn-dihydropyrans in good yields and diastereoselectivity. 
During his studies towards the total synthesis of ambruticin, D.J. Bayston 
developed this ISMS condensation of vinyl silanes with aldehydes and 
                                                     
15 G. S. Viswanathan, J. Yang, C.-J. Li, Org. Lett. 1999, 1, 993-995. 
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acetals and showed that it can also lead to the formation of dihydropyrans 
bearing a trisubstituted double bond (scheme 15)16.  
 
Scheme 15 
By placing two substituents on the annelating agent, and depending upon 
their relative stereochemistry, trans-DHP can also be prepared using the 
same methodology17.  
 
Scheme 16 
Based on the same principle, the group of Panek used a protected 
homoallylic alcohol bearing an allylsilane. By varying the stereochemistry, 
they were able to access the eight possible different stereoisomers of the 
DHP. 
The syn-annelating agent 4.044 leads to the cis-trans diastereomer 4.045 
whilst the anti-silane 4.046 gives rise to the trans-trans diastereomer 4.047 
18 (scheme 17).  
                                                     
16 I. E. Markó, D. J. Bayston, Tetrahedron 1994, 50, 7141-7156. 
 
17 I. E. Markó, A. P. Dobbs, V. Scheirmann, F. Chellé, D. J. Bayston, Tetrahedron 
Lett. 1997, 38, 2899-2902.  
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CO2Me
SiMe2Ph
OTMS
TMSOTf
CH2Cl2
O
Ph+ OMeO2C Ph85 %
dr: C2-C6 syn/anti 25:1
CO2Me
SiMe2Ph
OTMS
TMSOTf
CH2Cl2
O
Ph
+
OMeO2C Ph
87 %
dr: C2-C6 syn/anti <1:30
4.044 4.045
4.046 4.047
 
Scheme 17 
Finally, more recent studies by the same group showed that the use of (Z)-
crotylsilanes 4.048 and 4.050 affords the trans-cis adduct 4.049 and the all 
cis-derivative 4.051 respectively19 (scheme 18). 
                                                                                                                            
18 H. Huang, J. S. Panek, J. Am. Chem. Soc. 2000, 122, 9836-9837. 
 
19 I. E. Wrona, J. T. Lowe, T. J. Turbyville, T. R. Johnson, J. Beignet, J. A. Beutler, 
J. S. Panek, J. Org. Chem. 2009, 74, 1897-1916. 
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CO2Me
SiMe2Ph
OTMS
TMSOTf
CH2Cl2+ OMeO2C OBn
66 %
dr : 12:1
O
OBn
4.048 4.049
CO2Me
SiMe2Ph
OTMS
TMSOTf
CH2Cl2+ OMeO2C OBn
60 %
dr: 15:1
O
OBn
4.050 4.051
 
Scheme 18 
More recently, the group of Hinkle developed a BiBr3-initiated 
intermolecular addition followed by ISMS cyclisation with cis-
diastereoselectivity20 (scheme 19). 
R1
TMS
OTES
+ R2CHO
BiBr3 (5 %)
CH2Cl2r.t., 12 h
OR1 R2
11 examples
47-98 %R1 = H, C5H11, Ph
R2 = alkyl, aryl
4.052 4.053
 
Scheme 19 
Further studies showed that when the alcohol is not protected and the 
reaction is carried out with an epoxide, BiBr3 is not appropriate anymore to 
facilitate the rearrangement of the epoxide to the corresponding aldehyde, 
thus no reaction occurs. In contrast, bismuth triflate promoted the reaction to 
                                                     
20 a. Y. Lian, R. J. Hinkle, J. Org. Chem. 2006, 71, 7071-7074. b. R. J. Hinkle, Y. 
Lian, L. C. Speight, H. E. Stevenson, M. M. Sprachman, L. A. Katkish, M. C. 
Mattern, Tetrahedron 2009, 65, 6834-6839. 
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afford the desired dihydropyrans. More detailed studies showed that an 
initial Lewis acid/base interaction between Bi(OTf)3 and the corresponding 
substrates generates TfOH in situ, which in turn catalyzed the reaction21 
(scheme 20).  
 
Scheme 20 
I.4. Olefin ring closing metathesis 
Olefin metathesis is a unique carbon skeleton redistribution in which carbon 
carbon double bonds are rearranged in the presence of metal carbene 
complexes. Since its discovery, it has been widely used in organic synthesis 
for the formation of C-C bonds22. This transformation has been applied to 
the synthesis of various dihydropyrans and a few examples are depicted 
below.  
The group of Mulzer used this approach for the formation of the 
dihydropyran present in Laulimalide. Addition of a minimum amount of 
                                                     
21 R. F. Lambert, R. J. Hinkle, S. E. Ammann, Y. Lian, J. Liu, S. E. Lewis, R. D. 
Pike, J. Org. Chem. 2011, 76, 9269-9277. 
 
22 For a review, see: R. H. Grubbs, S. Chang, Tetrahedron 1998, 54, 4413-4450.  
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Grubbs I catalyst provided the desired dihydropyran 4.058 in an excellent 94 
% yield23 (scheme 21). 
 
Scheme 21 
The dihydropyran 4.060 was also prepared using Grubbs I catalyst in good 
yield. This adduct is a key intermediate in the synthesis of the bioactive 
natural product cacospongionolide B24 (scheme 22). 
 
Scheme 22 
Ring-closing metathesis has also been used in our laboratory for the 
synthesis of jerangolid D (see chapter II and III). Repeating this reaction was 
the starting point of this thesis. 
                                                     
23 J. Mulzer, M. Hanbauer, Tetrahedron Lett. 2000, 41, 33-36. 
 
24 M. de Rosa, A. Solladié-Cavallo, A. Scettri, Tetrahedron Lett. 2000, 41, 1593-
1596. 
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II. Results 
As presented in the objectives, we started our work by attempting to 
reproduce the synthesis that was developed in our laboratory and applying 
this route to the synthesis of various analogues of DHP 2.025. In this part, 
we will first present the synthesis of different substrates, followed by our 
results for the SMS reaction and the end of the sequence. As we encountered 
some problems with this approach, we will then discuss the solutions we 
employed to reach our goal. 
II.1. SMS + RCM 
As a reminder, the original sequence is described in scheme 23. 
 
Scheme 23 
II.1.1. Substrates synthesis 
In order to carry out the SMS reaction, aldehyde 2.035 and silyl ether 2.036 
had to be synthesised. However, for stability reasons, aldehyde 4.061 
bearing a TBDPS protecting group was synthetized and used instead of 
2.035 which bears a TBS protecting group. Moreover, silyl ether 2.036 was 
prepared in its racemic version in order to simplify that synthetic step. Two 
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other silyl ethers were prepared as well to test them in the reaction and form 
some new analogues. 
II.1.1.1. Synthesis of aldehyde 4.061 
Aldehyde 4.061 can be prepared in two steps starting from commercially 
available (S)-ethyl lactate 4.062 in excellent yields (scheme 24)25.  
Scheme 24 
II.1.1.2. Synthesis of racemic silyl ether 2.036 
Silyl ether 4.066, which is the racemic version of 2.036, was synthesised in 
two steps by the addition of ethyl Grignard to methacrolein26 followed by 
alcohol silylation27 in very good yields (scheme 25).  
 
Scheme 25 
The same conditions were used with acrolein to afford silyl ether 4.069 in 
excellent yields (scheme 26). 
                                                     
25 a.Y. Takashima, Y. Kaneko, Y. Kobayashi, Tetrahedron 2010, 66, 197-207. b. Jiri 
Pospisil, PhD thesis, UCL 2006. 
26 J. Cossy, D. Bauer, V. Bellosta, Tetrahedron 2002, 58, 5909-5922. 
27 L. Baudrenghien, Master thesis, UCL 2009. 
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Scheme 26 
Addition of propyl Grignard to acrolein, followed by silylation using the 
same conditions as above, delivered silyl ether 4.072 in excellent yields 
(scheme 27).  
 
Scheme 27 
II.1.2. SMS reaction 
With the desired substrates in hand, the SMS reaction was carried out using 
the conditions that were described in our group (scheme 28). 
O TMSTMSO
OTBDPS + +
O
OTBDPS
45 %
TMSOTf
DCM, -78 °C, 5 h
4.063 4.066 2.037
4.073a
O
OTBDPS
4.073b
+
 
Scheme 28 
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The proposed mechanism for the SMS reaction is described in scheme 29. It 
is believed that oxonium 4.078 is generated under the reaction conditions. 
The addition of the allylsilane 2.037 is then believed to proceed according to 
the Felkin-Anh transition state 4.079, thus delivering the syn adduct. 
O
OTBS
H
TMS-OTf O
OTBS
H
TMS
+ OTMS O
OTBS
OTMS
TMS
TfO
O
OTBS
OTMS
TMS-OTf
O
OTBS
OTMS TMS
O
OTBS
TMS
2.037
2.035 2.036
O
OTBS
2.038
OTBS
Me H
O HR
re
4.074 4.075
4.076
4.077
4.078
4.079
 
Scheme 29 
In our case, since the silyl ether 4.066 is racemic, we were expecting to form 
the two syn-diastereomers. Indeed, compounds 4.073a and 4.073b were 
isolated in a 1:1 ratio. However, a much lower yield was afforded.  
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The mixture of diastereomers 4.073 was next engaged in the rest of the 
sequence. Ring closing metathesis afforded the corresponding dihydropyran 
which was directly deprotected. This last step proved to be quite hard, taking 
five days and proceeding in poor yields (scheme 30). 
Scheme 30  
The reaction was then applied to substrate 4.069 using the same conditions 
as above (scheme 31). 
Scheme 31  
We were disappointed to see the formation of 4 diastereomers in only 22 % 
yield. The same observation was made with substrate 4.072 (scheme 32). 
 
Scheme 32  
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In view of these disappointing preliminary results, we decided to go back 
and try to access the enantiomerically pure silyl ether in order to reproduce 
exactly the results described previously in the laboratory. The structure of 
the silyl ether 4.066 might indeed have a big influence on the 
disatereoselectivity of the reaction.  
II.1.3. Attempts to obtain allylic alcohols 
enantiomerically pure 
II.1.3.1. Esterification 
The first option was to esterify the allylic alcohol with an enantiopure acid in 
order to form two diastereomers, which could be separated by column 
chromatography and then hydrolysed to furnish the desired enantiomerically 
pure allylic alcohols. The following reactions were performed using racemic 
silyl ether 4.068 because it is cheaper to access and would then be 
transposed to 4.065 when the right conditions were found. 
The first attempt was the coupling with ibuprofen. The reaction afforded the 
corresponding ester in good yield28 (scheme 33). Unfortunately, the two 
diastereomers can not be separated on silica gel column chromatography.  
 
Scheme 33 
                                                     
28 B. Linclau, A. J. Boydell, R. S. Timofte, K. J. Brown, V. Vinader, A. C. 
Weymouth-Wilson, Org. Biomol. Chem. 2009, 7, 803-814. 
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The second partner that was tried was naproxen. This time, the desired ester 
was isolated in moderate yield. Alas, once again, we were not able to 
separate the two diastereomers (scheme 34). 
OH
O
ODCC, DMAPnaproxen
DCM, r.t., 20 h
4.068 4.085
46 %
MeO
 
Scheme 34 
A final attempt was made using benzylated lactic acid 4.082 which can be 
synthesized in two steps from (S)-ethyl lactate in good yields (scheme 35).  
 
 
 
Scheme 35 
Two different allylic alcohols were coupled with acid 4.088 in moderate 
yields but unfortunately, this strategy failed to deliver the separated 
diastereomers (scheme 36).  
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Scheme 36 
At this point, we realized that to be successful, this approach would require 
the generation of a large number of esters without ever being sure of finding 
out the right one. Therefore, we decided to abandon this separation method 
and turn our attention to a kinetic resolution instead. 
II.1.3.2. Kinetic resolution 
II.1.3.2.1. Botanochemistry 
We decided to apply a methodology that was developed in our laboratory 
and that we nicknamed “botanochemistry”. This method employs pieces of 
vegetables or fruits to perform various asymmetric transformations, such as 
enantioselective reductions and ester hydrolysis. Among the vegetables 
tested, beetroots were found to be particularly suited for the kinetic 
resolution of benzylic alcohols29. To test this method, the corresponding 
acetate was initially formed in quantitative yield (scheme 37). 
                                                     
29 A. Vandenberghe, PhD thesis, UCL 2012. 
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Scheme 37 
Acetate 4.085 was then dissolved in EtOH at pH 7 and pieces of beetroots 
were added (scheme 38). The reaction was stirred at 23 °C and its progress 
was monitored by chiral gas chromatography. 
  
Scheme 38 
To our disappointment, the two peaks corresponding to the acetate substrates 
decreased at the same rate as the two signals for the corresponding alcohols 
appeared. Unfortunately, this system turned out to be non selective for our 
substrate.  
II.1.3.2.2. Sharpless resolution 
Our last attempt was to use the Sharpless kinetic resolution which is well 
documented and is particularly efficient for allylic alcohols25,30. This precise 
reaction had been done on a large scale in our laboratory a few years ago. 
Unfortunately, analysis by chiral gas chromatography showed that the 
                                                     
30 V. S. Martin, S. S. Woodard, T. Katsuki, Y. Yamada, M. Ikeda, K. B. Sharpless, 
J. Am. Chem. Soc. 1981, 103, 6237-6240. 
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resolution did not proceed and the recovered alcohol was still racemic 
(scheme 39). 
 
Scheme 39 
In fact, it transpired that one of the components of the Sharpless catalytic 
mixture was ineffective. The kinetic resolution was successfully repeated 
later on but in the meantime, we had decided to move on and to use the 
racemic silyl ether again. However, this time we would use the TBS-
protected aldehyde as the coupling partner in order to ease the deprotection 
step which was rather tricky. 
II.1.4. SMS with TBS-protected aldehyde 
II.1.4.1. Synthesis of aldehyde 2.031 
Thus, (S)-ethyl lactate 4.055 was protected with a TBS group and the ester 
function was reduced to the corresponding aldehyde with Dibal-H in 
excellent yields3132 (scheme 40). 
                                                     
31 G. D. Joly, E. N. Jacobsen, Org. Lett. 2002, 4, 1795-1798.  
32 It is important to remove the last traces of acid after the work-up and to prepare 
the aldehyde immediately before using it in order to avoid any epimerization. 
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Scheme 40 
II.1.4.2. SMS 
Once again, the reaction was carried out using the same previous conditions 
(scheme 41).  
Scheme 41  
We were delighted to find out that, in this case, the two syn-diastereomers 
4.095a and 4.095b were the major ones (ratio syn/anti: 8:1). Unfortunately, 
the yield was still quite low. We were also rather surprised to isolate some of 
the symmetric acetal 4.096. Its presence can partially explain the moderate 
yield of the reaction (figure 1). 
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O
OTBS
O
4.096  
Figure 1 
At this point, we tried to optimize the reaction conditions in order to increase 
the yield. Initially, the reaction was followed by chiral gas chromatography 
during 24 hours. After that time, the allylsilane and the aldehyde were 
consumed. The diastereomers 4.095 were isolated in 24 % yield and some 
silyl ether 4.066 was recovered. 
Special distillation of the dichloromethane33 coupled with enhanced 
purification of allylsilane 2.037 enabled the yield to increase to 39 %. Once 
again, acetal 4.096 was isolated in 23 % yield (ratio 4.095a,b/4.096 = 1:0.6). 
Some silyl ether 4.066 was recovered as well.  
Since aldehyde 2.035 is never recovered, we employed an excess of it at the 
onset of the reaction. Unfortunately, no improvement could be observed and 
the product was isolated in 27 % yield.  
One possible explanation for the low yield of this reaction relies on a 
competitive reaction that would consume both the aldehyde and the 
allylsilane. In every reaction they disappear whilst the silyl ether is still 
present. Indeed, a Sakurai addition of the allylsilane to the aldehyde would 
be a possibility, but this adduct 4.097 has never been isolated (scheme 42). 
                                                     
33 Special DCM is washed 4 times with concentrated sulfuric acid then with water, 
dried over calcium chloride and finally distilled from CaH2. 
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Scheme 42 
At this stage, we have no rationalization to offer. 
We then decided to employ other triflates as Lewis acids. Bi(OTf)3 was first 
attempted, unfortunately no reaction was observed either at -78 °C or at 
room temperature (scheme 43).  
O
TMS
TMSO
OTBS + + O
OTBS
Bi(OTf)3
DCM, -78 °C to r.t., 18 h
2.035 4.066 2.037 4.095
Scheme 43 
Suprisingly, when using Zn(OTf)2, aldehyde 2.035 and acetal 4.096 were 
observed suggesting that this Lewis acid is much milder than TMSOTf 
(scheme 44). After purification, the acetal 4.096 was isolated in moderate 
yield. 
 
 Scheme 44 
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In light of this result, we decided to access the desired adduct 4.095 in two 
steps, using Zn(OTf)2 to form the acetal and then submit this compound to 
the action of a stronger Lewis acid in the presence of allyltrimethylsilane.  
Our first attempt was to add allylsilane and TMSOTf directly to the reaction 
mixture, without isolating the acetal. After 48 hours, 4.096 was still the 
major product (scheme 45). No Sakurai reaction appears to be occuring. 
 
Scheme 45 
A particularly puzzling observation stems from the attempted preparation of 
acetal 4.096 by the direct reaction between 2.035 and 4.066 catalyzed by 
zinc triflate. Indeed, in the absence of allyltrimethylsilane, no acetal 4.096 
could be detected. After 24 hours, 1.1 equivalents of allylsilane were added. 
The acetalisation then proceeded smoothly and after another 24 hours, the 
condensation stopped since the silyl ether was totally consumed. Acetal 
4.096 was then isolated in 32 % yield (scheme 46).  
 
Scheme 46 
At the moment, we have no plausible explanation to offer that accounts for 
the requisite presence of the allylsilane in this ketalisation reaction. 
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Our last attempt was to stir together aldehyde 2.031 and silyl ether 4.066 in 
the presence of TMSOTf at 0 °C (scheme 47). In this case, the temperature is 
too high and only degradation of the aldehyde was observed. 
 
Scheme 47 
Despite the low yield, we were able to isolate the desired product 4.090 and 
to continue the sequence. Ring-closing metathesis, followed by TBAF 
deprotection, yielded dihydropyran 4.075 in 79 % over two steps (scheme 
48). At this point, the two diastereomers could easily be separated by silica 
gel column chromatography. 
 
Scheme 48 
At this point, in view of the disappointing results obtained with the direct 
three-components SMS reaction or the acetal formation, and since the 
optimization and study of this reaction was not the main goal of this thesis, 
we decided to move on to another approach and synthetize our fragments via 
a different sequence. 
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II.2. ISMS 
The approach we decided to follow is based on another methodology which 
was developed in our lab in the early 1990s and was introduced previously in 
this chapter (vide supra I.3). The key step is an ISMS cyclization. In his 
studies towards the total synthesis of ambruticin, Dr. D. Bayston developed 
the sequence described in scheme 49 to prepare the fully functionalized 
right-hand fragment of the natural product34. 
Scheme 49  
Based on these results, we decided to use this sequence and replace aldehyde 
4.100 by aldehyde 2.035 (scheme 50). After deprotection, the very same 
DHP 4.099 we are trying to synthesise from the beginning should be 
obtained.  
                                                     
34 I. E. Markó, D. J. Bayston, Synthesis 1996, 297-304. 
DIHYDROPYRAN SYNTHESIS  113 
 
 
Scheme 50 
 
II.2.1. Substrates synthesis 
Propargylic anion equivalents such as organometallic reagents 4.105 (M=Li 
or MgX) provide an important route to acetylenic compounds (figure 2). 
C
R2
R3
R3 R1
M
R1
R2
M
4.105a 4.105b   
Figure 2 
However, their use is limited by the tendency of these ambident nucleophiles 
to react with electrophiles to produce both allenic and acetylenic products. 
For example, when reacted with aldehydes or ketones, they afford a mixture 
of homopropargylic and homoallenic alcohols35. Transmetallations with 
several metals (e.g. Sn36, Zn37, Ce38, Cu39,...) have been described in the 
                                                     
35 R. L. Danheiser, D.J. Carini, J. Org. Chem. 1980, 45, 3927-3929. 
36 J. A. Marshall, J.F. Perkins, M. A. Wolf, J. Org. Chem. 1995, 60, 5556-5559. 
37 J. A. Marshall, N. D. Adams, J. Org. Chem. 1998, 63, 3812-3813. 
38 U. Groth, C. Kesenheimer, J. Neidhöfer, Synlett 2006, 12, 1859-1862. 
39 a. E. Vedejs, W. H. Dent, D. M. Gapinski, C. K. McClure, J. Am. Chem. Soc. 
1987, 109, 5437-5446. b. K. R. Fandrick, D. R. Fandrick, J. T. Reeves, J. Gao, S. 
Ma, W. Li, H. Lee, N. Grinberg, B. Lu, C. H. Senanayake, J. Am. Chem. Soc. 2011, 
133, 10332-10335. 
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literature to displace the equilibrium and form preferably the homoallenic 
reagent 4.105b, thus allowing the selective synthesis of homopropargylic 
alcohols. 
This new sequence starts with the formation of homopropargylic alcohol 
4.109. Deprotonation of trimethyl(prop-1-yn-1-yl)silane 4.096 with tbutyl 
lithium, followed by exchange with copper, forms the corresponding 
allenylcuprate 4.100. The latter is then added onto the aldehyde to access the 
desired homopropargylic alcohol 4.101 selectively (scheme 51). 
 
Scheme 51 
Addition of in situ deprotonated 4.106 to aldehyde 2.035 led to the formation 
of adduct 4.110 in moderate yield (scheme 52).  
 
Scheme 52 
It appears that some of the aldehyde undergoes loss of the silicon protecting 
group under the reaction conditions. Therefore, we decided to prepare the 
benzylated aldehyde 4.111 which should not undergo deprotection during 
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this transformation. It was synthetized in two steps from (S)-ethyl lactate in 
excellent yields40 (scheme 53).  
 
 
Scheme 53 
Addition of the anion of 4.106, in the presence of copper iodide, leads to the 
desired product 4.112 in only 45 % yield as a mixture of two epimers of the 
newly formed chiral center (ratio = 1:1) (scheme 54). 
 
Scheme 54 
It transpires that the addition of the allenylcopper reagent to 4.108 is a rather 
slow process and a longer reaction time is required to reach completion. 
Thus, the yield of 4.112 could be increased to 74 % by stirring the reaction 
for 3 hours instead of 20 minutes. A change in the work-up also improved 
the process. 
                                                     
40 Fujisawa Pharmaceutical Co., Ltd. Patent: US6359145 B1, 2002. b. D. Enders, S. 
von Berg, B. Jandeleit, Org. Synth. 2002, 78, 177. 
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Protection of the free alcohol with DHP yields 4.113 and 4.114 which are 
ready for the reduction of the triple bond to the corresponding (Z)-double 
bond (scheme 55). 
OH
OR
TMS
OTHP
OR
TMS
R = TBS 4.110
R = Bn 4.112
DHP, PPTS
DCM, 24h, r.t.
R = TBS 4.113
R = Bn 4.114
quant.
 
Scheme 55 
Different methods to transform an alkyne to the corresponding substituted 
(Z)-alkene are described in the literature. The major ones are described in the 
next section. 
II.2.2. From alkynes to substituted (Z)-alkenes 
The needed transformation at this point is the conversion of alkyne 4.115 
into the corresponding substituted (Z)-vinylsilane 4.116 (scheme 56). 
 
Scheme 56 
The first method that could be used for such a transformation is the 
hydroboration of the C-C triple bond41 followed by transmetalation and 
carbodemetalation or halogenation42.  
                                                     
41 N. G. Bhat, C. P. Aguirre, Tetrahedron Lett. 2000, 41, 8027-8031. 
42 H. C. Brown, T. Hamaoka, N. Ravindran, J. Am. Chem. Soc. 1973, 17, 5786-5788. 
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For example, the group of Utimoto described the hydroboration of 1-
trimethylsilyl-1-octyne with excess dicyclohexylborane to give vinylborane 
4.110 regioselectively. The resulting mixture was treated with methyl 
lithium followed by methyl iodide to afford vinylsilane 4.118 in excellent 
yield (scheme 57)43. 
R TMS R TMS
B
4.115 4.117
R = n-C6H13 94 % yieldR = CH2OCMe2OMe 80 % yield
BH
2
2
H 1. MeLi
2. CH3I
Me
TMS
H
R
4.118
>99 % Z
Scheme 57 
A more recent example described a copper(I) iodide-catalyzed transfer of 1-
(trimethylsilyl)-1-alkenyl group from boron to tin to form compound 4.121 
in excellent yield (scheme 58). 
Scheme 58 
 Further functionalization either through iodination or palladium-catalyzed 
cross-coupling reactions allows the synthesis of trisubstituted vinylsilanes 
with high stereospecificity and excellent yields (scheme 59)44.  
                                                     
43 K. Uchida, K. Utimoto, H. Nozaki, J. Org. Chem. 1976, 17, 2941-2942. 
44 M. Hoshi, K. Shirakawa, K. Takeda, Synlett 2001, 3, 403-405. 
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Bu3Sn
TMS
H
C4H9
4.122
I2
-15 °C to r.t.
I
TMS
H
C4H9
4.12363 %
Bu3Sn
TMS
H
C4H9
4.122
I
+
Pd(PPh3)4 (10 mol %)CuCl (5 eqs), LiCl (6 eqs)
DMSO, 60 °C, 24 h TMS
H
C4H9
4.124493 %  
Scheme 59 
A second option is to use the hydrozirconation reaction employing Schwartz 
reagent. When applied to silyl acetylenes, this transformation has been 
shown to proceed with good levels of regio- and stereoselectivity to give the 
α-silyl alkenyl zirconium complexes45. Iodination of these complexes allows 
the formation of 1-iodo-(trimethylsilyl)-1-alkenes such as 4.126 in excellent 
yield which can further be transformed using, for example, palladium(0)-
catalyzed cross-coupling reactions (scheme 60)46. 
BnO
TMS
Me
1. Cp2Zr(H)Cl, THF, 55 °C, 1 h
2. I2, CH2Cl2, r.t., 15 min.
BnO
Me
I
TMS
87 %4.125 4.126  
Scheme 60 
Hydroalumination, which has been extensively studied by Eisch and 
Zweifel47, is another option. Hydroalumination of (1-alkynyl)silanes with 
Dibal-H in ether solvents proceeds in a stereo- and regiospecific manner to 
                                                     
45 X. H. Zhu, W. X. Zheng, W. X. Huang, Synth. Commun. 1998, 78, 4165-4170. 
46 A. Arefolov, N. F. Langille, J. S. Panek, Org. Lett. 2001, 21, 3281-3284. 
47 a. J. J. Eisch, W. C. Kaska, J. Am. Chem. Soc. 1966, 88, 2213. b. G. Zweifel, C. C. 
Whitney, J. Am. Chem. Soc.1967, 89, 2753. 
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afford ((Z)-1-alumino-1-alkenyl)silanes which can then be halogenated or 
complexated with methyl lithium and subsequently alkylated48. 
For example, alkyne 4.127 reacted with Dibal-H to give aluminosilane 4.128 
which was treated in situ with iodine to furnish compound 4.129 in excellent 
yield (scheme 61)49. 
 
Scheme 61 
As planned earlier, we decided to use the hydroalumination reaction of the 
internal alkyne, followed by an in situ methylation, to access the (Z)-
vinylsilane needed for the ISMS cyclisation. Unfortunately, this simple 
sequence turned out to be much harder to put in practice. 
II.2.3. Hydroalumination 
Initially, we followed the experimental procedure described by Dr D. 
Bayston. Hence, acetal 4.114 was stirred in Et2O at 0°C and Dibal-H was 
added. The mixture was then brought to room temperature and after 10 
minutes, iodine was added. Ten minutes later, the reaction mixture was 
quenched and worked-up. Disappointingly, only deprotected starting 
material 4.112 was recovered (scheme 62).  
                                                     
48 a. J. J. Eisch, G. A. Damasevitz, J. Org. Chem. 1976, 12, 2214-2215. b. K. 
Uchida, K. Utimoto, H. Nozaki, J. Org. Chem. 1976, 12, 2215-2216. 
49 G. Zweifel, W. Lewis, J. Org. Chem. 1978, 14, 2739-2744. 
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Scheme 62  
Since no addition of Dibal-H took place, we thought that the reaction time 
must have been far too short and thus decided to leave the hydroalumination 
to proceed overnight before adding the iodine (table 1, entry 2). Alas, only 
deprotected starting material was again recovered.  
During his seminal contribution to the hydroalumination of alkynes, Zweifel 
has reported the crucial role played by the solvent. In fact, the 
stereochemistry depends on the solvent used. Selective cis hydroalumination 
is observed when the reaction is carried out in donar solvents (diethyl ether 
or tertiary amines). On the other hand, (E)-1-alumino-1-silyl-1-alkenes 4.132 
are obtained when the reaction medium is a hydrocarbon solvent (scheme 
63)50. 
 
Scheme 63 
It has been suggested that hydroalumination reactions are kinetically 
controlled in a syn manner. Donar solvents decrease the rate of 
hydroalumination but they stabilize the initial syn configuration. In the case 
                                                     
50 G. Zweifel, J. Miller, Org. React. 1984, 32, 375. 
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of non-polar solvents, the anti adduct results from subsequent isomerization 
to the more stable configuration through a second addition of Dibal-H51.  
Therefore, we envisioned that the solvent in which Dibal-H was in solution 
might play a role in the fate of this reaction. Thus, Dibal-H in toluene was 
employed for hydroalumination of 4.114. In this case, a 1:1 ratio of 
deprotected the desired product 4.133 and the starting material was obtained 
(table 1, entry 3). Product 4.133 was isolated after purification in 25 % yield. 
Encouraged by this result, we tried the reaction with Dibal-H in hexane 
which is one of the solvents usually employed in hydroalumination 
reactions52. Unfortunately, it wasn’t fruitful (table 1, entry 4-8).  
 
Entry Dibal-H Eq.
Time 
before 
adding I2 
Results 
1 1M in Et2O 2 10 min. 
Deprotected Starting 
Material 
2 1M in Et2O 2 o.n. 
Deprotected Starting 
Material 
3 1M in Toluene Acros 2 o.n. 
Product/SM 1:1 25 % 
yield 
                                                     
51 J. J. Eisch, M. W. Foxton, J. Org. Chem. 1971, 23, 3520-3526. 
52 H. P. On, W. Lewis, G. Zweifel, Synthesis 1981, 999-1001. 
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4 1M in hexane p.a 2 o.n. Deprotected Starting Material 
5 1M in distilled hexane 2 o.n. Product 14 % yield 
6 1M in hexane Acros 2 o.n. 
Deprotected Starting 
Material 
7 1M in hexane Acros 3 o.n. Small amount product 
8 1M in hexane Acros 4 o.n. Decomposition 
Table 1 
A survey of the literature indicates that, depending upon the structure of the 
alkyne substrate, it is necessary to warm the reaction mixture for the 
hydroalumination to proceed. Therefore, we reacted 4.114 with two 
equivalents of Dibal-H at 50 °C. Gratifyingly, product 4.133 could be 
isolated in 28 % yield. Increasing the amount of Dibal-H to three equivalents 
raised the yield to 40 % (table 2). 
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Dibal-H Eq. Time before adding I2 Temperature Yield 
1M in hexane Acros 2 o.n. 50 °C 28 % 
1M in hexane Acros 3 o.n. 50 °C 40 % 
Table 2 
Though the yield is rather modest, we had some of the desired vinyliodide in 
our hands. It was then decided to explore its conversion into the methylated 
alkene 4.135 before optimizing further the alumination/iodination sequence. 
For that purpose, product 4.133 was reprotected before being subjected to 
methylation in the presence of methyl lithium. Final deprotection afforded 
the thought-after vinylsilane 4.135 in 37 % yield over three steps (scheme 
64). 
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OH
OBn
OTHP
OBn
PPTS, DHP
DCM, r.t., 24 h
TMS
I I
TMS
OTHP
OBn
TMSOH
OBn
TMS
MeLi (1.5 eqs)
THF, r.t.
PPTS, EtOH
60 °C, o.n.
4.133 4.130
4.1344.135 37 % yield over 3 steps  
Scheme 64 
At this point, we had secured the sequence leading to the desired vinylsilane. 
Unfortunately, this route is by far too long, possesses too many 
protection/deprotection steps and overall the yield is rather low. To render 
such an approach truly competitive and efficient, it became mandatory to 
attempt the direct, one-pot transformation of 4.112 to the (Z)-alkyne 4.135. 
In the event, substrate 4.112 was reacted with Dibal-H at 50 °C overnight, 
after which time MeLi was added, followed by MeI at room temperature. 
The reaction was stirred for another night to furnish the desired product 
4.135 in a pleasing 70 % yield (scheme 65).  
OH
OBn
TMS
OH
OBn1) Dibal-H (3 eqs)
Et2O, 50 °C, o.n.
2) MeLi, MeI
r.t., o.n.
TMS
4.112 4.13570 %  
Scheme 65 
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Protection of the free alcohol with a TMS group was attained in excellent 
yield and the corresponding product 4.136 was engaged in the next step 
without any further purification (scheme 66). 
OH
OBn
TMS
TMSCl, Et3N
DCM, 0 °C to r.t., 3 h
OTMS
OBn
4.135 4.136
96 %
TMS
 
Scheme 66 
Cyclisation of adduct 4.136 with propionaldehyde, catalyzed by TMSOTf, 
furnished the desired protected dihydropyran 4.138 in good yield as a 
mixture of the two syn-diastereomers 4.138a and 4.138b in a 1:1 ratio 
(scheme 67). 
O
BnO
TMSOTfcat
DCM, -78 to -30 °C, 2 h
H H
OOTMS
OBn
+
4.136 4.137
4.138a
62 %
O
BnO H H
4.138b
TMS
+
 
Scheme 67 
The ISMS cyclisation is believed to take place through a 6-membered ring 
transition state, as described in scheme 68. The transition state 4.139 in 
which the R substituent of the aldehyde occupies an equatorial position in 
order to decrease the 1,3-diaxial repulsion is preferred, thus leading to the 
formation of syn-dihydropyrans. Moreover, the reaction is favoured with a 
(Z)-vinylsilane. In the case of the (E)-vinylsilane 4.142, the carbocation is 
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not stabilized by the silicon hyperconjugative effect and it can not be 
eliminated easily.  For that to occur,  the chair needs to flip; the substituents 
are then axial disfavouring that transition state. 
 
Scheme 68 
In addition to DHPs 4.138 a and b, an aliphatic product was also isolated. 
Spectroscopic analysis revealed it to possess the over-reduced structure 
4.144 probably originating from the hydroalumination step (figure 3). 
 
Figure 3 
When looking at the 1H NMR of pure product 4.135 (spectrum 1) and the 1H 
NMR of the mixture of 4.135 and 4.144 (spectrum 2), it is not that obvious 
to detect side-product 4.144, especially because both products are composed 
of two diastereomers (figure 4). It is only when pure 4.144 (spectrum 3) was 
isolated after the ISMS step and fully characterized that we realized that this 
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product had been there all along, in a ratio of 28 % to 44 %, as calculated 
from the crude 1H NMR. 
This side-product 4.144 probably originates from a second addition of Dibal-
H to form intermediate 4.13350. This species is probably stable because of 
the possible coordination between the alcohol and the aluminium therefore 
leading to the formation of 4.146 after the acidic work-up (scheme 69). 
Scheme 69 
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Figure 4 
To solve this problem, the number of equivalent of Dibal-H was lowered 
from three to two. This solution eliminated adduct 4.144 but other troubles 
started to appear. As a new bottle of Dibal-H was used, the last one being 
empty, the reaction provided a mixture of protonated and methylated 
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products, 4.147 and 4.135 respectively, which proved to be really difficult to 
separate. 
We found out that the conversion for the mixture of adducts 4.135 and 4.147 
varied between 10 to 23 % with a ratio changing according to the different 
conditions (table 3). Addition of EtMgCl, to deprotonate the alcohol function 
of 4.112 increased the conversion but only adduct 4.147 was isolated. 
 
Conditions 4.135 : 4.147 Conversion in mixture 
3 days 1 : 1 10 % 
10 eqs MeI 0.63 : 1 23 % 
3 eqs MeI freshly distilled 1 : 0.42 17 % 
Addition -78°C 1 : 0.58 20 % 
Addition EtMgCl 0 : 1 54 % 
Table 3 
When employing 3 equivalents of Dibal-H and using a new bottle of MeLi, 
we were dismayed to observe that the conversion stayed again at 22 %, with 
a ratio of 1 : 0.71 in favour of 4.135. Going back to the original conditions 
was even worse and we had to conclude that this bottle of Dibal-H had 
definitely a problem.  
We ordered a new bottle of Dibal-H. In this case, using 4 equivalents of 
MeLi and 5 equivalents of MeI, the conversion was much better, and the two 
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undesired products 4.144 and 4.147 were almost completely suppressed 
(table 4). The conditions in entry 4 were used until the bottle was empty. 
OH
OBn1) Dibal-H
Et2O, 50 °C
2) MeLi (4 eqs)
MeI (5 eqs)
TMS OH
OBn
TMS
H
+
4.135 4.147
4.112 OH
OBn
TMS
4.144
+
 
Entry Conditions 4.135 : 4.147 : 4.144 Conversion in mixture 
1 2.8eqs Dibal-H 1 : 0.2 76 % 
2 3eqs Dibal-H 1 : 0.05 : 0.5  72 % 
3 MeLi/MeI -78°C 1 : 0.1 : 0.45 72 % 
4 1 eq THF 1 : 0.1 : 0.39 70 % 
Table 4 
Unfortunately, when a new bottle was employed again, the reaction stopped 
working and no conversion was observed. 
It thus transpires that this step is not reproducible due to a varying quality of 
the hydroaluminating agent. What exactly is the problem could not be 
determined. It is possible that, depending upon the lot of Dibal-H, some 
impurities are present that inhibit the reaction on our substrate. In any case, 
attempting to optimize this process has taken a lot of time and energy and, 
due to its erratic nature, it was decided to find another alternative. Among 
the various methods known to convert 4.112 to 4.135, we selected the 
hydrozirconation. 
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Before the reproductibility issues started, the sequence using Dibal-H 
afforded the protected DHP 4.138 in 25 % overall yield starting from 
substrate 4.112 (scheme 70). 
 
Scheme 70 
II.2.4. Hydrozirconation 
The process of hydrozirconation was developed by Schwartz in the 70s as a 
highly valued route to functionalized carbon chains53. The reagent, 
Cp2Zr(H)Cl, reacts with alkenes and alkynes at the least hindered position to 
form the corresponding alkyl- and alkenylzirconium derivatives. 
Electrophilic halogenation reagents (e.g., Br2, I2, NBS or NCS,...) react with 
alkyl- and alkenylzirconium complexes to yield the corresponding organic 
halides54 (scheme 71). 
 
                                                     
53 J. Schwartz, J. A. Labinger, Angew. Chem. Int. Ed. 1976, 15, 333-340. 
54 D. W. Hart, T. F. Blackburn, J. Schwartz, J. Am. Chem. Soc. 1975, 3, 679-680. 
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Scheme 71 
The reagent, Cp2Zr(H)Cl, is nowadays commercially available but is quite 
expensive and has a short shelf-life. Two literature procedures for its 
preparation from inexpensive Cp2ZrCl2 were originally available. The first 
one used LiAl(OtBu)3H to reduce zirconocene dichloride but suffered from 
three problems: high cost of the reducing agent; difficulty to isolate the 
product by filtration; overreduction to Cp2ZrH255. The second method 
employed bis (2-methoxyethoxy)aluminium hydride (RED-Al) but Schwartz 
reagent prepared in this manner contained 30 % of sodium chloride and little 
details about the experimental procedure were provided in the paper56.  
Ten years later, the group of Buchwald reported an experimentally simple 
procedure for the preparation of Schwartz’s reagent on large scale which 
does not need expensive reducing agents. They discovered that the use of 
filtered solutions of LiAlH4 in ether simplified product isolation and that 
Cp2ZrH2 could be rapidly converted to Cp2Zr(H)Cl by reaction with 
methylene chloride (scheme 72) 57. 
                                                     
55 P. C. Wailes, H. Weigold, J. Organomet. Chem. 1970, 24, 405. 
56 D. B. Carr, J. Schwartz, J. Am. Chem. Soc. 1979, 101, 3521-3531. 
57 S. L. Buchwald, S. J. LaMaire, R. B. Nielsen, B. T. Watson, S. M. King, 
Tetrahedron Lett. 1987, 28, 3895-3898. 
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Scheme 72 
Unfortunately, the issue of stability over time remained an inconveniance.  
Therefore, methods for the in situ generation have also been developed58. 
The group of Lipshutz developed a process using LiEt3BH (superhydride) as 
the source of hydride. In this case, the by-product is presumably Et3B which 
is a mild Lewis acid, tolerant towards sensitive groups such as THP-
protected alcohols59. 
Based upon the latter procedure, substrate 4.112 was added to a solution of 
in situ generated Cp2Zr(H)Cl. After 15 minutes, a solution of iodine was 
added (scheme 73). A mixture of iodinated and protonated products was 
isolated in 40 % yield (1:1.3 ratio).  
 
Scheme 73 
Based on these observations, we wondered if the capture of the 
vinylzirconium intermediate was not slower than expected. Hence, we 
decided to wait for three hours after addition of iodine and to isolate the 
                                                     
58 E.-i. Negishi, T. Takahashi, Synthesis 1988, 1-19. 
59 B. H. Lipshutz, R. Keil, E. L. Eiisworth, Tetrahedron Lett. 1990, 31, 7257-7260. 
134             DIHYDROPYRAN SYNTHESIS 
adduct thus produced. After purification, the iodinated product was obtained 
in 20 % yield. However, after spectroscopic analysis, we realized that this 
compound was not the expected product 4.133 but its regioisomer 4.157 
(figure 5). We then found a report from Liu and Ready in which it is 
described that homopropargylic alcohols undergo directed hydrozirconation 
with the zirconium proximal to the directing group60. 
 
Figure 5 
To better understand this regioselectivity, they compared homopropargylic 
alcohol 4.158a to its methyl ether 4.158b (scheme 74). These experiments 
showed that converting the free alcohol to a methyl ether substantially 
diminished the regioselectivity of hydrozirconation. 
Scheme 74  
To explain this regioselectivity, they propose a model involving an 
intramolecular hydrozirconation with an alkoxy-zirconium hydride, forming 
a five-membered chelate which is very stable and likely contributes to the 
                                                     
60 X. Liu, J. M. Ready, Tetrahedron 2008, 64, 6955-6960. 
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resistance of the oxazirconacycle 4.163 to isomerization to the distal product 
(scheme 75).  
 
Scheme 75 
To avoid this regioselectivity problem, we decided to protect the free alcohol 
with a THP group. To our delight, hydrozirconation, using the conditions 
described by Panek61, followed by iodation overnight, allowed us to isolate 
the desired product 4.130 in 68 % yield (scheme 76). 
Scheme 76  
The subsequent methylation was attempted as before, by adding methyl 
lithium to the iodinated adduct 4.130. Unexpectedly, in this case, no reaction 
was observed (scheme 77). 
 
Scheme 77 
                                                     
61 A. Arefolov, N. F. Langille, J. S. Panek, Org. Lett. 2001, 3, 3281-3284. 
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The transformation of vinyl iodides into the corresponding methyl-
substituted alkenes has been performed using a variety of reagents. In our 
case, it is believed that addition of MeLi to 4.164 results in the formation of 
the vinylic anion 4.165 and of MeI by a transmetallation process. Addition 
of the anion on MeI then leads to the desired alkene 4.166 (scheme 78). 
 
Scheme 78 
It is possible that the presence of numerous oxygen atoms in our substrate 
may lead to complexation of the vinyllithium species (intermolecular), 
resulting in a decreased reactivity. 
To overcome this limitation, it was decided to employ the corresponding 
cuprate, which is less prone to such coordination. For example, Corey has 
shown that treatment of iodide 4.167 by Me2CuLi resulted in a smooth and 
high yielding conversion into 4.169 via the intermediate copper derivative 
(scheme 79)62. 
 
Scheme 79 
In the event, addition of CuCN to the reaction mixture proved to be 
successful to methylate 4.13063. Further deprotection with PPTS afforded 
pure product 4.135 in 80 % yield over two steps (scheme 80). 
                                                     
62 E. J. Corey , G. H. Posner, J. Am. Chem. Soc. 1967, 15, 3911-3912. 
63 G. L. Simpson, T. P. Heffron, E. Merino, T. F. Jamison, J. Am. Chem. Soc. 2006, 
128, 1056-1057. 
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Scheme 80 
Silylation of the free alcohol followed by ISMS cyclisation afforded the 
benzylated DHP 4.138 in excellent yields (scheme 81). 
 
 
Scheme 81 
At this point, we turned our attention to the deprotection of the benzyl group. 
A first attempt was made using iron trichloride. Unfortunately, these 
conditions led to the degradation of the starting material (table 5, entry 1). 
Deprotection with boron trichloride64 did not take place, and only the starting 
material was recovered (table 5, entry 2). Lithium in liquid ammonia65 
afforded the desired product in moderate yield (table 5, entry 3). 
                                                     
64 O.-Y. Jeon, E. M. Carreira, Org. Lett. 2010, 12, 1772-1775. 
65 A. Merz, S. Anikin, B. Lieser, J. Heinze, H. John, Chemistry – A European 
Journal 2003, 9, 449-455. 
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Gratifyingly, lithium/naphthalenide66 gave the desired deprotected DHP 
4.099 in very good yield (table 5, entry 4).   
 
Entry Deprotecting agent Yield 
1 FeCl3 Decomposition 
2 BCl3 Starting Material
3 Li/NH3 50 % 
4 Li/naphthalene 77-83 % 
Table 5 
It is noteworthy that, after deprotection, the two diastereomers could finally 
be separated by silica gel column chromatography. Diastereomer 4.099b 
possesses the same stereochemistry as the right-hand fragment of jerangolid 
D and was extensively described by Dr J. Pospisil in his Ph.D. thesis. 
Protons 1 and 2 in these molecules have different chemical shifts and 
multiplicity. After full characterization and comparison with known data, the 
two disatereomers were attributed as shown in figure 6. 
                                                     
66 E. Alonso, D. J. Ramón, M. Yus, Tetrahedron 1997, 53, 14355-14368. 
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Figure 6 
Oxidation of the free alcohol to the corresponding ketone 4.170 was 
performed on the mixture of diastereomers. This transformation is complete 
within 3 hours. However, after purification, ketone 4.170 was isolated in 
only 18 % yield due to the high volatility of this compound (scheme 82). 
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Scheme 82 
Overall, this approach enabled us to obtain the desired protected DHP 4.138 
in 30 % overall yield starting from adduct 4.112 in a reproducible manner 
(scheme 83)! 
 
Scheme 83 
In conclusion, DHP 4.099 can be synthetized in 10 steps with an overall 
yield of 20 % starting from commercially available (S)-ethyl lactate. 
II.3. Sequence with no methyl 
In parallel, we also wanted to access dihydropyran lacking the methyl group 
at the C3 position. In order to prepare them, we modified our current route, 
though decided to keep the same starting material 4.112.  
Hydroalumination, followed by acidic work-up, was initially attempted. The 
desired product 4.147 was formed, as well as the (E)-isomer 4.171 and the 
overeduced product 4.144 (scheme 84). 
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Scheme 84 
Since we have encountered previously numerous problems with this 
reaction, we turned our attention to other known methods for the semi-
reduction of alkynes to the corresponding (Z)-alkene. The solution that 
immediately comes to mind for an organic chemist is to use Lindlar’s 
catalyst. This had been tried before in the lab and a mixture of (E) and (Z) 
isomers was formed. Many procedures have been reported in the literature 
for the conversion of an alkyne into a (E) or a (Z)-alkene. A brief selection is 
summarized in scheme 8567. 
                                                     
67 a. J. S. Yadav, S. Chandrasekhar, R. Kache, Synth. Commun. 1995, 25, 4035-
4043. b. E. –i. Negish, D. Choueiry, in Preparation of Alkenes, J. M. J. Williams, 
Ed., Oxford University Press, Oxford, 1996, 137-155. c. R. S. Paley, A. deDios, A. 
Estroff, J. A. Lafontaine, C. Montero, D. J. McCulley, M. B. Rubio, M. P. Ventura, 
H. L. Weers, R. F. delaPradilla, S. Castro, R. Doraod, M. Morente, J. Org. Chem 
1997, 62, 6326-6343. d. J. Howarth, in Preparation of Alkenes, J. M. J. Williams, 
Ed., Oxford University Press, Oxford, 1996, 117-136. 
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O
CO2tBu
(CH2)6CH3
H2, P2-Ni
EtOH
97 % O
CO2tBu
(CH2)6CH3
Na/NH3
H2, RhCl(PPh3)3
Benzene
84 %
Ts Ts
EtEt
1. NaBH4, BF3OEt2diglyme
2. AcOH
EtEt
4.172 4.173
4.174 4.175
4.176 4.177
4.178 4.17970 %  
Scheme 85 
Among these, we selected the P2-nickel catalyst. This catalyst is formed by 
reducing nickel acetate in the presence of sodium borohydride in MeOH. 
The active species is then stabilized by ethylene diamine and is used in 
catalytic amounts with hydrogen to reduce triple bonds to the corresponding 
(Z)-double bonds68. 
This procedure was then applied to our substrate. Surprisingly, in the 
presence of 5 mol % of catalyst, ~5 % conversion of the starting material 
was observed. Increasing the amount of P2-Ni resulted in similar rise in the 
                                                     
68 a. D. F. Taber, R. J. Herr, D. M. Gleave, J. Org. Chem. 1997, 62, 194-198 b. H. C. 
Brown, C. A. Brown, J. Am. Chem. Soc. 1963, 85, 1005-1006. 
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formation of product 4.147. This result prompted us to employ 
stoeichiometric quantities of the catalyst.  
To our delight, pure vinyl-silane 4.147 was isolated in 80 % yield (scheme 
86). 
 
Scheme 86 
This reaction proceeds efficiently, is highly reproducible and the yields vary 
from 80 to 89 %. 
The rest of the sequence was carried out as described in the previous section. 
Silylation of the free alcohol was accomplished in excellent yield (scheme 
87). 
 
Scheme 87 
ISMS cyclisation with propionaldehyde, in the presence of a catalytic 
amount of TMSOTf, produced the protected DHP 4.181 in 77 % yield 
(scheme 88). 
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Scheme 88 
Debenzylation using the Li-naphthalenide protocol generated the 
corresponding secondary alcohol 4.182 in good yield (scheme 89). 
O
BnO
O
HOH H H H
4.181 4.182
Li, naphthalene
THF, -20 °C, 2 h
72 %
 
Scheme 89 
Once again, the two diastereomers of 4.182 could be separated by silica gel 
column chromatography at this step.  
Oxidation of the mixture of two diastereomers to the corresponding ketone 
was performed extremely carefully since we surmise that this compound, 
like its methylated analogue, should be highly volatile. These precautions 
allowed us to isolate 4.183 in good yield (scheme 90). 
 
Scheme 90 
In conclusion, DHP 4.183 can be synthetized in 8 steps with an overall yield 
of 18 % starting from commercially available (S)-ethyl lactate. 
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II.4. Other analogues 
II.4.1. Hydrozirconation of the free alcohol 
During our studies on the optimisation of the hydrozirconation of alkyne 
4.112, product 4.157 could be isolated when the alcohol function was not 
protected. This adduct looks interesting in the context of the generation of 
diversely substituted DHP systems and the construction of modified 
jerangolid analogues. Therefore, it was decided to take advantage of this 
adduct to synthetize an analogue with the methyl group at position C4 
instead of C3. 
Substrate 4.112 was thus reacted again with Schwartz reagent to afford 
adduct 4.157 in low yield (scheme 91). 
OH
OBn
TMS
OH
OBn1) Cp2ZrCl2superhydride
THF
2) I2
4.112
I
TMS
4.157
23 %
 
Scheme 91 
Further methylation afforded compound 4.184 in excellent yield. Vinylsilane 
4.184 was sufficiently pure to be engaged in the subsequent step without 
further purification (scheme 92).  
OH
OBn
I
TMS
4.157
OH
OBn
TMS
4.184
MeLi, CuCN
Et2O, r.t., 18 h
90 %
 
Scheme 92 
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It should be noted however that this compound is very sensitive to acids and 
decomposes rapidly in their presence. NMR spectra have to be taken in 
basified deuterated chloroform and the next step should be carried out as 
quickly as possible after obtention of 4.184. 
The ISMS cyclisation was perfomed directly on adduct 4.184 in the presence 
of 1.1 equivalents of TMSOTf to afford DHP 4.185 in modest yield (scheme 
93). It is possible that the sensitivity of 4.184 towards acids is responsible for 
the low yield. 
 
Scheme 93 
The regioisomeric adduct 4.186 was also detected in this reaction. It 
originates from the isomerisation of the double bond, probably induced by 
the presence of traces of TfOH formed during the reaction (figure 7). The 
temperature during the ISMS cyclisation should therefore be controlled very 
carefully to avoid this isomerisation.  
 
Figure 7 
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II.4.2. Hydrosilylation 
The hydrosilylation of alkenes and alkynes describes the addition of Si-H 
bonds across carbon-carbon double or triple bonds respectively (scheme 94). 
 
Scheme 94 
Metal-catalyzed hydrosilylation of alkynes is the most straightforward, 
atom-economical access to vinylsilanes. The stereochemical outcome of this 
transformation strongly depends upon different parameters such as the metal 
employed, its ligands, the substituents on both the alkyne and the silane, the 
solvent, the temperature69... A large number of metals and systems have been 
described in the literature. For example, the group of Trost reported a highly 
regioselective, ruthenium-based system, which promotes trans addition to 
internal and terminal alkynes to afford the corresponding α isomers 4.190 
and 4.19170. Ruthenium71 and Rhodium72 catalysis allow the access to the 
trans addition product 4.192 β-(Z). On the other hand, the platinum-
catalyzed hydrosilylation of alkynes has shown to proceed by cis addition to 
form exclusively adducts 4.190, 4.193 β-(E) and 4.194 (scheme 95)73.  
                                                     
69 S. Dierick, PhD Thesis, UCL 2013 
70 B. M. Trost, Z. T. Ball, J. Am. Chem. Soc. 2005, 127, 17644-17655. 
71 Y. Na, S. Chang, Org. Lett. 2000, 2, 1887-1889. 
72 M. P. Doyle, K. G. High, C. L. Nesloney, J. W. Clayton, J. Lin, Organometallics 
1991, 10, 1225-1226. 
73 L. N. Lewis, K. G. Sy, G. L. Bryant, P. E. Donahue, Organometallics 1991, 10, 
3750-3759. 
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Scheme 95 
Our group has developed a series of N-heterocyclic carbenes platinum(0) 
complexes that are excellent catalysts for the hydrosilylation of alkynes to 
form the β-(E) isomer 4.193 as the major product in excellent yields74. 
Based on further work on the hydrosilylation of alkynes currently on-going 
in our group, we decided to apply this methodology to homopropargylic 
alcohol 4.112 to form yet another analogue of the dihydropyran portion of 
jerangolid D. 
Hydrosilylation in the presence of our platinum catalyst 4.195 and bis-
trimethyl silyloxysilane (kindly given by Dr F. Chellé) afforded compound 
4.196 in good yield (scheme 96). 
                                                     
74 a. G. de Bo, G. Berthon-Gelloz, B. Tinant, I. E. Markó, Organometallics 2006, 25, 
1881-1890. b. G. Berthon-Gelloz, J-M. Schumers, G. de Bo, I. E. Markó, J. Org. 
Chem. 2008, 73, 4190-4197. 
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OBn
4.112
Si
TMS
4.196
OTMS
OTMS
H Si
OTMS
OTMS
(IPr)Pt(dvtms)
Neat
53 %
N N
Pt
Si
O Si
(IPr)Pt(dvtms)
4.195  
Scheme 96 
The regiochemistry was determined by 1H NMR analyses. If compound 
4.184 was formed, proton 4 would appear as a doublet of doublet and a 
strong correlation between protons 3 and 4 would be observed in COSY 
experiment. In our case, proton 2 is a singlet and no correlation is observed 
between protons 1 and 2 in COSY NMR (figure 8). As for the configuration 
of the alkene, it is assumed that the (Z)-isomer is formed based upon the 
mechanism of the reaction. However, this was not proved unambigously. 
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Figure 8 
Morover, this result is in agreement with the results described by Dr. Steve 
Dierick during his PhD thesis. When homopropargylic alcohol 4.198 was 
hydrosilylated, the major product was the β isomer 4.199a (scheme 97)69. 
Scheme 97 
ISMS cyclisation in the presence of 1.1 equivalents of TMSOTf afforded the 
desired DHP 4.200 in good yield (scheme 98). 
O
BnO
Si
H HOH
OBn
Si
TMS
4.196
OTMS
OTMS
OTMSTMSO
TMSOTf (1.1 eq)
DCM, -78 to -30 °C, 2 h
79 %
4.200
O
+
4.137  
Scheme 98 
As a note of caution, it is important to quench the reaction with a dilute 
solution of acid (0.1M HCl) if DHP 4.200 is to be obtained in good yields. 
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Indeed, when a more concentrated acidic solution is used, some desilylation 
product is observed, thus leading to a reduced yield. 
Debenzylation was finally attempted using lithium naphthalenide. 
Unfortunately, in this case, degradation was observed and no single product 
could be isolated (scheme 99). 
 
Scheme 99 
Nevertheless, whilst adduct 4.201 cannot be directly incorporated into 
jerangolid analogues, it is a useful intermediate since the presence of the 
silyl group should enable further functionalisations at that particular 
position. These could include Hiyama cross-coupling reactions with a 
variety of aromatic, vinylic or acetylenic partners (scheme 100)75. 
                                                     
75 a. K. Takahashi, T. Minami, Y. Ohara, T. Hiyama, Tetrahedron Lett. 1993, 51, 
8263-8266. b. Y. Hatanake, T. Hiyama, J. Org. Chem. 1988, 53, 918.  
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Scheme 100  
The reactions described in this last paragraph can clearly benefit from some 
optimization but the results already obtained appear to be quite promising. 
In conclusion, we have developed a general method to access various 
dihydropyrans starting from the same substrate, the homopropargylic alcohol 
4.112, by modifying in a diverse manner, its carbon-carbon triple bond. 
In the next chapter, we will present our results on the modifications 
performed on the dihydropyran's double bond to reach various 
tetrahydropyrans, and especially the right-hand portion of jerangolids B, E 
and H. 
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I. Synthesis of the right-hand part of Jerangolids 
B, E and H 
In the previous chapter, we discussed the synthesis of dihydropyran 4.138 
and its deprotected version 4.099b which corresponds to the right-hand 
fragment of jerangolid D (figure 1). 
 
Figure 1 
With our desired dihydropyrans in hand, we started to functionalize the 
double bond in order to construct the right-hand fragment of jerangolids B, E 
and H (figure 2). Indeed, in these compounds, the stereochemistry at C14 is 
still unknown. 
 
Figure 2 
For that purpose, introduction of the –OH function in a stereoselective and 
regioselective manner was envisaged. Reduction of the trisubstituted double 
bond of 4.138 should afford the right-hand subunit of jerangolid E.  
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I.1.  Right-hand subunit of jerangolid B  
I.1.1. Epoxidation on benzylated DHP 
Dihyropyran 4.138 was epoxidized with m-CPBA to yield two diastereomers 
in moderate yield (scheme 1). 
O O
O
BnOBnO H H H Hm-CPBA, DCM
0 °C, 45 min.
4.138 5.001
50 %
2 dias  
Scheme 1 
The epoxides were separated by silica gel column chromatography and 
noesy experiments were performed on each one. They confirmed that the 
stereochemistry at C2-C6 is syn in both molecules (figure 3).  
 
Figure 3 
We think that the stereochemistry of these epoxides is the one depicted in 
figure 3. In fact, there is a strong Noe correlation between H2’ and H7’ in 
compound 5.003 which is not present in compound 5.002. Still, this does not 
tell us the absolute stereochemistry and the epoxides that were formed could 
as well be the ones depicted in figure 4. 
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Figure 4 
Unfortunately, noesy experiments did not enable us to confirm that 
unambigously. At this point, for the clarity of the reader, we will consider 
arbitrarily that epoxides 5.002 and 5.003 were the ones obtained. 
Each epoxide was then opened with lithium aluminium hydride. Opening of 
5.002 led to a mixture of two products which would not separate. After 
analysis, it was shown that the hydride opened the epoxide at the C4 position 
as expected, leading to 5.006, but also at the C3 position to form THP 5.007 
in a 1:2 ratio in favour of the latter (scheme 2). 
 
Scheme 2 
The preferential formation of THP 5.007 can be explained by the fact that 
the generation of 5.006 would require the passage through a higher energy 
boat-like transition state (scheme 3). 
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Scheme 3 
Opening of 5.003 also led to a mixture of two products in a 5:1 ratio, this 
time in favour of THP 5.008 which is the desired one. This THP was isolated 
after silica gel column chromatography in 54 % yield (scheme 4). 
 
Scheme 4 
In this case, opening of the epoxide at the C4 position is favoured because it 
goes through a chair-like transition state, which explains the opposite 
selectivity from above (scheme 5). 
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O
BnO H H
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5.009
5.003
 
Scheme 5 
A Noe effect between the proton at C2 and the methyl group (CH3)7’ 
confirmed their cis relationship, hence the stereochemistry depicted in figure 
5. 
O
CH3OH
BnO H H
5.008
2'6'
7'
 
Figure 5 
In order to verify the stereochemistry proposed in this section, it was 
necessary to carry out the same reactions on one single diastereomer. 
I.1.2. Epoxidation on one diastereomer 
Epoxidation was carried out on the deprotected diastereomer 4.099b using 
the same conditions as above (scheme 6). Once again, a major epoxide 
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isomer was observed that could be easily isolated in 30 % yield. The ratio 
was calculated in the crude NMR and is 3.5:1.  
 
Scheme 6 
Noesy experiments confirmed once again that the 2,6 protons are syn and 
showed a correlation between H2 and methyl (CH3)7 suggesting that the 
epoxide is pointing down (figure 6). 
 
Figure 6 
In order to confirm unambiguously that stereochemistry, the free alcohol was 
esterified with p-bromobenzoyl chloride in the presence of Et3N and DMAP 
leading to the desired benzoate 5.011 in moderate yield (scheme 7). 
O
O
HO H H
5.010
O
O
O H H
5.011
O
Br
Cl
O
Br
Et3N, DMAP
DCM, r.t., 18 h
50 %  
Scheme 7 
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Fortunately, ester 5.011 proved to be nicely crystalline. Recrystallisation of 
the white solid enabled us to obtain a single crystal which was submitted to 
an X-ray diffraction structure analysis (figure 7).   
 
Figure 7 
This study confirmed that the epoxide is pointing toward the α-face of the 
molecule, i.e. anti to the 2,6 hydrogens. This was a rather unexpected result 
since axial approach on the half-chair form of 4.099b should be little 
discriminating and if so, should favor the β-epoxide. The selectivity can be 
explained by the presence of the hydroxyl group, which probably directs the 
approach of the peracid on the α-face of the alkene (figure 8). 
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Figure 8 
In addition to the stereochemistry of the epoxide, this analysis confirmed all 
the absolute stereochemistry of the chiral centres present in this molecule, 
proving unambiguously the 2,6-syn stereochemistry and the fact that no 
epimerization occured during the whole sequence to form this DHP. 
Opening of the epoxide with LiAlH4 afforded the corresponding diol and 
cleaved ester 5.012 in 52 % yield (scheme 8).  
 
Scheme 8 
At this point, we know unambigously the absolute stereochemistry of 
compound 5.012. If compound 5.008 has the stereochemistry we proposed in 
section 1.I.1, after deprotection, it should be the exact same compound as 
5.012. This experiment was therefore carried out using lithium naphthalenide 
in moderate yield (scheme 9). 
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Scheme 9 
Gratifyingly, the exact same compound was obtained, thus confirming the 
stereochemistry that we proposed earlier. These results prompt us to confirm 
that the epoxidation of our dihydropyrans using m-CPBA is directed by the 
oxygen as described in figure 8. 
Benzoylation of the secondary alcohol was attempted but the quantities were 
too small and no single crystal could be obtained (scheme 10). 
O
OH
HO H H
5.012
O
OH
O H H
5.013
O
Br
Cl
O
Br
Et3N, DMAP
DCM, r.t., 18 h
40 %  
Scheme 10 
Comparison of the NMR spectra of compounds 5.006, 5.008 and 5.012 
shows that 5.008 and 5.012 have the same relative stereochemistry between 
hydrogens H2’ and H6’ and the methyl substituent (CH3)7’; the latter one 
occupying an equatorial positon (figure 9).  
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Figure 9  
The methyl group in 5.012 is equatorial. The chemical shift for that 
equatorial methyl is 24.53 ppm in CDCl3. The chemical shifts for the methyl 
group in 5.008 are 25.68 ppm in MeOD and 24.40 ppm in CDCl3 
respectively, which is thus also equatorial. In contrast, the chemical shift for 
the methyl of 5.006 is 20.00 ppm in MeOD and 20.43 ppm in CDCl3, thus 
being axial.  
NMR data for natural Jerangolid B describe a chemical shift for that same 
methyl group of 25.83 ppm in MeOD. Moreover, the values for H2' and C3' 
in 5.008 are similar to the ones in Jerangolid B (figure 10). 
 
Figure 10 
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These values prompt us to suggest that the methyl group in jerangolid B 
occupies an equatorial position whilst the –OH function is axial, as indicated 
in figure 11. 
 
Figure 11 
Opening of the epoxide was also carried out using HClO4 in water1. Further 
benzoylation with para-bromobenzoyl chloride afforded the desired product 
as a white solid in 44 % yield over the two steps (scheme 11).  
 
 
Scheme 11 
However, the stereochemistry obtained for diol 5.014 and its derived ester 
5.015 was the opposite of what was expected based upon the mechanism of 
                                                     
1 I. C. González, C. J. Forsyth, J. Am. Chem. Soc. 2000, 122, 9099-9108.  
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this reaction (scheme 12). In fact, in acidic media, the reaction mechanism 
goes through the formation of a carbocation, which is favoured on tertiary 
carbon centers. For that reason, path b was expected. 
O
O
H HRO
HO
H
H
O H
H
O
OH
HHHO
OH
O
OH
HHHO
OH
5.014a 5.014b
path bpath a
 
Scheme 12 
If compound 5.014b was formed, a large axial-axial coupling constant 
between H4' and H5’ should be observed. However, the very small coupling 
constant (J = 2.85Hz) between H4 and H5 indicates that H4 can not be axial, 
thus should be equatorial with the secondary alcohol anti to the tertiary one 
(figure 12).  
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Figure 12 
This selectivity can be explained by the fact that this molecule is a rigid 
system and the Furst-Platner rule can be applied (scheme 13). The approach 
going through a chair-like transition state is favoured, thus leading to the 
formation of compound 5.014a. 
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Scheme 13 
Noesy experiments confirmed this stereochemistry. Correlation between H2 
and H6 as well as between H2 and Me3 confirms their syn relationship. H4 
correlates with Me3 which is normal because they are both in equatorial 
position (figure 13). 
OOH
OH
MeR H
H H
4
5.014a
H
H5
6 2
 
Figure 13 
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Epoxidation was also carried on DHP 4.182b bearing no methyl group at 
position C3. In this case, the yield was low and the ratio between the two 
epimers of the epoxide is 1:1.4 (scheme 14). At this stage, compounds 
5.016a and 5.016b could not be separated. 
 
Scheme 14 
The mixture of the two diastereomers was then benzoylated in moderate 
yield and the resulting esters were easily separated by silica gel column 
chromatography (scheme 15).  
 
Scheme 15 
Comparison of the 1H NMR spectra of epoxides 5.018a and 5.018b gave us 
some information about the stereochemistry of the epoxides. Unfortunately, 
the coupling constants did not help us because in both molecules, H4 and H9 
do not see each other. However, when examining H7, there is a difference of 
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chemical shift between the equatorial and the axial protons between the two 
compounds. In 5.018a, H7eq has a chemical shift of 2.16 ppm and H7ax of 
1.76 ppm whilst in 5.018b, H7’eq has a chemical shift of 1.95 ppm and 
H7ax of 1.83 ppm (figure 14). Comparison of these values with the ones 
obtained for epoxide 5.003 which has been demonstrated earlier to be α , in 
which H7eq has a chemical shift of 2.14 ppm and H7ax of 1.75 ppm prompt 
us to propose that epoxide 5.018a is also α.  
 
Figure 14 
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Recrystallisation of each diastereomer was attempted to confirm the absolute 
stereochemistry of both epoxides but unfortunately, no single crystals could 
be obtained. 
We then turned our attention to the synthesis of the right-hand THP of 
jerangolid E and H through hydrogenation of the double bond of DHP 4.138. 
I.2. Right-hand subunit of jerangolid E and H 
Dihydropyran 4.138a and its isomer 4.138b were therefore hydrogenated in 
the presence of palladium on charcoal. If the reaction is not stereoselective, 
four diastereomers are expected. Much to our surprise, five isomers were 
observed in 1H and 13C NMR. Each product contains the free alcohol 
(scheme 16). 
 
Scheme 16 
Chiral GC analysis, after purification by silica gel column chromatography, 
confirmed the presence of five different molecules. 
In order to understand what happened and to simplify the spectra, 
hydrogenation was carried out using the same conditions as described above, 
but on the pure diastereomer 4.099b (scheme 17). 
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Scheme 17 
In this case, three diastereomers were observed and isolated as well as a 
compound containing a tetrasubstituted double bond 5.021 (figure 15).  
The free alcohol was then oxidized to the corresponding ketone in a NMR 
tube to remove the chiral centre at C8. The resulting mixture of products was 
analyzed by chiral GC analysis and three different diastereomers were still 
present, showing that the third product did not come from epimerization at 
C8. The three diastereomers are thus the ones drawn in figure 14. 
O
HO HO
HO H H O
HO H H
+ +
5.019 5.020 5.021  
Figure 15 
These hydrogenation conditions thus appear to promote the migration of the 
double bond to the C2-C3 position which can migrate back and then further 
be hydrogenated, leading to the observed epimerization at the C2 position in 
compound 5.020.  
To avoid this problem, ethanol was replaced by ethyl acetate as the solvent 
of the reaction2. To our delight, changing the solvent led to the formation of 
only two diastereomers though in low yield (scheme 18).  
                                                     
2 N. K. Garg, D. D. Caspi, B. M. Stoltz, J. Am. Chem. Soc. 2004, 126, 9552-9553.  
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Scheme 18 
The two epimers could not be separated by silica gel column 
chromatography. However, careful analysis of the NMR spectra allowed us 
to attribute the signals to each diastereomer. This attribution enabled us to 
define the stereochemistry at the newly formed chiral centre for each isomer. 
The methyl group Me7 displays very different chemical shifts between the 
two compounds in 13C NMR. Me7 has a chemical shift of 11.46 ppm in 
CDCl3 whilst Me7’ appears at 17.88 ppm (figure 16). 
 
 
Figure 16 
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A literature search enabled us to find two examples describing the same 
types of THP rings. In the total synthesis of tetronomycin, the group of 
Yoshii synthesized the two epimers at C3 of THP 5.022 and 5.0233 (figure 
17). 
 
Figure 17 
The axial methyl substituent possesses a chemical shift of 11.93 ppm whilst 
the equatorial methyl appears at 17.61 ppm in CDCl3. 
Schneider also synthetized highly substituted THP rings4. In the case of 
compounds 5.024 and 5.025, the axial methyl group has a chemical shift of 
12.6 ppm whilst the equatorial methyl group is present at 17.5 ppm in CDCl3 
(figure 18). 
 
Figure 18 
In jerangolid E, the chemical shift for the methyl group at C14 is 17.98 ppm 
in MeOD. NMR spectra of coumpounds 5.019a and 5.019b were also 
                                                     
3 K. Hori, N. Hikage, A. Inagaki, S. Mori, K. Nomura, E. Yoshii, J. Org. Chem. 
1992, 57, 2888-2902.  
4 C. Schneider, A. Schuffenhauer, Eur. J. Org. Chem. 2000, 73-82.  
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measured in MeOD and the chemical shifts were 11.81 ppm and 18.03 ppm, 
respectively. 
Moreover, as shown in figure 15, H4' in 5.019a has a chemical shift of 3.30 
ppm in 1H and 83.1 ppm in 13C NMR in MeOD whilst H4 in 5.019b (in 
which the methyl is equatorial) has a chemical shift of 2.83 ppm in 1H and 
86.19 ppm in 13C NMR in MeOD. In Jerangolid E, the same proton has a 
chemical shift of 2.87 ppm in 1H and 85.92 ppm in 13C NMR in MeOD. 
All these informations prompt us to propose that the methyl group in 
jerangolid E occupies the equatorial position. The full structure of jerangolid 
E is thus shown in figure 19. 
O
MeO
O
H3C
MeO HH
Me = 17.98 ppmJerangolid E
H = 2.87 ppm and 85.92 ppm
 
Figure 19 
In conclusion, the modifications we have performed on our previously 
prepared DHPs have allowed us to determine the absolute stereochemistry of 
jerangolid B, E and H as well as to synthetize new analogues of the right-
hand part of the jerangolids. 
II. Esterifications 
As stated in the objectives, since the dihydropyran moiety is also present in 
ambruticin, we wanted to synthetize different esters starting from DHP 4.099 
in order to mimic the rest of the molecule. 
The strategy is always the same, using DCC and DMAP as coupling agents 
between alcohol 4.099 and different commercially available acids. 
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Coupling with crotonic acid afforded the desired DHP 5.026 in good yield 
(scheme 19).  
 
Scheme 19 
The two diastereomers were then separated by silica gel column 
chromatography. 
Cinnamic acid was also used as the coupling agent and the reaction was 
performed on each diastereomer separately (scheme 20). 
O
HO H H
4.099b
O
HO Ph
DMAP, DCC, DCM
0 °C to r.t., 18 h
O
O H H
O
5.028
49 %
O
HO H H
4.099a
O
HO Ph
DMAP, DCC, DCM
0 °C to r.t., 18 h
O
O H H
O
5.027
43 %
 
Scheme 20 
Finally, diastereomer 4.099a was coupled with hexa-2,4-dienoic acid in low 
yield after two purifications by silica gel column chromatography (scheme 
21). 
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Scheme 21 
In conclusion, five new molecules, mimics of jerangolid D, have been 
successfully synthetized. These compounds shall be submitted to biological 
evaluation in order to estimate their potential antifungal activities.
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At this point, numerous subunits of Dihydropyran C have been obtained. It 
was thus time to prepare lactone A in order to possess both fragments that 
are needed to assemble the jerangolids and their analogues. 
O
O
O
H3C
MeO HH
1
8 15
5
A
B
C O
O
H3C
MeO
1
OH
6
7
+
TBSO SO2Ph
+
O
O H H
A B
C
7 8
15
2.001
2.030
2.031
Scheme 1 
I. Lactone synthesis 
The route we followed to access lactone 2.030 for our total synthesis of 
jerangolid D was described in chapter two and is presented again in scheme 
2. 
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Scheme 2 
A couple of modifications had to be made to this strategy for the following 
reasons: 
- (R)-benzylated glycidol is particularly expensive. 
- Et2AlCN is no longer commercially available. 
For these reasons, (S)-glycidol was protected using benzyl bromide and 
Et2AlCN was replaced by KCN. Moreover, the setup and optimisation of the 
sequence was first carried out with racemic glycidol before being applied to 
the optically pure starting material. 
Each step will be described in this section. It should be noted that this work 
has been done in collaboration with two master students, Sophie Moreau and 
Jean-François Body. The Blaise reaction was subsequently optimized by 
Damien Dewez. 
I.1. Glycidol protection 
Racemic glycidol 6.001 was deprotonated with sodium hydride (NaH). The 
resulting alkoxide was reacted with benzyl bromide (BnBr) in the presence 
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of tetrabutylammonium iodide (TBAI)1 to afford protected glycidol 6.002 in 
62% yield (scheme 3). Addition of TBAI is believed to lead to the in situ 
generation of benzyl iodide by substitution of the bromine atom by iodide 
(Finkelstein reaction), which is a better leaving group. The SN2 reaction 
should thus be facilitated. 
 
Scheme 3 
Due to the moderate yield in ether 6.002, some modifications were 
implemented. First, THF was replaced by DMF2 (table 1, entry 2). The use 
of this polar solvent reduced the reaction time to 16 hours but did not alter 
the yield. Removal of TBAI lowered the yield to 38 % (table 1, entry 3), 
whilst changing the base to NaHMDS only gave 48 % yield (table 1, entry 
4). 
                                                     
1 S. Czernecki, C. Georgoulis, C. Provelenghiou, Tetrahedron Lett. 1976, 17, 3535-
3536.  
2 R. Barbe, J. Hasserodt, Tetrahedron 2007, 63, 2199-2207.  
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Entry Additive Base Solvent Time (h) Yield (%) 
1 TBAI NaH THF 48 62 
2 TBAI NaH DMF 16 62 
3 / NaH DMF 16 38 
4 TBAI NaHMDS DMF 16 48 
Table 1 
Unfortunately, we were not able to further improve the yield under basic 
conditions.  
In order to protect the glycidol under acidic conditions, benzyl bromide was 
replaced by trichloro acetamide, this reagent, in conjunction with an acid 
catalyst, has been employed in chapter 4 for the protection of ethyl lactate 
(table 2). 
 
Entry Solvent Acid Time (h) Yield (%) 
1 EP MeSO3H 48 0 
2 DCM MeSO3H 16 0 
3 DCM / EP (1 : 1) TfOH 18 0 
Table 2 
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Surprisingly, these conditions did not afford the desired product 6.002. In all 
cases, the starting material was recovered at the end of the reaction. 
Finally, the former system was kept and used to protect enantiomerically 
pure glycidol 6.003 (scheme 4). Nonetheless, for some unknown reason, the 
yield was even lower than in the case of racemic glycidol. 
 
Scheme 4 
Glycidol was also protected with a TBS group in quantative yield as an 
alternative to the moderate yield obtained with the benzyl group (scheme 5). 
 
Scheme 5 
I.2. Opening of the epoxide 
As mentioned earlier, new conditions for the opening of the epoxide had to 
be found since Et2AlCN is no longer commercially available. The use of 
KCN in a mixture of EtOH/H2O afforded the corresponding nitrile 6.006 in 
moderate yield3 (scheme 6). 
                                                     
3 A. Kamal, G. B. Ramesh Khanna, Tetrahedron: Asymm. 2001, 12, 405-410.  
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Scheme 6 
Changing the ratio of solvent and increasing the number of equivalents of 
KCN led to a remarkable increase in the yield and nitrile 6.006 could be 
isolated in up to 92 % (scheme 7). 
 
Scheme 7 
These conditions were then applied to the enantiomerically pure epoxide 
6.004. Again, adduct 2.032 was obtained with an excellent yield (scheme 8). 
 
Scheme 8 
The TBS protected glycidol was also treated under the same conditions. 
However, product 6.007 was isolated in moderate yield (scheme 9). 
 
Scheme 9 
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Alcohol 6.008 was identified as a minor side product but its formation does 
not explain the low recovery of 6.007 (figure 1). One plausible explanation 
lies in the deprotection of the TBS group under these conditions, leading to 
glycidol 6.001, which is extremely soluble in water, and would be lost 
during the work-up. 
HO OTBS
CN
6.008
4%  
Figure 1 
Nitrile 6.006, being readily prepared, can now be used in the next step which 
is a Blaise reaction. This transformation involves the addition of an 
organozinc reagent on a nitrile, affording, after hydrolysis, a β-ketoester. 
I.3. Blaise reaction  
The reaction was first carried out using methyl bromoacetate under the 
conditions described in scheme 10. Methanesulfonic acid was replaced by 
trifluoromethanesulfonic acid which should play the same activating role for 
zinc4. Unfortunately, the β-ketoester was not formed at all and the starting 
material was recovered (scheme 9). 
Scheme 10 
                                                     
4 H. Shin, B. S. Choi, K. K. Lee, H.-w. Choi, J. H. Chang, K. W. Lee, D. H. Nam, 
N.-S. Kim, Synthesis 2004, 2629-2632.  
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From this result, it appears that changing the acid might not have been a 
good idea. Thus, we repeated the reaction, using methanesulfonic acid and 
20 mesh zinc5. Once again, the starting material was recovered (scheme 11). 
Scheme 11 
The literature provides numerous methods for the activation of zinc to be 
used in the generation of organozinc derivatives. Among these, a procedure 
describing a pre-activation of the zinc by HCl was selected6. These 
conditions were then applied to our substrate but once again failed to deliver 
the desired product (scheme 12). 
Scheme 12 
After having changed different parameters such as the granulometry of zinc, 
the activation method and the reaction time, we suspected a problem in the 
activation of the nitrile. For that reason, the use of BF3-etherate, a Lewis acid 
known to bind to the nitrogen atom of nitriles7, and hence make them more 
electrophilic was attempted. Unfortunately, no conclusive result could be 
obtained (scheme 13). 
                                                     
5 20 mesh is the granulometry of the zinc. 
6 X. Gao, M. Nakadai, B. B. Snider, Org. Lett. 2003, 5, 451-454.  
7 J. L. Fry, R. A. Ott, J. Org.Chem. 1981, 46, 3333-3335. 
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Scheme 13 
In desperation, we wondered if the free alcohol present on the nitrile might 
interfere with the reaction, by preventing the formation of the zincate or by 
protonating it before it has time to react. Indeed, although a couple of 
reactions are described in the literature in which a free alcohol is present in 
the substrate8, in the majority of cases, the function is initially first protected 
with a TMS4,9 or TBS10 group.  
Thus, alcohol 6.006 was protected with a TMS group almost quantitatively 
as described in scheme 14. 
 
Scheme 14 
Conditions reported in the literature4 were applied to nitrile 6.011. 
Gratifyingly, the desired compound 6.010 could be obtained, though in 
moderate yield (scheme 15). 
                                                     
8 a. F.-D. Wang, J.-M. Yue, Synlett 2005, 2077-2079 b. T. Kyoko, M. Tatsuya, O. 
Yoshio, H. Tamejiro, Tetrahedron Lett. 1993, 34, 8263-8266.  
9 J. Syed, S. Förster, F. Effenberger, Tetrahedron: Asymm. 1998, 9, 805-815.  
10 J. H. Kim, H. Shin, S.-g. Lee, J. Org. Chem. 2012, 77, 1560-1565.  
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Scheme 15 
Encouraged by this result, we tested these conditions with 2-methyl 
bromopropanoate 6.012. The desired β-ketoester 6.013, necessary for the 
synthesis of the natural product, was formed but the yield was poor (scheme 
16) and an important quantity of the deprotected nitrile was recovered. 
Scheme 16 
Different tests were then performed to evaluate the reproducibility of this 
key-transformation. A decrease in the yield indicates that these conditions 
are not optimal for the preparation of compound 6.013. This can be 
explained by the fact that the TMS group is sensitive towards very acidic 
conditions. Therefore, if an important quantity of acid (useful for the 
activation of zinc) remains in the reaction, the silyl ether can be deprotected, 
leading to the free alcohol, which inhibits the process, as described earlier. 
To solve this problem, the zinc was pre-activated using HCl and then washed 
carefully with water, ethanol and diethyl ether to remove any traces of acid 
then dried under vacuum.  
These precautions enabled us to prepare β-ketoester 6.010 in 70 % yield 
(scheme 17). 
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Scheme 17 
These conditions were subsequently applied to the coupling between 
substrate 6.011 and the less reactive α-bromopropanoate 6.012. As expected, 
compound 6.013 was formed in moderate yield (scheme 18).  
Scheme 18 
Optimisation of the workup as well as neutralising the silica before 
purification allowed us to isolate the desired product in 57 % yield 
reproducibly and on several grams scale. These conditions were successfully 
applied to the enantiomerically pure nitrile 2.032 to afford the desired β-
ketoester 2.033 needed for the total synthesis of jerangolid D in 58 % yield 
(scheme 19). 
Scheme 19 
The β-ketoesters were finally engaged in the next step in order to accomplish 
the cyclisation and thus obtain the desired protected lactones akin to the 
western subunit of jerangolid D and its analogues. 
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I.4. Lactonization and deprotection 
β-ketoester 6.010 was cylised in the presence of TMSCl and an excess of 
methanol to afford lactone 6.014 in 86 % yield (scheme 20). 
MeO OBn
O O OH
6.010
TMSCl, MeOH
DCM, -78 to 0 °C, 24 h
O
MeO
O
OBn
6.01486 %
 
Scheme 20 
Substrate 6.013 was also cyclized under these conditions to form lactone 
6.015, though in a lower yield (scheme 21). 
MeO OBn
O O OH
6.010
TMSCl, MeOH
DCM, -78 to 0 °C, 24 h
O
MeO
O
OBn
6.01550 %
Scheme 21  
Other conditions were also investigated to cyclise β-ketoester 2.033. For 
example, lactonization using sodium hydroxide, followed by methylation of 
the resulting β-ketolactone with dimethyl sulfate and potassium carbonate11 
afforded lactone 2.034 in 41 % yield (scheme 22). 
                                                     
11 H. Hagiwara, K. Kimura, H. Uda, J. Chem. Soc., Perkin Trans. 1 1992, 693-700.  
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MeO OBn
O O OH
2.033
O
MeO
O
OBn
2.034
1. NaOH, THF
2. Me2SO4, K2CO3acetone, 48 h
41 %  
Scheme 22 
In summary, protected lactone 2.034, a direct precursor of the lactone 
fragment of jerangolid D, has been synthetized in four steps with an overall 
yield of 15.5 %. 
These lactones could be further deprotected, using iron trichloride, as 
described in our total synthesis of jerangolid D. These conditions enabled us 
to isolate the corresponding hydroxy lactones 6.016 and 6.017 in good yields 
(schemes 23 and 24). 
 
Scheme 23 
 
Scheme 24 
These conditions still need to be applied to lactone 2.034 but should not be a 
problem. 
These lactones could then be oxidized and coupled to the rest of the 
molecule using a Julia-Kocienski olefination. 
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II. Lactone analogues 
As stated in the objectives, we wanted to synthesise three analogues of the 
lactone moiety of jerangolid D (figure 2). The racemic version of lactone 
3.009 has already been prepared during our study of the Blaise reaction. 
O
OBn
O
MeO
O
OBn
O
Me O
OBn
O
3.009 3.010 3.011  
Figure 2 
The syntheses of lactones 3.010 and 3.011 will be described in this section. 
II.1. Synthesis of lactone 3.011 
II.1.1. Via ring closing metathesis 
Our approach to the synthesis of lactone 3.011 is based on a strategy used for 
the total synthesis of the natural product goniothalamine 6.018 by Dr. 
Pospisil12 (figure 3). The key step of this sequence is a ring closing 
metathesis. 
 
Figure 3 
                                                     
12 J. Pospíšil, I. E. Markó, Tetrahedron Lett. 2006, 47, 5933-5937.  
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The synthesis begins from the protected epoxides 6.002 and 6.005 described 
at the beginning of this chapter. The oxirane function of protected glycidols 
6.002 and 6.005 was opened with a vinyl Grignard in the presence of a 
copper (I) salt to form the homoallylic alcohols 6.019 and 6.020 in excellent 
yields (scheme 25). 
 
Scheme 25 
Copper iodide is added to the reaction in catalytic quantities to form the 
corresponding cuprate. The latter is more nucleophilic and less basic than the 
Grignard reagent, reacting regioselectively, through an SN2 mechanism, on 
the less substituted carbon centre of the oxirane function. Moreover, the 
nature of the halogen in the Grignard reagent is of no importance since both 
of them afford the desired product in similar yields. 
Esterification of both homoallylic alcohols with acryloyl chloride in the 
presence of Et3N leads to the formation of dienes 6.021 and 6.022 in good 
yields (scheme 26). 
 
Scheme 26 
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Ring closing metathesis using Grubbs catalyst allows the cyclisation of the 
dienes to the corresponding protected lactones. Three different catalysts have 
been tested to optimize the reaction: Grubbs first generation 6.023 (Grubbs 
I), Grubbs second generation 6.024 (Grubbs II) and Hoveyda-Grubbs 6.025 
(figure 4). 
 
 
Figure 4 
As shown in table 3, the Grubbs second generation complex is the best 
catalyst for this cyclisation: the yield is higher and the conversion is 
complete after only one hour. When Grubbs first generation or Hoveyda-
Grubbs catalysts were employed, the reaction was significantly slower and a 
complete conversion could not be achieved. 
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Molecule Catalyst (mol%) Time (min) Conversiona Yield (%) 
6.021 6.023 (8) 960 Incomplete 34 
6.021 6.024 (3) 60 Complete 56 
6.021 6.025 (3) 60 Incomplete ndb 
6.022 6.024 (4) 60 Complete 78 
aObserved on TLC : starting material’s spot has disappeared or not 
bnd = not determined 
Table 3 
These optimized conditions were then applied to both dienes. Gratifyingly, 
the two protected lactones 6.026 and 6.027 were isolated in good yields 
(scheme 27). 
 
Scheme 27 
The best results were obtained with Grubbs II catalyst 6.024. This 
observation can be explained by the higher reactivity of this species as 
compared to its first generation analogue 6.023. In fact, the presence of an 
NHC ligand accelerates the dissociation of the phosphine ligand whilst 
rendering the ruthenium more electrophilic. Addition of the complex on the 
more electron rich double bond is thus a faster process. Moreover, this 
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catalyst is more thermally stable and less degradation or dimerisation 
reactions can be observed, as compared to the Grubbs I reagent. 
Finally, lactone 6.027 was deprotected using tetrabutylammonium fluoride 
in THF13, affording the primary alcohol 6.028 in 39 % yield (scheme 28). 
 
Scheme 28 
Overall, lactone 6.028 was synthetized in five steps and 24 % overall yield 
from commercially available glycidol. 
This lactone 6.028 is of great interest because it can be further modified to 
form new compounds similar to jerangolid D. In fact, the double bond 
enables the introduction of a wide range of new functionalities thus giving 
rise, after coupling, to various analogues.  
However, the synthesis described here cannot be transposed on a larger scale 
due to the high cost of the Grubbs catalyst. For this reason, another pathway 
for the synthesis of this lactone was developed. 
II.1.2. Via intramolecular esterification 
To avoid the use of Grubbs catalyst, an intramolecular esterification of an 
intermediate such as 6.029 in order to generate the lactone moiety has been 
envisioned14 (scheme 29). 
                                                     
13 X.-L. Wang, W.-F. Huang, X.-S. Lei, B.-G. Wei, G.-Q. Lin, Tetrahedron 2011, 
67, 4919-4923.  
14 Only lactone 6.027 has been synthetized with this pathway 
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Scheme 29 
Opening of the oxirane with the in situ generated anion of methyl propiolate, 
in the presence of BF3-etherate, allows the formation of homopropargylic 
alcohol 6.030 in excellent yield15 (scheme 30). 
OTBS
OHO
O
6.030
O
OTBS
O
O
n-BuLi, BF3.OEt2THF6.005 91 %  
Scheme 30 
Partial hydrogenation of the triple bond to the corresponding (Z)-double 
bond, using Lindlar’s catalyst and quinoline, leads to compound 6.029 in 
good yield (scheme 31). 
 
Scheme 31 
                                                     
15 R. J. Maguire, S. P. Munt, E. J. Thomas, J. Chem. Soc., Perkin Trans. 1 1998, 
2853-2864.  
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Different conditions have been tried to access the desired protected lactone 
6.027 from this intermediate 6.030. These are described in table 4. 
 
Entry Reagents Solvent Temperature (°C) Yield (%) 
1 TMSCl, MeOH DCM 0 then r.t. Degradation 
2 TMSCl, MeOH DCM -78 then r.t. Degradation 
3 PPTS16 MeOH 0 then r.t. SM 
4 NaH DMF r.t. SM + Degradation 
Table 4 
Unfortunately, none of these conditions led to the formation of the desired 
product. A search in the literature reveals that the Yamaguchi reaction is one 
of the most powerful methods for the intramolecular esterification of 
hydroxyacids. It was thus decided to apply it in our case. 
The mechanism of this reaction is described in scheme 32. After 
deprotonation, the carboxylate of 6.031 attacks 2,4,6-trichlorobenzoyl 
chloride to form the mixed anhydride 6.033. DMAP then adds to the more 
accessible carbonyl function to generate the corresponding acyl pyridinium 
salt 6.034. Addition of the alcohol to the activated carbonyl is fast and leads, 
after deprotonation, to the formation of the desired ester 6.035. 
                                                     
16 B. Das, S. Nagendra, C. Ravindra Reddy, Tetrahedron: Asymm. 2011, 22, 1249-
1254.  
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Scheme 32 
Ester 6.029 was thus transformed into the corresponding acid, which was 
then reacted with Yamaguchi’s reagent 6.032 and pyridine (instead of 
DMAP) to yield the desired lactone (scheme 32). 
 
Scheme 33 
During saponification of ester 6.029, formation of lactone 6.027 is already 
observed in a ratio lactone/acid of 1:7. It would therefore be interesting to 
modulate these conditions in order to directly access the desired lactone and 
in good yield by a simple base-catalyzed process. 
The conditions for Yamaguchi’s reaction have been slightly modified 
compared to the literature, by replacing DMAP with pyridine. In this case, 
the latter plays a triple role: solvent, base and leaving group. Moreover, it 
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has been shown that the use of pyridine results in the isomerization of the 
double bond17. The two isomers of the acid can thus be cyclised into the 
same lactone, thus obviating the need for a selective reduction of the triple 
bond. 
Finally, deprotection of the TBS group with TBAF afforded lactone 6.028 in 
39 % yield (scheme 34). 
 
Scheme 34 
Compound 6.028 has been prepared in six steps with an overall yield of 
11%, which is lower than the one obtained with the first sequence. However, 
a bigger amount of lactone can be sythetised with this more economical 
pathway and some steps can still be optimised. 
II.2. Synthesis of lactone 3.010 
The strategy for the synthesis of this lactone is the same as the one used for 
lactone 3.011: ring-closing metathesis to cyclise the diene and form the 
trisubstituted lactone. 
Starting from the same intermediate 6.020, esterification with methacryloyl 
chloride led to diene 6.036 in moderate yield (scheme 35). 
                                                     
17 M. Ono, X. Y. Zhao, Y. Shida, H. Akita, Tetrahedron 2007, 63, 10140-10148.  
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Scheme 35 
The conditions for the ring-closing metathesis had been optimised earlier 
and were reproduced without further modifications. Unfortunately, the yield 
is much lower in this case (scheme 36). This can be explained by the 
presence of a methyl group on the more electrophilic double bond which 
increases the steric hindrance and disfavours the ring closing metathesis. 
This reaction is indeed very sensitive to steric hindrance. 
 
Scheme 36 
Finally, lactone 6.037 was deprotected using TBAF to deliver the 
corresponding primary alcohol in 49 % yield (scheme 37). 
 
Scheme 37 
206                          LACTONE SYNTHESIS 
Overall, lactone 6.038 was obtained in five steps with a global yield of 6 %, 
staring from commercially available glycidol. The three last steps can 
definitely be further optimized to increase the overall yield. 
In summary, the lactone present in jerangolid D has been successfully 
synthesized along with three new analogues in moderate to good yields. The 
synthesis of these new analogues still needs to be applied to the 
enatiomerically pure starting material but that should not be a problem.
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I. Central fragment synthesis 
As stated in the objectives, it would be interesting to modify the central part 
of the jerangolid family. Some examples are presented in figure 1. 
 
Figure 1 
In order to form these olefins using two Julia olefinations, it is necessary to 
prepare the corresponding sulfones. In this chapter, we describe the synthesis 
of four intermediates that were synthetized by Sophie Moreau during her 
master thesis (figure 2). 
 
Figure 2 
The strategy developed for the synthesis of 7.001 and 7.002 starts with the 
1,4 addition of thiophenol to methyl acrylate or methacrylate. The ester 
function can further be reduced to the corresponding alcohol followed by 
protection with a TBS group. Finally, the sulfides can be oxidized to the 
desired sulfones (scheme 1). 
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Scheme 1 
The intermediate 7.012 can be reached by transforming one –OH function in 
diol 7.011 into the corresponding sulfur derivative. The remaining alcohol 
can be protected with a TBS group and finally the sulfur can be oxidized to 
afford fragment 7.003 (scheme 2). 
 
Scheme 2 
Finally, addition of thiophenol to bromoester 7.013 would allow the 
formation of derivative 7.014. The ester function can then be reduced to the 
corresponding alcohol followed by its protection with a TBS group. 
Oxidation of the sulfur would lead to the desired sulfone 7.004 (scheme 3). 
O
Br OMe
SH
Base OPhS OMe PhO2S OTBS+
7.013 7.008 7.014 7.003  
Scheme 3 
These syntheses are described in the following sections. The main objective 
was to try to couple these fragments with dihydropyran 2.001 which is the 
reason why the steps in these syntheses have not been optimized. 
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I.1. Synthesis of esters 7.009, 7.010, 7.014  
Esters 7.009 and 7.010 were prepared using a procedure described in the 
literature1. 
R
O
OMe +
SH
Et3N, CH2Cl2
0 °C to r.t., 2 h
PhS OMe
O
R
R=H: 7.005
R=Me 7.006
7.008 R=H: 99 % 7.009R=Me: 45 % 7.010  
Scheme 4 
Thiophenol was stirred with methyl acrylate or methyl methacrylate in the 
presence of triethylamine to furnish compounds 7.009 and 7.010 in 99 % and 
45 % yields respectively. The moderate yield obtained for compound 7.010 
can be explained by the loss of the product during the workup of the 
reaction. 
In the case of ester 7.014, thiophenol was stirred with bromoester 7.013 in 
the presence of triethylamine to afford the desired compound in very good 
yield2 (scheme 5). 
 
Scheme 5 
                                                     
1 P. Bakuzis, M. L. Bakuzis, J. Org. Chem. 1981, 2, 235-239. 
2 K. Miura, N. Fujisawa, H. Saito, D. Wang, A. Hosomi, Org. Lett. 2001, 16, 2591-
2594. 
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I.2. Reduction of the ester functions 
The most commonly used method to reduce esters to the corresponding 
alcohols employs lithium aluminium hydride. This technique has thus been 
applied to our substrates3 (scheme 6). 
 
Scheme 6 
After treatment and filtration of the crude mixture, the alcohols are obtained 
in excellent yields without purification.  
I.3. Synthesis of alcohol 7.012 
Alcohol 7.012 was obtained by treating diol 7.011 with Ph2S2 in the presence 
of tributyl phosphine in moderate yield4 (scheme 7). 
 
Scheme 7 
I.4. Protection of the alcohol functions 
The four alcohols were then protected with a TBS group in the presence of 
imidazole in good yields (scheme 8). 
                                                     
3 T. Hirie, H. Tanida, J. Org. Chem. 1980, 24, 4961-4965. 
4 K. J. Hale, M. Frigerio, S. Manaviazar, Org. Lett. 2001, 23, 3791-3794. 
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n=1 R1=R2=H 7.016n=1 R1=Me, R2=H 7.017n=0 R1=R2=H 7.018n=1, R1=R2=Me 7.012
n
TBSCl, Im
THF, 0 °C to r.t.PhS OH
R1 R2 PhS OTBS
R1 R2
n
n=1 R1=R2=H: 70 % 7.019n=1 R1=Me, R2=H: 67 % 7.020n=0 R1=R2=H: 62 % 7.021n=1, R1=R2=Me: 80 % 7.022  
Scheme 8 
I.5. Oxidation into sulfones 
A classical method employing two equivalents of mCPBA in the presence of 
NAHCO3 has been used to oxidize sulfurs into the corresponding sulfones 
(scheme 9). 
 
Scheme 9 
The yields are moderate which could come from the low purity of mCPBA 
used for these reactions. 
These fragments are now ready to be coupled with dihydropyran 2.001. A 
couple of tests were run but the results were not encouraging. Because of a 
shortage of time, these experiments were abandoned but hopefully, Kevin 
Debrus will find a practical methodology to couple all these fragments easily 
during his PhD thesis.
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I.1. General conclusions and perspectives 
At the beginning of this work, we were interested in the synthesis of 
jerangolid D and some new analogues based on the retrosynthesis in scheme 
1. 
O
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O
H3C
MeO HH
1
8 15
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A
B
C O
O
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1
OH
6
7
+
TBSO SO2Ph
+
O
O H H
A B
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7 8
15
2.001
2.030
2.031
Scheme 1 
We started our work with the synthesis of dihydropyran C, based on the 
strategy developed by Dr J. Pospisil during his Ph.D. thesis. Unfortunately, 
in our case, the yield and the selectivity for the SMS reaction were much 
lower (scheme 2). Despite the low yield, we were able to isolate the desired 
product 4.095 and to continue the sequence. Ring-closing metathesis, 
followed by TBAF deprotection, yielded dihydropyran 4.099 in 79 % over 
two steps (scheme 3). 
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Scheme 2 
 
Scheme 3 
At this point, in view of the disappointing results obtained with the direct 
three-components SMS reaction or the acetal formation, and since the 
optimization and study of this reaction was not the main goal of this thesis, 
we decided to move on to another approach and synthetize our fragments via 
a different sequence. 
This new sequence has two key steps: the reduction of an alkyne to the 
corresponding substituted (Z)-alkene and an ISMS cyclyzation. 
After many optimizations, we were able to develop a synthesis to access the 
desired dihydropyran C in good yields and excellent reproducibility. It 
includes the reduction of alkyne 4.112 via a hydrozirconation/methylation 
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process to the (Z)-vinylsilane 4.135 and its subsequent cyclization to the 
corresponding DHP 4.138 (scheme 4). 
OTHP
OBn
TMS
OTHP
OBn
I
1) Cp2ZrCl2superhydride
THF
2) I2, o.n.
OH
OBn
TMS
DHP, CSA
DCM
4.112 4.114 4.130
quant. 68 %
TMS
 
 
Scheme 4 
Gratifyingly, this approach enabled us to obtain the desired protected DHP 
4.138 in 30 % overall yield starting from adduct 4.112 in a reproducible 
manner (scheme 5)! 
 
Scheme 5 
In addition, starting from the same compound 4.112, we employed other 
reducing agents to form original (Z)-vinylsilanes which were further cylized, 
via an ISMS cyclization, to form new dihydropyrans analogues with 
interesting structures in moderate to excellent yields (figure 1). 
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Figure 1 
The second part of this work was devoted to the synthesis of the right-hand 
part of jerangolids B, E and H in which the stereochemistry at C14 is still 
unknown (figure 2). 
 
Figure 2 
Starting from our previously synthetized DHP 4.099b, we were able to reach 
the right-hand part of jerangolids B and H through the epoxidation of the 
double bond and the opening of this epoxide. Therefore, we proposed that 
the methyl group in jerangolid B occupies an equatorial position whilst the –
OH function is axial, as indicated in figure 3. 
 
 
Figure 3 
Hydrogenation of the same double bond enabled us to access the right-hand 
part of jerandolid E. Thus, we suggested that the methyl group in jerangolid 
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E occupies the equatorial position. The full structure of jerangolid E is thus 
shown in figure 4. 
. 
Figure 4 
On the other hand, the synthesis of the left-hand lactone A of jerangolid D 
was completed in good yields and in a reproducible manner (figure 5). 
O
MeO
O
OBn
2.034  
Figure 5 
This lactone 2.034 still needs to be deprotected to complete the sequence. 
Three new analogues of this lactone were also prepared in their racemic 
version (figure 6).  
O
OH
O
MeO
O
OH
O
Me O
OH
O
6.016 6.038 6.028  
Figure 6 
These syntheses also have to be transposed to the enatiomerically pure 
version. 
Finally, four different sulfones mimicking the central fragment B were 
prepared in moderate yield. 
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At the end of this work, we have synthetized a variety of compounds, 
analogues of each fragment of the family of jerangolids. The next step would 
naturally be, after oxidation, to couple them in order to form a library of new 
analogues of jerangolid D. One way to couple them would be to use the 
strategy developed by Dr J. Pospisil, using two subsequent Julia olefination 
(scheme 6). 
SO2Ph
OTBS
1) n-BuLi, THF, -78 °C
2) 2.001, -78 °C, 2 h
3) BzCl, -78 °C to r.t.
4) Me2N(CH2)3OH
OTBSO H H
PhO2S
OBz
OTBSO H
SmI2HMPA
THF, -78 °C
0-61 % over 2 steps
E/Z: >95:1
H
1) n-BuLi, THF, -78 °C
2) 2.001, -78 °C, 2 h
OTBSO H H
PhO2S
OR SmI2HMPA
THF, -78 °C
2.031 2.036
2.038, R=H
2.036, R=Bz
2.037Bz2OSc(OTf)3CH3CN, r.t.
52-67 % over 3 steps
E/Z >95:1
Path 1
Path 2
Scheme 6 
However, this approach is long, not always reproducible and there are a lot 
of fragments to couple. For these reasons, it would be interesting to develop 
an easy one-pot process using a double Julia olefination with a bis-sulfone 
such as 8.001 (figure 7). 
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Figure 7 
All these compounds that we prepared should as well be submitted to 
biological evaluation in order to estimate their potential antifungal activities.
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I. Instrumentation and chemicals 
Unless otherwise noted, all manipulations were performed under an argon 
atmosphere using standard glassware.  Diethyl ether and THF were distilled 
on sodium/benzophenone under argon atmosphere. Dichloromethane, 
triethylamine and trimethylsilyl chloride were distilled on CaH2. Solvents 
used for work-up were of technical grade. Commercial reagents were 
purchased from Acros, Sigma-Aldrich, ABCR, TCI or Fluorochem and used 
as received unless stated otherwise. Infrared spectra (IR) were recorded on a 
Shimadzu FTIR-8400S spectrometer. Wave numbers are given in cm-1. 1H 
and 13C NMR spectra were recorded on BRUKER Avance II (300 MHz for 
1H and 75 MHz for 13C). 1H and 13C NMR chemical shifts are reported 
relative to CDCl3 (7.26, 77.16 ppm). Chemical shifts (δ) and coupling 
constants are respectively reported in ppm and Hertz (Hz). If necessary, the 
structures were confirmed by 2 dimensional analyses (COSY, HMQC and 
HMBC). 1H spectra are described as explained below: chemical shift 
(multiplicity, integration, attribution, coupling constant(s) Hz). 13C spectra 
are described as explained below: chemical shift (attribution). Multiplicity is 
given as follows: s = singlet, d = doublet, t = triplet, q = quartet, quint = 
quintuplet, m = multiplet, dd = doublet of doublet, td = triplet of doublet, qd 
= quartet of doublet and br = broad. When the compound is present as a 
mixture of two diastereomers, the attribution is written Hx for one 
diastereomer and Hx’ for the other one. High resolution Mass Spectra 
(HRMS) and Mass Spectra (MS) were obtained from a Thermo Scientific 
Qexactive, with accurate mass reported for the molecular ion [M+H]+ or 
suitable fragment ions. Spectra are described in the following way: m/z 
(intensity, %), [Fragmentation]. GC analyses were recorded on a Thermo 
Finningan Trace GC apparatus with a CHIRALSIL-DEX CB (25m, 0.25 
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mm, 25 µm) column. Column chromatography was carried out on silica gel 
(ROCC 60, 40-63 µm). TLC analyses were performed on commercial 
aluminum plates bearing a 0.25 mm layer of Merck Silica gel 60F254.  
II. Chapter 4: Dihydropyran synthesis 
II.1. Substrates synthesis 
II.1.1. Synthesis of esters 4.063, 4.087 and 4.094 
II.1.1.1. Ester 4.063 
 
To a solution of (S)-ethyl lactate (15 g, 127 mmol) and imidazole (5 g, 42 
mmol) in THF (0.5 M) at 0°C was added TBDPS-Cl (14 g, 51 mmol) 
carefully. The reaction mixture was stirred at room temperature overnight. 
Water was then added and the aqueous phase was extracted with ethyl 
acetate. The organic phases were combined, washed with water and brine 
and dried over Na2SO4, filtered and concentrated under reduced pressure. 
The product was obtained without purification as a slightly yellow oil; yield: 
15 g (quantitative). 
 (S)-ethyl 2-((tertbutyldiphenylsilyl)oxy)propanoate 4.0631 
                                                     
1 Jiri Pospisil, PhD thesis, UCL 2006 
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CAS number: [102732-44-5] 
1H NMR (300MHz, CDCl3): δ 7.70-7.65 (m, 4H, Har) 7.41-7.35 (m, 6H, 
Har), 4.26 (q, 1H, H2, J=6.9 Hz), 4.02 (q, 2H, H4, J=7.2 Hz), 1.36 (d, 3H, H1, 
J=6.9 Hz), 1.14 (t, 3H, H5, J=7.2 Hz), 1.08 (bs, 9H, Htbu). 
13C NMR (75MHz, CDCl3): δ 173.9 (C3), 136.0-135.8-134.9-133.7-133.3-
129.9-127.8-127.7-127.6 (Cph), 69.1 (C2), 60.7 (C4), 26.9 (Ctbu), 21.4 (Ctbu), 
19.4 (C1), 14.2 (C5). 
Data are in agreement with literature values. 
II.1.1.2. Ester 4.087 
 
To a solution of (S)-ethyl lactate (10 g, 85 mmol) and benzyl 
trichloroimidate (26 g, 102 mmol) in petroleum ether (260 mL) was added 
triflic acid (0.3 mL) dropwise. The resulting mixture was stirred at room 
temperature overnight. The precipitate was then filtered and the filtrate was 
concentrated under reduced pressure. The crude mixture was purified by 
silica gel column chromatography (eluent: PE/Et2O 100:1) to afford the pure 
product as a colorless oil; yield: 16.33 g (93 %). 
 (S)-ethyl 2-(benzyloxy) propanoate 4.0872 
                                                     
2 Enders D., von Berg S., Jandeleit B. Org. Synth. 2002, 78, 177 
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CAS number : [54783-72-1] 
1H NMR (300MHz, CDCl3) : δ 7.40-7.29 (m, 5H, Har), 4.70 (d, 1H, H6 J=12 
Hz), 4.45 (d, 1H, H6, J=12 Hz), 4.22 (q, 2H, H4, J=9 Hz), 4.05 (q, 1H, H2, 
J=6 Hz), 1.44 (d, 3H, H1, J=6 Hz), 1.30 (t, 3H, H5, J=9 Hz). 
13C NMR (75MHz, CDCl3) : δ 173.2 (C3), 136.6-128.4-127.9-127.8 (Car), 
74.0 (C2), 71.9 (C4), 60.8 (C6), 18.7 (C1), 14.2 (C5). 
Data are in agreement with literature values. 
II.1.1.3. Ester 4.094 
 
To a solution of (S)-ethyl lactate (15 g, 127 mmol) and imidazole (13 g, 190 
mmol) in DCM (0.5 M) at 0°C was added TBS-Cl (21 g, 140 mmol) 
carefully. The reaction mixture was stirred at room temperature overnight. 
Water was then added and the aqueous phase was extracted with 
dichloromethane. The organic phases were combined, washed with brine and 
dried over Na2SO4, filtered and concentrated under reduced pressure. The 
product is obtained without purification as a colorless oil; yield: 30 g 
(quantitative). 
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 (S)-ethyl 2-((tertbutyldimethylsilyl)oxy)propanoate 4.0943 
 
CAS number : [105198-38-7] 
1H NMR (300MHz, CDCl3) : δ 4.29 (q, 1H, H2, J=6.6 Hz), 4.21-4.10 (m, 
2H, H4), 1.37 (d, 3H, H1, J=6.9 Hz), 1.26 (t, 3H, H5, J=7.2 Hz), 0.88 (s, 9H, 
HTBS), 0.08 (s, 3H, HTBS), 0.05 (s, 3H, HTBS). 
13C NMR (75MHz, CDCl3): δ 174.2 (C3), 68.6 (C2), 60.8(C4), 25.8 (CTBS), 
21.4 (CTBS), 18.4 (C1), 14.3 (C5), -4.8 (CTBS), -5.2 (CTBS). 
Data are in agreement with literature values. 
II.1.2. Synthesis of aldehydes 4.061, 4.111 and 2.035 
II.1.2.1. Aldehyde 4.061 
 
To a solution of silylated ester (5 g, 14 mmol) in DCM (0.1M) was added 
DIBAL-H (15.4 ml, 15.4 mmol) dropwise at -78°C. The reaction mixture 
was stirred at -78°C for 3 hours. Acetone was added to quench the remaining 
DIBAL-H. HCl 1 M was then added dropwise at -78°C and then the reaction 
mixture was allowed to warm up to 0°C. The aqueous phase was extracted 
twice with dichloromethane. The organic phases were combined, washed 
with NaHCO3 sat and brine, dried over Na2SO4, filtered and carefully 
                                                     
3 Joly, G. D.; Jacobsen, E. N. Org. Lett. 2002, 4, 1795.  
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concentrated under reduced pressure. The crude mixture was purified by 
silica gel column chromatography (eluent: PE/Et2O 35:1) to afford the pure 
product as a colorless oil; yield: 
4.1 g (93 %). 
 (S)-ethyl 2-((tertbutyldiphenylsilyl)oxy)propanal 4.0614 
 
CAS number: [135367-18-9] 
1H NMR (300MHz, CDCl3): δ 9.64 (s, 1H, H3), 7.67 (m, 4H, HAr), 7.60 (m, 
6H, HAr), 4.12 (qd, 1H, H2, J=6.9 Hz, J=1.2 Hz), 1.23 (d, 3H, H1, J=6.9 Hz), 
1.10 (s, 9H, HTBu). 
13C NMR (75MHz, CDCl3): δ 204.0 (C3), 138.5-127.7 (Cph), 77.4 (C2), 27.1 
(CtBu), 19.4 (CtBu), 18.5 (C1). 
Data are in agreement with literature values. 
II.1.2.2. Aldehyde 4.111 
 
To a solution of benzylated ester (5 g, 24 mmol) in DCM (240 mL) was 
added DIBAL-H (1 M in DCM, 26.4 ml, 26.4 mmol) dropwise at -78°C. The 
reaction mixture was stirred at -78°C for 3 hours. Acetone was added to 
quench the remaining DIBAL-H. HCl 1M was then added dropwise at 
-78°C and the reaction mixture was allowed to warm up to 0°C. The aqueous 
                                                     
4 Baudrenghien L., Master thesis UCL 2009 
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phase was extracted with dichloromethane (3x). The organic phases were 
combined and washed with NaHCO3 sat and brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude mixture was 
purified by silica gel column chromatography (eluent: PE/Et2O 35:1) to 
afford the pure product as a colorless oil; yield: 
4.1 g (93 %). 
 (S)-ethyl 2-(benzyloxy) propanal 4.1112 
 
CAS number: [81445-44-5] 
1H NMR (300MHz, CDCl3): δ 9.68 (s, 1H, H3), 7.38-7.31 (m, 5H, Har), 4.66 
(d, 1H, H5, J=12 Hz), 4.60 (d, 1H, H5, J=12 Hz), 3.90 (qd, 1H, H2, J=9 Hz, 
3Hz), 1.33 (d, 3H, H1, J=9 Hz). 
13C NMR (75MHz, CDCl3): δ 203.4 (C3), 137.3-128.6-127.9 (Car), 79.4 (C2), 
72.0 (C5), 15.5 (C1). 
Data are in agreement with literature values. 
II.1.2.3. Synthesis of aldehyde 2.035 
 
To a solution of silylated ester (6 g, 26 mmol) in DCM (0.1 M) was added 
DIBAL-H (28 ml of 1M solution, 28.4 mmol) dropwise at -78°C. The 
reaction mixture was stirred at -78°C for 2 hours. Acetone was added to 
quench the remaining DIBAL-H. HCl 1 N was then added dropwise at -78°C 
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and then the reaction mixture was allowed to warm up to 0°C. The aqueous 
phase was extracted twice with dichloromethane. The organic phases were 
combined and washed with NaHCO3 sat and brine, dried over Na2SO4, 
filtered and carefully concentrated under vacuum. The crude mixture was 
purified by silica gel column chromatography (eluent: PE/Et2O 35:1) to 
afford the pure product as a colorless oil; yield: 4.5 g (93 %). 
 (S)-ethyl 2-((tertbutyldimethylsilyl)oxy)propanal 2.0353 
 
CAS number: [87727-28-4] 
1H NMR (300MHz, CDCl3): δ 9.61 (s, 1H, H3), 4.09 (qd, 1H, H2, J=6.9Hz, 
J=0.9Hz), 1.27 (d, 3H, H1, J=6.9Hz), 0.91 (s, 9H, HTBS), 0.1 (s, 3H, HTBS), 
0.09 (s, 3H, HTBS). 
13C NMR (75MHz, CDCl3): δ 204.4 (C3), 74.0 (C2), 25.9 (CTBS), 18.6 
(CTBS), 18.3 (C1), -4.8 (CTBS), -4.6 (CTBS). 
Data are in agreement with literature values. 
II.1.3. Synthesis of lactic acid 4.088 
OEt
O
OBn
4.087
LiOH
THF, r.t., 5 h
95 %
OH
O
OBn
4.088  
To a solution of benzylated ester (3.9 g, 18.6 mmol) in THF (0.1 M) at 0°C 
was added a solution of lithium hydroxide (1.6 g, 37.2 mmol) in water (0.2 
M). The resulting solution was warmed up to room temperature and stirred 
for five hours. It was then quenched with a 1M solution of HCl and extracted 
with dichloromethane (4x). The organic phases were combined, washed with 
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brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
The pure product was obtained as a white solid; yield: 3.2 g (95 %). 
 (S)-2-benzyloxypropionic acid 4.0885 
 
CAS number : [33106-32-0] 
1H NMR (300MHz, CDCl3) : δ 7.37-7.32 (m, 5H, Har), 4.70 (d, 1H, H4, 
J=11.7 Hz), 4.54 (d, 1H, H4, J=11.7 Hz), 4.11 (q, 1H, H2, J=6.9 Hz), 1.49 (d, 
3H, H1, J=6.9 Hz). 
13C NMR (75MHz, CDCl3): δ 178.1 (C3), 137.5-128.6-127.8-127.4 (Car), 
77.2 (C2), 71.8 (C4), 16.2 (C1). 
Data are in agreement with literature values. 
II.1.4. Synthesis of racemic allylic alcohols 4.065, 
4.068 and 4.071 
II.1.4.1. General procedure 
To a suspension of activated magnesium (1.4 eq) in diethyl ether (1 M) 
under inert atmosphere was added a crystal of iodine (solution turn to 
yellow) and then a few drops of ethyl bromide to start forming the Grignard 
reagent. Once the reaction went from yellow to colorless, the rest of the ethyl 
bromide (1.2 eq) was carefully added dropwise. The reaction was 
exothermic and went quickly to diethyl ether reflux which was controlled 
with an ice bath. The reaction mixture was stirred for an hour. Aldehyde (1 
                                                     
5 Hoppe, I.; Schöllkopf, U. Lieb. Ann. Chem. 1983, 1983, 372.  
236                                    EXPERIMENTAL PART 
eq) was then added dropwise at 0°C and the reaction mixture was stirred 
overnight. NH4Clsat was added and the aqueous phase was extracted three 
times with diethyl ether. The organic phases were combined, washed with 
brine, dried over Na2SO4, filtered and carefully concentrated under reduced 
pressure.  
II.1.4.2. Synthesis of 4.065 
 
 2-methylpent-1-en-3-ol 4.0656 
 
The reaction was carried out on 243 mmol (17 g). 
The crude mixture was purified by distillation (Teb 110-120°C) to afford the 
pure product as a colorless oil; yield: 18.6 g (77 %). 
CAS number: [2088-07-5] 
1H NMR (300MHz, CDCl3): δ 4.93 (bs, 1H, H1), 4.84 (bs, 1H, H1), 4.00-
3.95 (m, 1H, H3), 1.71 (s, 3H, H6), 1.58-1.54 (m, 2H, H4), 0.89 (t, 3H, H5, J= 
7.5 Hz).  
13C NMR (75MHz, CDCl3): δ 147.2 (C2), 111.1 (C1), 77.2 (C3), 27.6 (C4), 
17.4 (C6), 9.7 (C5). 
Data are in agreement with literature values. 
                                                     
6 J. Cossy, D. Bauer, V. Bellosta, Tetrahedron 2002, 58, 5909.  
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II.1.4.3. Synthesis of 4.068 
 
 1-penten-3-ol 4.0687 
 
The reaction was carried out on a 50 mmol scale (2.8 g of acrolein). 
The crude mixture was purified by distillation (Teb 100-110 °C) to afford the 
pure product as a colorless oil; yield: 4.31 g (88 %) 
CAS number: [616-25-1] 
1H NMR (300MHz, CDCl3): δ 5.91-5.80 (m, 1H, H2), 5.22 (d, 1H, J=17.1 
Hz, H1), 5.11 (d, 1H, J=10.5 Hz, H1), 4.02 (m, 1H, H3), 1.56 (m, 2H, H4), 
0.92 (t, 3H, J=6 Hz, H5).  
13C NMR (75MHz, CDCl3): δ 141.1 (C2), 114.9 (C1), 74.7 (C3), 30.0 (C4), 
9.7 (C5). 
Data are in agreement with literature values. 
II.1.4.4. Synthesis of 4.071 
 
                                                     
7 V. N. Odinokov, R. R. Vakhidov, R. N. Shakhmaev, V. V. Zorin, Chem. Nat. 
Compd. 1996, 32, 912.  
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 Hex-1-en-3-ol 4.0718 
 
The reaction was carried out on 89 mmol (5 g). 
The crude mixture was purified by distillation (Teb 135-140°C) to afford the 
pure product as a colorless oil; yield: 8.65 g (97 %). 
CAS number: [4798-44-1] 
1H NMR (300MHz, CDCl3): δ 5.91-5.80 (m, 1H, H2), 5.20 (d, 1H, H1, 
J=17.2 Hz), 5.08 (d, 1H, H1, J= 11.3 Hz), 4.13-4.06 (m, 1H, H3), 1.53-1.46 
(m, 2H, H4), 1.43-1.35 (m, 2H, H5), 1.19 (t, 3H, H6, J=9 Hz).  
13C NMR (75MHz, CDCl3): δ 141.3 (C2), 114.4 (C1), 72.9 (C3), 39.1 (C4), 
18.5 (C5), 13.9 (C6). 
Data are in agreement with literature values. 
II.1.5. Silylation of allylic alcohols with TMS-Cl 
II.1.5.1. General procedure 
To a solution of allylic alcohol (1 eq) in pentane (0.2 M) under inert 
atmosphere at 0°C was added Et3N (1 eq) dropwise. The mixture was stirred 
for 5 minutes after which TMS-Cl (1 eq) was added dropwise. The reaction 
mixture was allowed to warm up to room temperature and stirred for 2h30. It 
was then filtered and the solid was rinsed thoroughly with pentane. The 
combined solutions were carefully removed under reduced pressure without 
heating.  
                                                     
8 W. F. Bailey, X. L. Jiang, J. Org. Chem. 1994, 59, 6528.  
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II.1.5.1. Synthesis of silyl ether 4.066 
 
 Trimethyl(2-methylpent-1-en-3-yloxy)silane 4.0664 
 
The reaction was carried out on 30 mmol (3 g). 
The crude mixture was purified by silica gel column chromatography 
(eluent: PE/Et2O 50:1) to afford the pure product as a colorless oil; yield: 4 g 
(77 %).  
CAS number: [902769-00-0] 
1H NMR (300MHz, CDCl3): δ 4.85-4.83 (m, 1H, H1), 4.76-4.74 (m, 1H, 
H1), 3.91 (t, 1H, H3, J= 6.3 Hz), 1.66 (s, 3H, H6), 1.49 (q, 2H, H4, J=7.5 Hz), 
0.83 (t, 3H, H5, J=7.5 Hz), 0.09 (s, 9H, HTMS). 
13C NMR (75MHz, CDCl3): δ 147.7 (C2), 110.8 (C1), 78.3 (C3), 29.0 (C4), 
17.3 (C6), 10.3 (C5), 0.2 (CTMS). 
Data are in agreement with literature values. 
II.1.5.2. Synthesis of silyl ether 4.069 
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 3-(trimethylsilyloxy)-1-pentene 4.0699 
 
The reaction was carried out on 23 mmol (2 g). 
The crude mixture was purified by silica gel column chromatography 
(eluent: PE/Et2O 50:1) to afford the pure product as a colorless oil; yield: 
3.26 g (88 %). 
CAS number: [18388-22-2] 
1H NMR (300MHz, CDCl3): δ 5.86-5.76 (m, 1H, H2), 5.13 (d, 2H, J=17.1 
Hz, H1), 5.03 (d, 1H, J=10.2 Hz, H1), 3.98 (m, 1H, H3), 1.27 (m, 2H, H4), 
0.88 (t, 3H, J=6.2 Hz, H5), 0.11 (s, 9H, HTMS). 
13C NMR (75MHz, CDCl3): δ 141.6 (C2), 113.8 (C1), 75.3 (C3), 30.9 (C4), 
10.03 (C5), 0.35 (TMS). 
Data are in agreement with literature values. 
II.1.5.3. Synthesis of silyl ether 4.072 
 
 3-(trimethylsilyloxy) hex-1-ene 4.07210 
                                                     
9 a. M. J. Brown, T. Harrison, L. E. Overman, J. Am. Chem. Soc. 1991, 113, 5378. b. 
R. J. Fessenden, M. D. Coon, J. Org. Chem. 1964, 29, 1607.  
10 T. Hayashi, M. Konishi, K. I. Yokota, M. Kumada, J. Organomet. Chem. 1985, 
285, 359.  
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The reaction was carried out on 30 mmol (3 g). 
The crude mixture was purified by silica gel column chromatography 
(eluent: PE/Et2O 50:1) to afford the pure product as a colorless oil; yield:  
4.2 g (81 %). 
CAS number: [17869-38-4] 
1H NMR (300MHz, CDCl3): δ 5.86-5.75 (m, 1H, H2), 5.16-5.00 (m, 2H, 
H1), 4.09-4.01 (m, 1H, H3), 1.50-1.26 (m, 4H, H4 and 5), 0.87 (t, 3H, J=6.9 Hz, 
H6), 0.09 (s, 9H, HTMS). 
13C NMR (75MHz, CDCl3): δ 138.8 (C2), 115.7 (C1), 74.9 (C3), 31.4 (C4), 
16.4 (C5), 10.5 (C6), 0.41 (CTMS). 
Data are in agreement with literature values. 
II.1.6. Acylation 
 
To a solution of alcohol (1 g, 11.6 mmol), lutidine (1.62 mL, 13.9 mmol) 
and DMAP (0.028 g, 11.1 mmol) in DCM (116 mL) at 0°C was added Ac2O 
(1.32 mL, 13.9 mmol). The resulting mixture was stirred at 0°C for 4 hours 
and quenched with a saturated solution of NaHCO3, extracted with DCM 
(3x), washed with brine and filtered over a pad of silica gel to remove the 
remaining lutidine; yield: 1.2 g (quant.). 
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 Pent-1-en-3-yl acetate 4.09111 
 
CAS number: [10500-11-5] 
1H NMR (300MHz, CDCl3): δ 5.82-5.70 (m, 1H, H2), 5.29-5.14 (m, 3H, H1, 
3), 2.06 (s, 3H, H7), 1.66-1.58 (m, 2H, H4), 0.89 (t, 3H, H5, J=7.5 Hz). 
13C NMR (75MHz, CDCl3): δ 170.5 (C6), 136.4 (C2), 116.8 (C1), 76.1 (C3), 
27.3 (C7), 21.3 (C4), 9.5 (C5). 
Data are in agreement with literature values. 
II.1.7. Triple bond addition to aldehyde 
 
  
To 51 mL of THF at -78°C, was added tBuLi (1.9M in pentane, 14.8 mL, 28 
mmol) dropwise followed by trimethylsilyl prop-1-yne (4.15 mL, 28 mmol). 
The resulting mixture was stirred at -78 °C for 2h30 and then copper(I) 
iodide (2.9 g, 15.3 mmol) was added. The acetone/dry ice bath was replaced 
with an ice bath (0°C) for 30 minutes; the solution became dark red. The 
solution was once again lowered to -78°C and aldehyde 4.111 (2.4 g, 12.7 
mmol) was added dropwise. The reaction mixture was stirred for 2h at -78°C 
                                                     
11 Z. Rappoport, S. Winstein, W. G. Young, J. Am. Chem. Soc. 1972, 94, 2320.  
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and was added on a saturated NH4Cl solution at 0°C and stirred overnight. 
The aqueous phase was extracted with EtOAc (5x). The organic phases were 
combined and washed with a saturated solution of NH4Cl (4x), dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified by silica gel column chromatography (eluent: PE/Et2O 
30:1) to afford the pure product as a yellow oil and a mixture of 2 
diastereomers (1:1); yield: 3.0 g (74 %).  
 (2S)-2-(benzyloxy)-6-(trimethylsilyl)hex-5-yn-3-ol 4.112 
 
The two diastereomers were differentiated in NMR but the absolute 
stereochemistry at C8 is unknown. It has been attributed arbitrarely for the 
clarity of the spectra analysis. 
1H NMR (300MHz, CDCl3): δ 7.38-7.28 (m, 10H, Har), 4.69-4.46 (m, 4H, 
H5,5´), 3.82-3.78 (m, 1H, H8), 3.67-3.60 (m, 3H, H8´,7, 7´), 2.59-2.44 (m, 4H, 
H9,9´), 1.24 (d, 3H, J= 9 Hz, H6), 1.22 (d, 3H, J=9 Hz, H6´), 0.15 (s, 18H, H12, 
H12´).  
13C NMR (75MHz, CDCl3):  δ 138.4 (C4), 138.3 (C4´), 128.6-128.5 (C2,C2´), 
127.9-127.8 (C1,C1´,C3,C3´), 103.3 (C10´), 103.8 (C10), 87.4 (C11´), 87 (C11), 
76.5 (C7´), 76.2 (C7), 73.3 (C8´), 72.1 (C8), 71.3 (C5´), 71.1 (C5), 25.0 (C9´), 
24.4 (C9), 15.7 (C6´), 14.5 (C6), 0.2 (C12,12’). 
IR (film, cm-1): 698, 732, 777, 840, 970, 1002, 1072, 1249, 1454, 2175, 
2970. 
MS (ESI) m/z (%): 277.16 (32) [M+1]+, 299.14 (100) [M+Na]+. 
244                                    EXPERIMENTAL PART 
HRMS m/z: calculated for C16H25O2Si: 277.16205. Found: 277.16183. 
II.2. Synthesis of DHP 4.099 
II.2.1. Sequence via SMS reaction 
II.2.1.1. SMS reaction 
 
To a solution of aldehyde (0.31 g, 1.63 mmol) and silylated allylic alcohol 
(0.30 g, 1.75 mmol), in DCM (8.2 mL) was added allylsilane (0.21 mL, 1.80 
mmol). The reaction mixture was refrigerated to -78°C and TMSOTf was 
added (0.03 mL, 0.16 mmol). The resulting mixture was stirred at -78°C for 
3 hours then diisopropylamine was added at the same temperature to quench 
the reaction. Temperature was allowed to rise to room temperature and the 
mixture was then concentrated under reduced pressure. The crude product 
was purified by silica gel column chromatography (Eluent: PE/DCM 20:1  
5:1) to afford the desired product as a mixture of 2 diastereomers; Yield 0.19 
g (39 %). 
 Tert-butyldimethyl(((2S,3R)-3-(((R)-2-methylpent-1-en-3-
yl)oxy)hex-5-en-2-yl)oxy)silane and Tert-butyldimethyl(((2S,3S)-3-
(((S)-2-methylpent-1-en-3-yl)oxy)hex-5-en-2-yl)oxy)silane 4.095a 
ans 4.095b1,4 
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1H NMR (300MHz, CDCl3): δ 5.83-5.77 (m, 2H, H8 and 8’), 5.05-4.83 (m, 8H, 
H9, 9’, 11 and 11’), 3.98-3.92 (m, 2H, H4 and 2’), 3.90-3.79 (m, 1H, H2), 3.60 (t, 1H, 
H4’, J=7.2Hz), 3.36-3.31 (m, 1H, H3), 3.27-3.24 (m, 1H, H3’), 2.42-2.07 (m, 
4H, H7 and 7’), 1.63 (s, 3H, H12), 1.58 (s, 3H, H12’), 1.40-1.58 (m, 4H, H5 and 5’), 
1.13 (d, 3H, H1, J=6.3 Hz), 1.08 (d, 3H, H1’, J=6.3Hz), 0.88-0.83 (m, 24H, H 
6, 6’, and TBS), 0.04 (s, 12H, HTBS). 
13C NMR (75MHz, CDCl3): δ 145.1 (C10), 144.9 (C10’), 137.3 (C8), 136.0 
(C8’), 116.4-115.8-114.2-113-9 (C9, 9’, 11, 11’), 85.6 (C4), 84.2 (C4’), 80.4 (C3), 
79.0 (C3’), 70.6 (C2), 67.1 (C2’), 36.7 (C7), 33.2 (C7’), 26.5 (C5), 26.3 (C5’), 
26.0-25.9 (CTBS), 22.7 (CTBS), 18.5 (C1), 18.1 (C1’), 17.2 (CTBS), 16.6 (C12), 
16.4 (C12’), 10.5 (C6), 10.4 (C6’), -4.3/-4.5/-4.6 (CTBS). 
Data are in agreement with literature values. 
II.2.1.2. Grubbs metathesis 
O
OTBS
O
TBSO H HGC-1,DCM,
40 °C, 15h
4.095 4.099
91 %
 
To a solution of substrate (1 g, 3.2 mmol) in DCM (32 mL) was added 
Grubbs-I catalyst (0.132 g, 0.16 mmol). The mixture was stirred at 40°C 
overnight and then concentrated under reduced pressure. The crude solution 
246                                    EXPERIMENTAL PART 
was filtered on silica gel, rinsed with DCM and used without further 
purification in the next step. 
II.2.1.3. TBAF deprotection 
 
To a solution of substrate (1 g, 3.5 mmol) in THF (18 mL) was added TBAF 
(1 M in THF) (7 mL, 7 mmol). The reaction mixture was stirred at room 
temperature for 4 days, quenched with water and extracted with Et2O (3x). 
The organic phases were combined, washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. The crude product was purified by 
silica gel column chromatography (Eluent PE/Et2O 5:1) to afford the desired 
product as a mixture of 2 diastereomers. Yield: 0.43g (79 % over two steps).  
(See page 251 for analysis). 
II.2.2. Sequence via ISMS 
II.2.2.1. Hydroalumination 
 
To a solution of homopropargyl alcohol (1 g, 3.6 mmol) in THF (0.3 mL) 
and Et2O (12 mL) at 0°C was added dropwise DIBAL-H (1 M in hexane) 
(10.8 mL, 10.8 mmol). The resulting solution was stirred at 50°C for 24 
hours. The reaction mixture was then cooled to 0°C and MeLi (1.6 M in 
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Et2O) (6.8 mL, 10.8 mmol) was added dropwise. After stirring at room 
temperature for 30 minutes, methyl iodide (1.1 mL, 18.1 mmol) was added. 
The resulting solution was stirred at room temperature for 48 hours. The 
solution was poured onto HCl/ice and filtered over celite. The aqueous phase 
was extracted with Et2O (3x). The organic phases were combined, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude 
mixture was purified by silica gel column chromatography to afford the 
desired product inseparable from the side-product. 
 (2S,Z)-2-(benzyloxy)-6-(trimethylsilyl)hept-5-en-3-ol 4.135 and  
(2S)-2-(benzyloxy)-6)(trimethylsilyl)hexan-3-ol 4.144 
 
1H NMR (300MHz, CDCl3): δ 7.36-7.28 (m, 10H, Har), 6.11-5.99 (m, 1H, 
H10), 4.70-4.42 (m, 4H, H5 and 5’), 3.81-3.72 (m, 1H, H7), 3.55-3.39 (m, 3H, 
H7’, 8 and 8’), 2.31-2.26 (m, 2H, H9), 1.78 (s, 3H, H12), 1.51-1.32 (m, 4H, H10’ 
and 9’), 1.22-1.14 (m, 6H, H6 and 6’), 0.57-0.41 (m, 2H, H11’), 0.13 (s, 9H, H13), 
0.03 (s, 9H, H12’). 
13C NMR (75MHz, CDCl3):  δ 138.5 (C10), 137.8 (C4 and 4’), 128.5-127.8-
127.7 (C1,2,3,1’,1’,3’), 78.7 (C8), 74.9-73.5-72.8 (C8’,7,7’), 71.1-70.9 (C5,5’), 36.9-
36.0 (C9’,10’), 34.4 (C9), 24.8 (C12), 16.7 (C11’)  15.4 (C6,6’), 0.37- -1.56 (C13, 
12’) 
MS (ESI) m/z (%): 303.17 (23) [M’+Na]+,  315.17 (100) [M+Na]+ 
HRMS m/z: calculated for C17H28O2SiNa: 315.17554. Found: 315.17508. 
IR (film, cm-1): 696, 735, 837, 1074, 1088, 1248, 1373, 1454, 1616, 2906. 
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II.2.2.2. Hydrozirconation 
II.2.2.2.1. Protection with THP 
 
To a solution of substrate (1 g, 3.62 mmol) in DCM (18 mL) were added 
DHP (0.49 mL, 5.43 mmol) and CSA (0.08 g, 0.36 mmol). The resulting 
solution was stirred at room temperature for 18 hours. It was quenched with 
a saturated solution of K2CO3 and extracted with DCM (3x). The organic 
phases were combined, washed with a saturated solution of NaHCO3, dried 
over MgSO4, filtered and concentrated under reduced pressure. The product 
was used without further purification in the next step. 
II.2.2.2.2. Hydrozirconation 
OTHP
OBn
TMS
OTHP
OBn
I
1) Cp2ZrCl2superhydride
THF
2) I2 (o.n.)
4.114 4.130
68 %
TMS
 
To a solution of Cp2ZrCl2 (0.41 g, 1.38 mmol) in THF (4.6 mL) was added 
Et3BHLi (1.38 mL, 1.38 mmol) dropwise very slowly. The resulting white 
opaque solution indicates that Schwartz reagent is formed. The mixture was 
stirred for 1 hour hidden from light. A solution of substrate 4.114 (0.2 g, 
0.55 mmol) in THF (3 mL) was added dropwise and the resulting mixture 
was heated to 55°C for 1 hour. After cooling down, a solution of I2 (0.5 g) in 
THF (2 mL) was added dropwise and the mixture was stirred at room 
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temperature for 18 hours. The solution was then quenched with a saturated 
solution of Na2S2O3 and extracted with EtOAc (3x). The organic phases 
were combined, washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by 
silica gel column chromatography (eluent: PE/Et2O  20:1) to afford the 
desired product as a mixture of 4 diastereomers. Yield: 0.185 g (68 %). 
II.2.2.2.3. Methylation 
OTHP
OBn
TMS
I
OTHP
OBn
TMS
MeLi
CuCN
Et2O
4.130 4.134  
To a solution of CuCN (0.07 g, 0.83 mmol) in Et2O (1.3mL) at 0°C was 
added MeLi (0.7 mL of 1.6 M solution in Et2O, 1.14 mmol) dropwise. It was 
stirred for 15 minutes at 0°C and then the substrate (0.185 g, 0.38 mmol) 
was added dropwise. The resulting solution was stirred at 0°C for 24 hours. 
The mixture was then quenched with water and extracted with Et2O (3x). 
The organic phases were combined, washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was 
used without further purification in the next step.  
II.2.2.2.4. Deprotection 
 
The crude product (0.115 g, 0.235 mmol) was taken up in a mixture EtOH/ 
H2O (2.1/0.2 mL). PPTS was added (0.006 g, 0.024 mmol) and the resulting 
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solution was stirred at 65°C for 18 hours. It was then quenched with a 
saturated solution of NH4Cl and extracted with Et2O (3x). The organic 
phases were combined, washed with water, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by 
silica gel column chromatography (eluent: PE/Et2O 20:1) to afford the 
desired product as a yellow oil and a mixture of 2 diastereomers (1:1). Yield: 
0.079 g (88 %). (80 % over two steps). 
 (2S,Z)-2-(benzyloxy)-6-(trimethylsilyl)hept-5-en-3-ol 4.135 
 
1H NMR (300MHz, CDCl3): δ 7.33-7.29 (m, 10H, Har), 6.08-5.98 (m, 2H, 
H10 and 10’), 4.68-4.43 (m, 4H, H5 and 5’), 3.75-3.71 (m, 1H, H8), 3.54-3.49 (3H, 
H7, 7’ and 8’), 2.32-2.25 (m, 4H, H9 and 9’), 1.78 (s, 6H, H11 and 11’), 1.23 (t, 6H, H6 
and 6’, J=6Hz), 0.13 (s, 18H, HTMS).  
13C NMR (75MHz, CDCl3): δ 138.6-138.4-138.3-138.0-137.9-137.6 (C4, 
4’,10,10’,11,11’), 128.5-127.9-127.7 (C2,2’,3,3’,4,4’), 77.8 (C7) , 77.3 (C7’), 75.1 (C8), 
73.5 (C8’), 71.1 (C5), 70.9 (C5’), 35.3 (C9), 34.7 (C9’), 25.0 (C11), 24.9 (C11’), 
15.7 (C6), 14.0 (C6’), 0 (CTMS). 
MS (ESI) m/z (%): 315.17 (100) [M+Na]+, 331.15 (22) [M+K]+,  607.36 
(76) [2M+Na]+. 
HRMS m/z: calculated for C17H28O2NaSi: 315.17515. Found: 315.17508. 
IR (film, cm-1): 652, 696, 735, 752, 835, 997, 1028, 1074, 1132, 1248, 1373, 
1454, 2854, 2869, 2926, 2951, 3498. 
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II.2.2.3. Silylation 
 
To a solution of alcohol (0.58 g, 2 mmol) and TMSCl (0.3 mL, 2.4 mmol) in 
DCM (10 mL) at 0°C was added dropwise Et3N (0.35 mL, 2.6 mmol). The 
reaction mixture was stirred at room temperature overnight. Saturated 
NaHCO3 was added and the aqueous phase was extracted with 
dichloromethane (3x). The organic phases were combined, washed with 
water and brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude product was used without further purification in the next 
step. 
II.2.2.4. ISMS 
 
To a solution of substrate (0.32 g, 0.88 mmol) and propionaldehyde (0.07 
mL, 0.97 mmol) in DCM (4.4 mL) at -78°C was added TMS-OTf (0.06 mL, 
0.35 mmol). The resulting mixture was stirred for 2 hours and allowed to 
warm up to -30°C. Quench was performed at -30°C with pyridine followed 
by a saturated solution of NaHCO3. The aqueous phase was extracted with 
DCM (3x). The organic phases were combined, washed with 1M HCl, dried 
over Na2SO4 and concentrated under reduced pressure. The crude mixture 
was purified by silica gel column chromatography (eluent: PE/Et2O 30:1) to 
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afford the pure product as a yellow oil, mixture of 2 diastereomers (1:1); 
yield 0.18g (79%).  
 2-((S)-1-(benzyloxy)ethyl)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran 
4.138 
 
1H NMR (300MHz, CDCl3): δ 7.37-7.26 (m, 5H, Har), 5.56 (bs, 1H, H8), 
4.70-4.57 (m, 2H, H11), 4.09-3.95 (m, 1H, H4), 3.60-3.47 (m, 1H, H2), 3.45-
3.38 (m, 1H, H3), 2.08-2.05 (m, 2H, H7), 1.80-1.72 (m, 1H, H5), 1.58 (s, 3H, 
H10), 1.53-1.39 (m, 1H, H5), 1.22 (d, 3H, H1, J=6 Hz,), 0.90 (t, 3H, H6, J=6 
Hz). 
13C NMR (75MHz, CDCl3):  δ 139.2 (C12), 135.4 (C9), 128.4-127.8-127-5 
(Cph), 120.7 (C8), 78.5 (C4), 77.4 (C2 and 3), 71.4 (C11), 27.3 (C7), 25.9 (C5), 
19.1 (C10), 16.7 (C1), 8.9 (C6). 
MS (ESI) m/z (%): 91.05 (18), 261.18 (76) [M+1]+, 283.16 (100) [M+Na]+. 
HRMS m/z: calculated for C17H25O2: 261.18496. Found: 261.18491. 
IR (film, cm-1): 696, 733, 845, 910, 927, 1028, 1059, 1089, 1095, 1207, 
1371, 1454, 2897. 
II.2.2.5. Debenzylation 
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To a solution of naphthalene (1.77 g, 13.8 mmol) in THF (6 mL) was added 
lithium (0.1 g, 13.8 mmol). The solution was stirred at room temperature for 
2 hours and turned dark green after a few minutes. The substrate (0.72 g, 
2.77 mmol) was then added at -20°C and the solution was stirred at that 
temperature for 30 minutes. The resulting mixture was quenched with water 
and extracted with EtOAc (3x). The organic phases were combined, washed 
with water and brine, dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by silica gel column 
chromatography (eluent: PE/Et2O 8:1) to afford the 2 separated 
diastereomers as colorless oils; yield:0.363 g (77 %).  
 (S)-1-((2S,6S)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-yl)ethanol 
4.099a and (S)-1-((2R,6R)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran-
2-yl)ethanol 4.099b 
 
Dia 4.099a 
1H NMR (300MHz, CDCl3): δ 5.53 (bs, 1H, H8), 4.03 (bs, 1H, H4), 3.67-
3.60 (m, 1H, H2), 3.26-3.20 (m, 1H, H3), 2.89 (s, 1H, -OH), 1.91-1.88 (m, 
2H, H7), 1.81-1.72 (m, 1H, H5), 1.60 (s, 3H, H10), 1.59-1.43 (m, 1H, H5), 
1.15 (d, 3H, H1, J=6 Hz), 0.91 (t, 3H, H6, J=9 Hz). 
13C NMR (75MHz, CDCl3):  δ 135.6 (C9), 120.0 (C8), 78.2 (C4 and 3), 70.6 
(C2), 27.5 (C7), 25.7 (C5), 19.0 (C10), 18.0 (C1), 8.8 (C6). 
MS (ESI) m/z (%): 71.08 (100), 95.08 (33), 109.10 (41), 135.11 (41), 153.12 
(55) (-OBn), 171.14 (80) [M+1]+, 193.12 [M+Na]+ 
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HRMS m/z: calculated for C10H19O2: 171.13818. Found: 171.13796 
IR (film, cm-1): 739, 845, 870, 888, 927, 991, 1026, 1057, 1082, 1115, 1260, 
1367, 1377, 1464, 2933, 3441. 
 = -73.3 (c=1.6 M, CHCl3) 
Dia 4.099b1 
1H NMR (300MHz, CDCl3): δ 5.58 (bs, 1H, H8’), 4.09 (bs, 1H, H4’), 3.93-
3.90 (m, 1H, H2’), 3.49-3.39 (m, 1H, H3’), 2.20-2.11 (m, 1H, H7’),1.85-1.80 
(m, 1H, H7’), 1.78-1.70 (m, 1H, H5’), 1.60 (s, 3H, H10’), 1.56-1.44 (m, 1H, 
H5’), 1.15 (d, 3H, H1’, J=6 Hz), 0.88 (t, 3H, H6’, J=9 Hz). 
13C NMR (75MHz, CDCl3):  δ 135.2 (C9’), 120.5 (C8’), 78.2 (C4’), 76.1 (C3’), 
69.3 (C2’), 25.7 (C7’), 24.3 (C5’), 19.0 (C10’), 17.5 (C1’), 8.5 (C6’). 
Data are in agreement with literature values. 
II.3. Synthesis of DHP 4.182 
II.3.1. P2-nickel12 
 
To a solution of Ni(OAc)2.4H2O (0.13 g, 0.7 mmol) in MeOH (1 mL) was 
added carefully NaBH4 (0.06 g, 1.4 mmol); the solution turned black. The 
reaction vessel was evacuated and backfilled with hydrogen for 5 minutes. 
Ethylenediamine was added (0.2 mL, 2.8 mmol) followed by the substrate 
(0.4 g, 1.4 mmol). The resulting mixture was stirred for 18 hours under 
hydrogen. It was then filtered over silica gel and washed with MeOH. After 
                                                     
12 D. F. Taber, R. J. Herr, D. M. Gleave, J. Org. Chem. 1997, 62, 194. 
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concentration under reduced pressure, the residue was diluted in PE/EtOAc 
(1:1) and washed with water and brine. The organic phase was dried over 
Na2SO4, filtered and concentrated under reduced pressure to afford the 
desired product as a yellow oil, mixture of 2 diastereomers; yield: 0.16 g (80 
%).  
 (2S,Z)-2-(benzyloxy)-6-(trimethylsilyl)hex-5-en-3-ol 4.147 
 
1H NMR (300MHz, CDCl3): δ 7.34-7.25 (m, 10H, Har), 6.44-6.30 (m, 2H, 
H10,10’), 5.66 (d, 1H, H11, J=9 Hz), 5.62 (d, 1H, H11’, J=9 Hz), 4.68-4.42 (m, 
4H, H5,5’), 3.78-3.75 (m, 2H, H8,8’), 3.55-3.49 (m, 2H, H7,7’), 2.35-2.16 (m, 
4H, H9,9’), 1.20 (t, 6H, H6,6’, J=6 Hz), 0.11 (s, 18H, H12,12’). 
13C NMR (75MHz, CDCl3):  δ 144.6 (C10), 144.5 (C10’), 138.6 (C4), 138.4 
(C4’), 132.4-132.4-131.7 (C2,2’), 127.8-127.7 (C1,1’,3,3’), 77.1 (C7), 74.7 (C7’), 
73.2 (C8,8’), 71.1 (C5), 70.9 (C5’), 36.7 (C9), 36.1 (C9’), 15.6 (C6), 14.0 (C6’), 
0.2 (C12,12’). 
MS (ESI) m/z (%): 277.16 (32) [M-1]+, 301.16 (100) [M+Na]+. 
HRMS m/z: calculated for C16H26O2SiNa: 301.15939. Found: 301.15943. 
IR (film, cm-1): 696, 734, 761, 850, 993, 1027, 1072, 1247, 1375, 1454, 
1496, 1604, 2180, 2921, 2954. 
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II.3.2. ISMS 
 
To a solution of substrate (1 g, 2.97 mmol) and propionaldehyde (0.26 mL, 
3.56 mmol) in DCM (15 mL) at -78 °C was added TMS-OTf (0.21 mL, 0.5 
mmol). The resulting mixture was stirred for 2 hours and allowed to warm 
up to -30 °C. Quench was performed at -30°C with pyridine followed by a 
saturated aqueous solution of NaHCO3. The aqueous phase was extracted 
with DCM (3x). The organic phases were combined, washed with 1M HCl, 
dried over Na2SO4 and concentrated under reduced pressure. The crude 
mixture was purified by silica gel column chromatography (eluent (PE/Et2O 
30:1) to afford the pure product as a yellow oil and a mixture of 2 
diastereomers(1:1); yield 0.54 g (74 %).  
 2-((S)-1-(benzyloxy)ethyl)-6-ethyl-3,6-dihydro-2H-pyran 4.181 
 
1H NMR (300MHz, CDCl3): δ 7.37-7.26 (m, 10H, HAr), 5.85-5.78 (m, 2H, 
H8), 5.66-5.59 (m, 2H, H9), 4.71-4.56 (m, 4H, H10), 4.09-4.03 (m, 2H, H4), 
3.67-3.46 (m, 4H, H2 and 3), 2.17-1.91 (m, 4H, H7), 1.61-1.50 (m, 4H, H5), 
1.25 (d, 3H, H1, , J=6 Hz), 1.17 (d, 3H, H1’, J=6 Hz), 1.01-0.93 (m, 6H, H6). 
13C NMR (75MHz, CDCl3):  δ 139.4 (C11), 139.1 (C11’), 130.5 (C9), 130.2 
(C9’), 128.4-127.9-127.8-127.5-127.4 (Car), 124.8 (C8), 124.5 (C8’), 77.4 (C4 
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and 4’), 76.3-76.2 (C3,3’,2,2’), 72.1 (C10), 71.4 (C10’), 28.7 (C5), 28.6 (C5’), 27.3 
(C7), 26.8 (C7’), 16.6 (C1), 15.8 (C1’), 9.8 (C6), 9.6 (C6’). 
MS (ESI) m/z (%): 91.05 (46), 175.11 (100), 247.16 (28) [M+1]+, 269.15 
(100) [M+Na]+. 
HRMS m/z: calculated for C16H23O2: 247.16916. Found: 247.16926. 
IR (film, cm-1): 675, 696, 732, 1027, 1064, 1184, 1373, 1454, 2923. 
II.3.3. Deprotection 
O
BnO
O
HOH H H H
4.181 4.182
Li, naphthalene
THF, -20 °C, 2 h
72 %
 
To a solution of naphthalene (1.52 g, 11.9 mmol) in THF (18.5 mL) was 
added lithium (0.08g, 11.9 mmol). The solution was stirred at room 
temperature for 2 hours and turned dark green after a few minutes. The 
substrate (0.62 g, 2.38 mmol) was then added at -20°C and the solution was 
stirred at that temperature for 30 minutes. The resulting mixture was 
quenched with water and extracted with EtOAc (3x). The organic phases 
were combined, washed with water and brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude product was purified by 
silica gel column chromatography (eluent: PE/Et2O 8:1) to afford the 2 
separated diastereomers (1:1) as colorless oils; yield: 0.29 g (72 %). 
 (S)-1-((2S,6S)-6-ethyl-3,6-dihydro-2H-pyran-2-yl)ethanol 4.182a 
and (S)-1-((2R,6R)-6-ethyl-3,6-dihydro-2H-pyran-2-yl)ethanol 
4.182b 
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Dia 4.182a 
1H NMR (300MHz, CDCl3): δ 5.83-5.78 (m, 1H, H8), 5.67-5.63 (m, 1H, 
H9), 4.08-4.05 (m, 1H, H4), 3.70-3.61 (m, 1H, H2), 3.37-3.29 (m, 1H, H3), 
2.93 (bs, 1H, -OH), 1.98-1.92 (m, 2H, H7), 1.65-1.53 (m, 2H, H5), 1.16 (d, 
3H, H1, J=6 Hz), 0.96 (t, 3H, H6, J=9 Hz,). 
13C NMR (75MHz, CDCl3): δ 130.2 (C9), 124.1 (C8), 78.7 (C3), 76.0 (C4), 
70.6 (C2), 28.5 (C5), 27.3 (C7), 17.9 (C1), 9.6 (C6). 
 = -1.1 (c=1.1 M, CHCl3) 
Dia 4.182b 
1H NMR (300MHz, CDCl3): δ 5.87-5.82 (m, 1H, H8’), 5.67-5.59 (m, 1H, 
H9’), 4.10 (m, 1H, H4’), 3.94-3.91 (m, 1H, H2’), 3.53-3.47 (m, 1H, H3’), 2.27-
2.17 (m, 1H, H7’), 1.98-1.88 (m, 1H, H7’), 1.58-1.43 (m, 2H, H5’), 1.15 (d, 
3H, H1’, J=6 Hz), 0.92 (t, 3H, H6’, J=9 Hz). 
13C NMR (75MHz, CDCl3): δ 129.9 (C9’), 124.6 (C8’), 77.2 (C3’), 76.0 (C4’), 
69.3 (C2’), 28.5 (C5’), 24.2 (C7’), 17.6 (C1’), 9.4 (C6’). 
 = +14 (c=1.8 M, CHCl3). 
MS (ESI) m/z (%): 139.11 (16), 157.12 (6) [M+1]+, 179.10 (100) [M+Na]+ 
HRMS m/z: calculated for C9H17O2: 157.12224. Found: 157.12231. 
IR (film, cm-1): 790, 1075, 1353, 1485, 1650, 2922, 3440. 
EXPERIMENTAL PART  259 
 
II.4. Oxidation of DHP 4.099 and 4.182 
II.4.1. General procedure 
To a solution of substrate (1 eq) in DCM (0.2 M) was added dry NaHCO3 (4 
eqs). Dess-Martin periodane (1.2 eq) was then added at 0°C and the reaction 
was warmed up to room temperature and stirred for 3 hours. The reaction 
was filtered through a pad of celite and rinsed with Et2O (3x). The solvent 
was carefully concentrated. The products are highly volatile. 
II.4.2. Synthesis of ketone 4.170 
 
 1-(6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-yl)ethanone 4.170 
 
The reaction was carried out on 1.6 mmol (0.27 g). 
The crude mixture was purified by silica gel column chromatography 
(eluent: PE/Et2O 10:1) to afford the desired product as a clear oil and a 
racemic mixture of two enantiomers; yield: 0.047 g (18 %). 
1H NMR (300MHz, CDCl3): δ 5.56 (bs, 1H, H8), 4.08 (bs, 1H, H4), 3.98 (dd, 
1H, H3, J=3 Hz, J=9 Hz), 2.24  (s, 3H, H1), 2.13-2.08 (m, 2H, H7), 1.86-1.74 
(m, 1H, H5), 1.59 (s, 3H, H8), 1.55-1.47 (m, 1H, H5), 0.94 (t, 3H, H6, J=9 
Hz). 
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13C NMR (75MHz, CDCl3):  δ 210.2 (C2), 135.8 (C9), 119.7 (C8), 78.9 (C3), 
78.5 (C4), 27.5 (C7), 25.9 (C4), 25.8 (C1), 19.0 (C10), 8.8 (C6). 
MS (ESI) m/z (%): 141.12 (13), 169.12 (24) [M+1]+, 191.10 (100) [M+Na]+. 
HRMS m/z: calculated for C10H17O2: 169.12229. Found: 169.12231. 
IR (film, cm-1): 748, 850, 921, 1052, 1115, 1248, 1347, 1452, 1720, 2879, 
2935, 2966. 
Chiral GC: T=50°C (2 min) to 120°C (2 min); 10°C/min – T=120°C to 140 
°C (10 min); 5°C/min – T=140°C to 160°C (3 min); 30°C/min; tr : 14.4 min 
and 14.9 min.  
II.4.3. Synthesis of ketone 4.183 
 
 1-(6-ethyl-3,6-dihydro-2H-pyran-2-yl)ethanone 4.183 
 
The reaction was carried out on 1.25 mmol (0.19 g). 
The pure product was isolated as a racemic mixture of two enantiomers 
without purification; yield: 0.12 g (62%). 
1H NMR (300MHz, CDCl3): δ 5.85-5.66 (m, 1H, H8), 5.66-5.61 (m, 1H, 
H9), 4.14-4.10 (m, 1H, H4), 3.99 (dd, 1H, H3, J=4.5 Hz), 2.24 (s, 3H, H1), 
2.19-2.11 (m, 2H, H7), 1.62-1.54 (m, 2H, H5), 0.97 (t, 3H, H6, J=7.4 Hz). 
13C NMR (75MHz, CDCl3): δ 209.8 (C2), 130.3 (C9), 123.8 (C8), 79.2 (C3), 
76.3 (C4), 28.4 (C5), 21.2 (C7), 25.9 (C1), 9.5 (C6). 
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MS (ESI) m/z (%) : 95.01 (59), 177.09 (100) [M+Na]+. 
HRMS m/z: calculated for C9H14O2Na: 177.08862. Found: 177.08860. 
IR (film, cm-1): 733, 910, 1095, 1355, 1463, 1718, 2852, 2823, 2962. 
II.5. Synthesis of other DHPs 
II.5.1. Hydrozirconation 
 
To a solution of Cp2ZrCl2 (1.69 g, 5.79 mmol) in THF (15 mL) was added 
Et3BHLi (5.8 mL, 5.79 mmol) dropwise very slowly. The resulting white 
opaque solution indicates that Schwartz reagent is formed. It was stirred for 
1 hour hidden from light. A solution of substrate 4.112 (0.5 g, 1.81 mmol) in 
THF (5 mL) was added dropwise and the solution was heated to 55°C for 1 
hour. After cooling down, a solution of I2 (1.5 g) in THF (6 mL) was added 
dropwise and the mixture was stirred at room temperature for 18 hours. It 
was then quenched with a saturated aqueous solution of Na2S2O3 and 
extracted with EtOAc (3x). The organic phases were combined, washed with 
brine, dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O  30:1) to afford the desired product as a mixture of 2 
diastereomers (1:1). Yield: 0.17 g (23 %). 
 (2S,E)-2-(benzyloxy)-5-iodo-6-(trimethylsilyl)hex-5-en-3-ol 4.157 
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1H NMR (300MHz, CDCl3): δ 7.33-7.27 (m, 10H, Har), 6.53 (bs, 2H, 
H11,11’), 4.69-4.44 (m, 4H, H5,5’), 4.07-3.98 (m, 1H, H8,), 3.92-3.85 (m, 1H, 
H8’), 3.65-3.57 (m, 1H, H7), 3.56-3.48 (m, 1H, H7’), 2.65-2.43 (m, 4H, H9,9’), 
2.20 (d, 1H, -OH, J=6 Hz,), 1.98 (d, 1H, -OH’, J=6 Hz,), 1.25 (d, 3H, H6, 
J=6 Hz,), 1.20 (d, 3H, H6’, J=6 Hz,), 0.12 (s, 18H, H12,12’). 
13C NMR (75MHz, CDCl3): δ 147.8 (C11), 147.4 (C11’), 138.5 (C4), 138.3 
(C4’), 128.5-127.9-127.8 (C1,2,3,1',2',3'), 115.5 (C10), 115.4 (C10’), 77.0 (C7,7’), 
73.8 (C8), 73.0 (8’), 71.1 (5,5’), 48.3 (9), 47.2 (C9’), 15.7 (C6), 15.1 (C6’), 0.3 
(C12,12’). 
MS (ESI) m/z (%): 427.05 (85) [M+Na]+ 
HRMS m/z: calculated for C16H25O2INaSi: 427.05629. Found: 427.05607 
IR (film, cm-1): 696, 733, 841, 908, 972, 1028, 1072, 1088, 1248, 1377, 
1454, 1585, 2851, 2898, 2921, 2954.  
II.5.2. Methylation 
 
To a solution of CuCN (0.08 g, 0.92 mmol) in Et2O (2 mL) at 0°C was added 
MeLi (0.8 mL of 1.6 M solution in Et2O, 1.26 mmol) dropwise. It was stirred 
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for 15 minutes at 0°C and then the substrate (0.17 g, 0.42 mmol) was added 
dropwise. The resulting solution was stirred at 0°C for 24 hours. It was then 
quenched with water and extracted with Et2O (3x). The organic phases were 
combined, washed with brine, dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude product was used without further 
purification in the next step.  
II.5.3. Hydrosilylation 
 
A mixture of substrate (0.50 g, 1.81 mmol), MD’M (0.40 g, 1.81 mmol) and 
(IPr)Pt(dvtms) (0.056 g, 0.072 mmol) was stirred at 75 °C for 30 minutes. It 
was then cooled down to room temperature and concentrated under reduced 
pressure. The crude product was purified by silica gel column 
chromatography (eluent PE/Et2O 98:2) to afford the desired product as a 
clear oil and a mixture of two diastereomers (1:1); yield: 0.48 g (53 %).  
 (2S,E)-2-(benzyloxy)-5-(1,1,1,3,5,5,5-heptamethyltrisiloxan-3-yl)-6-
(trimethylsilyl)hex-5-en-3-ol 4.196 
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1H NMR (300MHz, CDCl3): δ 7.37-7.28 (m, 10H, Har), 6.33 (s, 1H, H11), 
6.32 (s, 1H, H11’), 4.69-4.50 (m, 4H, H5,5’), 3.84-3.78 (m, 2H, H8, 8’), 3.55-
3.47 (m, 2H, H7,7’), 2.60-2.35 (m, 5H, H9, 9’, OH), 2.21 (d, 1H, HOH’, , J=3 Hz), 
1.23 (d, 6H, H6, J=6 Hz), 0.15-0.10 (m, 60H, HTMS). 
13C NMR (75MHz, CDCl3): δ 159.4 (C10,10’), 147.3 (C11), 146.9 (C11’), 
139.05 (C4,4’), 128.4-127.8-127.8-127.5 (Car), 78.1 (C7,7’), 73.3 (C8), 73.2 
(C8’), 71.2 (C5), 71.1 (C5’), 38.8 (C9), 38.5 (C9’), 15.4 (C6), 15.2 (C6’), 2.0-
0.5-0.0 (CTMS). 
MS (ESI) m/z (%):102.13 (18), 171.12 (23), 229.11 (16), 306.29 (13), 
337.16 (28), 385.26 (40), 409.20 (55) [M-OTMS]+, 499.25 (100) [M+1]+, 
521.24 (62) [M+Na]+ 
HRMS m/z: calculated for C23H47O4Si4: 499.25471. Found: 499.25459. 
IR (film, cm-1): 696, 742, 754, 785, 839, 1041, 1064, 1250, 2955. 
II.5.4. ISMS 
II.5.4.1. General procedure 
To a solution of substrate (1 eq) and propionaldehyde (1.2 eq) in DCM (0.2 
M) at -78°C was added TMS-OTf (1.1 eq). The resulting mixture was stirred 
for 2 hours and let to warm up to -30°C. It was then quenched at that 
temperature with pyridine followed by a saturated aqueous solution of 
NaHCO3. The aqueous phase was extracted with DCM (3x). The organic 
phases were combined, washed with 0.1 M HCl, dried over Na2SO4, filtered 
and concentrated under vacuum. 
II.5.4.2. Synthesis of DHP 4.185 
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 2-((S)-1-(benzyloxy)ethyl)-6-ethyl-4-methyl-3,6-dihydro-2H-pyran 
4.185 
 
The reaction was carried out on 0.4 mmol (0.12 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O  30:1) to afford the desired product as a mixture of 2 
diastereomers (1:1). Yield: 0.026 g (24 %). 
1H NMR (300MHz, CDCl3): δ 7.38-7.29 (m, 10H, Har), 5.34-5.31 (m, 2H, 
H9,9’), 4.72-4.57 (m, 4H, H11,11’), 3.98-3.96 (m, 2H, H4,4’), 3.60-3.54 (m, 2H, 
H2,2’), 3.49-3.43 (m, 2H, H3,3’), 2.08-1.93 (m, 5H, H7,7’,5), 1.71 (s, 6H, H10,10’), 
1.55-1.49 (m, 3H, H5,5’), 1.25 (d, 3H, H2, J=6.2 Hz), 1.18 (d, 3H, H2’, J=6.1 
Hz), 0.98-0.93 (m, 6H, H6,6’) 
13C NMR (75MHz, CDCl3): δ 139.4 (C12’), 139.1 (C12), 132.5 (C8), 132.1 
(C8’), 128.4-127.9-127.8-127.5 (Car), 124.2 (C9’), 123.8 (C9), 77.7 (C3,3’)77.4 
(C2,2’), 76.3 (C4), 76.2 (C4’), 72.1 (C11’), 71.4 (C11), 31.9 (C7), 31.5 (C7’), 28.9 
(C5, 5’), 23.3 (C10,10’), 16.7 (C1), 15.8 (C1’), 9.9 (C6’), 9.7 (C6). 
MS (APCI) m/z (%): 85.06 (44), 137.13 (10), 151.11 (13), 261.18 (13) 
[M+1]+, 283.16 (100) [M+Na]+. 
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MS2: 81.07 (11), 91.05 (100), 95.08 (26), 105.07 (10), 131.08 (6), 137.13 
(23), 143.08 (15), 171.11 (12), 199.15 (11), 225.16 (14), 261.18 (23). 
HRMS m/z: calculated for C17H25O2: 261.18492. Found: 261.18491. 
IR (film, cm-1): 696, 735, 781, 814, 881, 987, 1011, 1028, 1090, 1161, 1207, 
1377, 1454, 2854, 2875, 2926, 2962. 
II.5.4.3. Synthesis of DHP 4.200 
 
 3-(2-((S)-1-(benzyloxy)ethyl)-6-ethyl-3,6-dihydro-2H-4-yl)-
1,1,1,3,5,5,5-heptamethyltrisiloxane 4.200 
 
The reaction was carried out on 0.36 mmol (0.18 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O  30:1) to afford the desired product as a mixture of 2 
diastereomers (1:1). Yield: 0.13 g (79 %). 
1H NMR (300MHz, CDCl3): δ 7.36-7.29 (m, 10H, Har), 5.95-5.93 (m, 2H, 
H9, 9’), 4.69-4.55 (m, 4H, H11,11’), 4.04-4.01 (m, 2H, H4,4’), 3.59-3.49 (m, 3H, 
H2,2’,3’), 3.43-3.38 (m, 1H, H3), 2.27-1.93 (m, 5H, H7,7’,5’), 1.61-1.50 (m, 3H, 
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H5,5’), 1.24 (d, 3H, H1’, J=6.2Hz), 1.17 (d, 3H, H1, J=6.1Hz), 1.00-0.92 (m, 
6H, H6,6’), 0.09-0.07 (m, 42H, HTMS). 
13C NMR (75MHz, CDCl3): δ 139.5 (C9’), 139.2 (C9), 135.3 (C8, 8’), 128.4-
127.9-127.8-127.5 (Car), 76.1-75.9-75.3 (C2,2’,3,3’,4,4’), 72.1 (C11’), 71.4 (C11), 
28.4-27.7 (C7,7’,5,5’), 16.6 (C1), 15.9 (C1’), 9.9 (C6’), 9.7 (C6), 2.0 (COTMS), -1.0 
(CTMS) 
MS (APCI) m/z (%): 171.12 (6), 211.15 (9), 239.10 (8), 377.20 (14), 467.25 
(100) 468.25 (41) 469.25 (11) [M+1]+ 
MS2: 91.05 (100), 121.10 (8), 205.07 (6), 221.08 (18), 239.08 (46), 359.19 
(4). 
HRMS m/z: calculated for C23H43O4Si3: 467.24694. Found: 467.24637. 
IR (film, cm-1): 696, 733, 754, 783, 841, 868, 980, 1051, 1148, 1252, 1375, 
1454, 2852, 2922, 2959. 
II.6. Synthesis of acetal 4.096 
 
To a solution of aldehyde (0.3 g, 1.59 mmol), silyl ether (0.29 g, 1.70 mmol) 
and allylsilane (0.28 mL, 1.75 mmol) in DCM (8 mL) was added Zn(OTf)2 
(0.06 g, 0.16 mmol) at -78 °C. The reaction was then warmed up to room 
temperature and stirred for 24 hours. The mixture was quenched with 0.1M 
HCl and extracted with DCM. The organic phases were combined, washed 
with a saturated solution of NaHCO3 and brine, dried over Na2SO4, filtered 
and concentrated under reduced pressure. The crude mixture was purified by 
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silica gel column chromatography (eluent PE/EtOAc 30:1) to afford the 
desired product as clear oil; yield: 0.26 g 
(52 %). 
 (((2S)-1,1)bis((2-methylpent-1-en-3-yl)oxypropan-2-yl)oxy)(tert-
butyl)dimethylsilane 4.096 
 
The reaction was carried out on 1.59 mmol of aldehyde (0.3 g). 
1H NMR (300MHz, CDCl3): δ 4.91-4.83 (m, 4H, H9), 4.30-3.64 (m, 4H, H2, 
3 and 6), 1.72-1.48 (m, 10H, H7 and 4), 1.16 (t, 3H, H1, J=6 Hz), 0.92-0.80 (m, 
15H, H8 and TBS), 0.10-0.1 (m, 6H, HTBS). 
 13C NMR (75MHz, CDCl3): δ 145.4, 145.0, 144.9, 144.5 (C5), 114.3, 114.1, 
114.0 (C9), 101.4-101.9 (C3), 85.1-84.4-82.7-81.7 (C6), 71.6-70.3 (C2), 26.0-
25.9 (CTBS), 18.6-18.5-18.3-18.2-16.8-16.7-16.5-16.4 (C7 and 4), 14.3 (C1), 
10.4-10.3-10.2 (C8), -4.5, -4.7 (CTBS). 
MS (ESI) m/z (%):118 (16), 188 (7), 271 (4), 335 (5), 393 (100) [M=Na]+, 
409 (62) [M+K]+. 
HRMS m/z: calculated for C21H42O3NaSi: 393.27954. Found: 393.27954. 
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II.7. Esterification with DMAP/DCC 
II.7.1. General procedure13 
To a solution of substrate (1 eq), DCC (1.1 eq) and DMAP (0.1 eq) in DCM 
(0.2M) was added naproxene or ibuprofen (1.1 eq). The resulting solution 
was stirred at room temperature for 20 hours. Mixture was then filtered and 
washed with DCM (3x). The organic phases were combined, dried over 
MgSO4, filtered and concentrated under reduced pressure.  
II.7.2. Synthesis of ester 4.084 
 
  (2S)-pent-1-en-3-yl 2-(4-isobutylphenyl)propanoate 4.084 
 
The reaction was carried out on 2.32 mmol (0.2 g). 
                                                     
13 B. Linclau, A. J. Boydell, R. S. Timofte, K. J. Brown, V. Vinader, A.C. 
Weymouth-Wilson, Org. Biomol. Chem. 2009, 7, 803.  
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The crude product was purified by silica gel column chromatography 
(eluent: PE/AcOEt 50:15:1) to afford the desired product as a mixture of 2 
diastereomers (1:1). Yield: 0.45 g (70 %). 
1H NMR (300MHz, CDCl3): δ 7.20 (d, 4H, H9,9', J=8.0 Hz), 7.07 (d, 4H, 
H10,10', J=8.1 Hz), 5.80-5.59 (m, 2H, H2,2'), 5.20-4.92 (m, 6H, H1,1', 3,3',), 3.74-
3.66 (m, 2H, H7,7'), 2.43 (d, 4H, H11,11', J=7.2 Hz), 1.87-1.78 (m, 2H, H12,12'), 
1.62-1.47 (m, 10H, H4,4',8,8'), 0.88-0.66 (m, 18H, H13,13',5,5'). 
13C NMR (75MHz, CDCl3): δ 174.2 (C6), 174.1 (C6’), 140.5 (Car), 137.0 
(Car), 136.4 (C2), 136.2 (C2’), 129.3-127.3-127.2 (C9,9’,10,10’), 116.6 (C1), 
116.1 (C1’), 76.1-75.8 (C11,11’,7,7’), 30.3 (C12,12’), 27.3 (C4), 27.2 (C4’), 22.4 
(C13,13’), 18.5 (C8), 18.3 (C8’), 9.4 (C5), 9.2 (C5’). 
II.7.3. Synthesis of ester 4.085 
 
 (2S)-pent-1-en-3-yl 2-(6-methoxynaphthalen-2-yl)propanoate 4.085 
 
The reaction was carried out on 2.3 mmol (0.2 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/acetone 95:590:10) to afford the desired product as a mixture 
of 2 diastereomers (1:1). Yield: 0.3 g (44 %). 
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1H NMR (300MHz, CDCl3): δ 7.70-7.68 (m, 6H, Har), 7.43-7.41 (m, 2H, 
Har), 7.15-7.11 (m, 4H, Har), 5.81-5.58 (m, 2H, H2,2'), 5.22-4.98 (m, 6H, 
H1,1',7,7'), 3.91 (s, 6H, H9,9'), 3.88-3.82 (m, 2H, H3,3'), 1.62-1.51 (m, 10H, 
H4,4',8,8'), 0.89-0.84 (m, 3H, H5), 0.70 (t, 3H, H5’, J=7.5 Hz). 
13C NMR (75MHz, CDCl3): δ 174.1 (C6), 157.7 (Car), 136.4-136.1-136.0-
135.9 (Car), 133.7 (C2), 129.4-129.0-127.1-126.5-126.1-119.0 (Car), 116.8 
(C1), 116.5 (C1’), 105.7 (Car), 77.1 (C7), 55.4 (C9), 45.8 (C3), 27.3 (C4), 27.2 
(C4’), 18.7 (C8), 18.6 (C8’), 9.5 (C5), 9.3 (C5’). 
MS (EI) m/z (%): 91 (16), 141 (10), 170 (8), 185 (100), 298 (37) [M] 
HRMS m/z: calculated for C19H22O3: 298.15635. Found: 298.15677. 
IR (film, cm-1): 671, 746, 783, 810, 892, 921, 989, 1030, 1055, 1087, 1120, 
1151, 1176, 1217, 1230, 1263, 1319, 1375, 1392, 1418, 1440, 1483, 1504, 
1604, 1728, 2873, 2933. 
II.7.4. Synthesis of ester 4.089 
 
 (2S)-pent-1-en-3-yl 2-(benzyloxy)propanoate 4.089 
 
The reaction was carried out on 11.6 mmol (1 g). 
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The crude product was purified by silica gel column chromatography 
(eluent: PE/AcOEt 50:1) to afford the desired product as a mixture of 2 
diastereomers. Yield: 0.5 g (33 %). 
1H NMR (300MHz, CDCl3): δ 7.38-7.26 (m, 10H, Har), 5.82-5.73 (m, 2H, 
H2,2'), 5.31-5.18 (m, 6H, H1,1',3,3'), 4.72 (d, 1H, H9, J=11.7 Hz), 4.70 (d, 1H, 
H9’, J=11.4 Hz), 4.44 (d, 2H, H9,9', 11.7 Hz), 4.06 (q, 2H, H7,7', J=6.6 Hz), 
1.73-1.46 (m, 4H, H4,4'), 1.46-1.43 (m, 6H, H8,8'), 0.92 (t, 6H, H5,5'). 
13C NMR (75MHz, CDCl3): δ 172.7 (C6), 137.7 (C2), 136.1 (C2’), 136.0 
(Car), 128.5-128.1-127-9 (Car), 117.4 (C5), 117.2 (C5’), 77.0 (C3,3’), 74.3 
(C7,7’), 72.1 (C9,9’), 27.4 (C4,4’), 19.0 (C8), 18.9 (C8'), 9.6 (C5,5’). 
MS (CI) m/z (%): 159 (10), 179 (45), 181 (100), 207 (34), 249 (12) [M+1]+. 
HRMS m/z: calculated for C15H21O3 : 249.14907. Found: 249.14951. 
IR (film, cm-1): 698, 734, 891, 933, 989, 1022, 1063, 1128, 1142, 1194, 
1265, 1454, 1732, 1747, 2904, 2916, 2966. 
II.7.5. Synthesis of ester 4.090 
 
 (2S)-hex-1-en-3-yl 2-(benzyloxy)propanoate 4.090 
 
The reaction was carried out on 5 mmol (0.5 g). 
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The crude product was purified by silica gel column chromatography 
(eluent: PE/AcOEt 50:1) to afford the desired product as a mixture of 2 
diastereomers. Yield: 0.76 g (58 %). 
1H NMR (500MHz, CDCl3): δ 7.36-7.28 (m, 10H, Har), 5.84-5.75 (m, 2H, 
H2,2'), 5.29-5.35 (m, 2H, H3,3'), 5.26 (dd, 2H, H1,1', J=8.8 Hz, J=1.5 Hz), 5.18 
(dd, 2H, H1,1', J=6.3 Hz, J=1.4 Hz), 4.71 (d, 1H, H10, J=7.0 Hz), 4.69 (d, 1H, 
H10’, J=6.9 Hz), 4.43 (d, 1H, H10,10', J=7.0 Hz), 4.05 (q, 2H, H8,8', J=6.0 Hz), 
1.68-1.64 (m, 2H, H4,4'), 1.62-1.58 (m, 2H, H4,4'), 1.45 (m, 6H, H9,9'), 1.39-
1.34 (m, 4H, H5,5'), 0.8-0.97 (m, 6H, H6,6'). 
13C NMR (75MHz, CDCl3): δ 172.7 (C7,7’), 137.7 (C2’), 136.4 (C2), 128.5-
128.1-128.0-127.9 (Car), 117.2 (C1’), 116.9 (C1), 75.2 (C3,3’), 75.6 (C8’), 75.2 
(C8), 72.1 (C10), 72.0 (C10’), 36.4 (C4,4’), 18.9-18.8-18.5 (C5,5’,9,9’), 13.9 (C6,6’). 
MS (CI) m/z (%): 83 (13), 91 (46), 132 (5), 159 (6), 173 (26), 179 (34), 181 
(100), 263 (5) [M+1]+. 
HRMS m/z: calculated for C16H22O3 : 263.16472. Found: 263.16473. 
IR (film, cm-1): 696.2, 738.7, 923.8, 956.6, 989.4, 1018.3, 1062.7, 1089.7, 
1112.8, 1139.8, 1193.8, 1267.1, 1371.3, 1454.2, 1732.0, 1743.5, 2858.3, 
2925.8. 
III. Chapter 5: modifications and analogues 
III.1. Epoxidation 
III.1.1. General procedure 
To a solution of DHP (1 eq) in DCM (0.4M) at 0°C was added mCPBA (1.5 
eq). The resulting mixture was stirred at 0°C for 45 minutes. The solution 
was quenched with saturated aqueous solution of K2CO3. The aqueous phase 
was extracted with DCM (3x). The organic phases were combined, washed 
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with saturated aqueous K2CO3, dried over Na2SO4, filtered and concentrated 
under reduced pressure. 
III.1.2. On the mixture of two diastereomers 
 
 (1S,2R,4R,6S)-4-((S)-1-(benzyloxy)ethyl)-2-ethyl-1-methyl-3,7-
dioxabicyclo[4.1.0]heptane 5.002 and (1S,2S,4S,6S)-4-((S)-1-
(benzyloxy)ethyl)-2-ethyl-1-methyl-3,7-dioxabicyclo[4.1.0]heptane  
5.003 
 
The reaction was carried out on 1.15 mmol (0.3 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O 30:1) to afford the desired product as a clear oil and a 
mixture of two diastereomers (1:1); yield: 0.16 g (50 %). 
Dia 5.002: 
1H NMR (300MHz, CDCl3): δ 7.34-7.28 (m, 5H, Har), 4.62 (d, 1H, H11, 
J=12 Hz), 4.55 (d, 1H, H11, J=12 Hz), 3.65 (dd, 1H, H4, J= 9 Hz, J=3 Hz), 
3.49-3.46 (m, 1H, H2), 3.38-3.33 (m, 1H, H3), 3.15-3.12 (m, 1H, H8), 2.21-
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2.16 (m, 1H, H7), 1.88-1.83 (m, 1H, H7), 1.75-1.50 (m, 2H, H5), 1.28 (s, 3H, 
H10), 1.16 (d, 3H, H1, J=6 Hz), 1.02 (t, 3H, H6, J=6 Hz). 
13C NMR (75MHz, CDCl3): δ 139.1 (Car), 128.4-127.7-127.5 (Car), 79.8 
(C4), 77.18 (C2), 73.7 (C3), 71.3 (C11), 59.8 (C8), 59.5 (C9), 27.6 (C7), 26.0 
(C5), 20.3 (C10), 16.7 (C1), 10.7 (C6). 
 = +37 (c=1.8M, CHCl3) 
Dia 5.003: 
1H NMR (300MHz, CDCl3): δ 7.33-7.28 (m, 5H, Har), 4.62 (d, 1H, H11’, 
J=12 Hz), 4.47 (d, 1H, H11’, J=12 Hz), 3.49-3.39 (m, 2H, H4’ and 2’), 3.12-3.06 
(m, 2H, H3’ and 8’), 2.18-2.11 (m, 1H, H7’), 1.85-1.52 (m, 3H, H7’ and 5’), 1.27 
(s, 3H, H10’), 1.22 (d, 3H, H1’, J=6 Hz), 1.02 (t, 3H, H6’, J=6 Hz). 
13C NMR (75MHz, CDCl3): δ 138.8 (Car), 128.5-128.0-127.7 (Car), 78.7 (C4’ 
or 2’), 77.6 (C2’ or 4’), 77.0 (C3’), 71.2 (C11’), 58.1 (C8’), 56.4 (C9’), 27.2 (C7’), 
23.7 (C5’), 18.7 (C10’), 16.6 (C1’), 10.4 (C6’). 
  = +32 (c=2.6M, CHCl3) 
MS (ESI) m/z (%): 299.16 (100) [M+Na]+, 575.33 (28) [2M+1]+ 
HRMS m/z: calculated for C17H25O3: 277.17988. Found: 277.17982. 
IR (film, cm-1): 696, 732, 1029, 1110, 1367, 1379, 1454, 2850, 2873, 2921. 
III.1.3. On one diastereomer 
 
  (S)-1-((1R,2R,4R,6R)-2-ethyl-1-methyl-3,7-
dioxabicyclo[4,1,0]heptan-4-yl)ethanol 5.010 
276                                    EXPERIMENTAL PART 
 
The reaction was carried out on 0.54 mmol (0.09 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O 10:1  1:1) to afford the desired product as a clear oil and 
a major diastereomer (3.5:1); yield: 0.03 g (30 %). 
1H NMR (300MHz, CDCl3): δ 3.87-3.78 (m, 1H, H2), 3.51 (dd, 1H, H4, J=9 
Hz,J=3 Hz), 3.18-3.09 (m, 2H, H3 and 8), 2.01-1.71 (m, 2H, H7), 1.63-1.42 (m, 
2H, H5), 1.27 (s, 3H, H10), 1.11 (d, 3H, H1, J=6 Hz), 1.01 (t, 3H, H6, J=6 Hz). 
13C NMR (75MHz, CDCl3): δ 78.3 (C4), 76.6 (C3), 69.2 (C2), 57.9 (C8), 56.3 
(C9), 23.9 (C7), 23.7 (C5), 18.7 (C10), 18.0 (C1), 10.4 (C6). 
MS (ESI) m/z (%): 187.13 (28) [M+H]+, 209.11 (100) [M+Na]+, 395.24 (28) 
[2M+Na]+ 
HRMS m/z: calculated for C10H19O3: 187.13296. Found: 187.13287 
IR (film, cm-1): 714, 854, 889, 947, 1034, 1049, 1059, 1090, 1116, 1297, 
1377, 1456, 1668, 2852, 2923, 2962, 3390. 
  = +47 (c=1.1M, CHCl3). 
III.1.4. On DHP 5.026 
 
 (1S)-1-((2R,4R)-2-ethyl-3,7-dioxabicyclo[4.1.0]heptan-4-yl)ethanol 
5.016 
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The reaction was carried out on 0.51 mmol (0.08 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O 15:1  0:1) to afford the desired product as a clear oil and 
a mixture of two diastereomers (1:1.4); yield: 0.025 g (28 %). 
1H NMR (300MHz, CDCl3): δ 4.07-3.95 (m, 3H, H2,2’,4’), 3.85 (t, 1H, H4, 
J=9 Hz), 3.63-3.61 (m, 2H, H8,8’), 3.58-3.53 (m, 1H, H3’), 3.43 (dt, 1H, H3, 
J=9 Hz, J=3 Hz), 3.27 (d, 2H, H9,9’, J=3 Hz), 2.33-2.12 (m, 4H, H7,7’), 2.10-
1.99 (m, 4H, H5,5’), 1.50-1.46 (m, 6H, H1,1’), 1.43-1.37 (m, 6H, H6,6’). 
13C NMR (75MHz, CDCl3): δ 77.2 (C3), 76.2 (C4’), 75.5 (C4), 72.9 (C3’), 
69.1 (C2), 69.0 (C2’), 54.8 (C9’), 51.9 (C8’), 51.7 (C9), 50.4 (C8), 27.1 (C5’), 
26.0 (C5), 24.4 (C7’), 23.0 (C7), 18.0 (C1), 17.6 (C1’), 10.1 (C6), 9.7 (C6’). 
MS (ESI) m/z (%): 155.11 (8), 195.09 (100) [M+Na]+, 367.21 (17) 
[2M+Na]+ 
HRMS m/z: calculated for C10H16O3Na: 195.09928. Found: 195.09917 
IR (film, cm-1): 861, 862, 875, 892, 1035, 1088, 1142, 1365, 1464, 2852, 
2874, 2922, 2964, 3406. 
III.2. Epoxide opening 
III.2.1. General procedure 
To a solution of substrate (1 eq) in Et2O (0.15 M) was added LiAlH4 (3 eqs). 
The reaction was stirred at room temperature for 18 hours. It was carefully 
quenched with water and extracted with Et2O (3x). The organic phases were 
combined, dried over Na2SO4 and concentrated under reduced pressure. 
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III.2.2. Synthesis of 5.012 
 
 (2R,3R,6R)-2-ethyl-6-((S)-1-hydroxyethyl)-3-methyltetrahydro-2H-
pyran-3-ol 5.012 
 
The reaction was carried out on 0.08 mmol (0.03 g). 
The crude mixture was purified by silica gel column chromatography (eluent 
PE/EtOAc 5:1 1:5) to afford the desired product as a yellow oil. Yield: 
0.008 g (52%). 
1H NMR (300MHz, CDCl3): δ 3.87-3.79 (m, 1H, H2), 3.25-3.20 (m, 1H, 
H3), 3.06 (dd, 1H, H4, J=3 Hz, J=12 Hz), 1.93 (bs, 2H, -OH), 1.81-1.76 (m, 
1H, H8), 1.68-1.45 (m, 5H, H8,7,5), 1.17 (d, 3H, H1, J=6 Hz), 1.09 (s, 3H, 
H10), 0.95 (t, 3H, H6, J=6 Hz).  
 13C NMR (75MHz, CDCl3): δ 85.8 (C4), 81.4 (C3), 69.7 (C2), 68.8 (C9), 
37.4 (C8), 24.5 (C10), 21.7-21.6 (C7,5), 18.3 (C1), 10.9 (C6). 
MS (ESI) m/z (%): 211.13 (100) [M+Na]+, 399.27 (8) [2M+Na]+ 
HRMS m/z: calculated for C10H20O3Na: 211.13056. Found: 211.13047 
IR (film, cm-1): 748, 762, 871, 998, 1055, 1060, 1355, 1464, 1650, 2852, 
2921, 2955, 3310. 
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III.2.3. Synthesis of 5.008 
 
 (2S,3S,6S)-6-((S)-1-(benzyloxy)ethyl)-2-ethyl-3-methyltetrahydro-
2H-pyran-3-ol 5.008 
 
The reaction was carried out on 0.19 mmol (0.052 g). 
The crude mixture was purified by silica gel column chromatography (eluent 
PE/EtOAc 10:1  5:1 1:1) to afford the desired product as a clear oil; 
yield: 0.028 g (54 %). 
1H NMR (300MHz, CDCl3): δ 7.36-7.27 (m, 5H, Har), 4.66 (d, 1H, H11, 
J=11.8 Hz), 4.50 (d, 1H, H11, J= 11.8 Hz), 3.50-3.43 (m, 1H, H2), 3.21-3.15 
(m, 1H, H3), 3.02 (dd, 1H, H4, J=10.1 Hz, J=2.9 Hz), 2.21 (bs, 1H, -OH), 
1.86-1.74 (m, 2H, H8), 1.59-1.52 (4H, H5 and 7), 1.25 (d, 3H, H1, J=6.2 Hz), 
1.09 (s, 3H, H10), 0.97 (t, 3H, H6, J= 7.4 Hz) 
13C NMR (75MHz, CDCl3): δ 138.9 (Car), 128.5-127.8-127.6 (Car), 85.8 
(C4), 81.6 (C3), 77.5 (C2), 71.5 (C11), 68.7 (C9), 37.5 (C8), 24.4 (C10), 24.1 
(C7 or 5), 21.6 (C5 or 7), 16.8 (C1), 10.8 (C6). 
MS (ESI) m/z (%): 261.18 (16) [M-OH]+, 296.22 (30), 301.17 (100) 
[M+Na]+ 
HRMS m/z: calculated for C17H27O3: 279.19550. Found: 279.19547 
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IR (film, cm-1): 696, 733, 779, 796, 918, 976, 1022, 1074, 1097, 1188, 1207, 
1269, 1296, 1369, 1454, 1784, 2852, 2823, 2962. 
III.2.4. Opening with HClO4 and benzoylation in situ 
 
O
OH
HHHO
OH
Cl
O
Br
Et3N, DMAP
DCM, r.t., 18 h
O
OH
HHO
OH
O
Br
44 % over two steps5.014 5.015  
To a solution of epoxide (0.011 g, 0.059 mmol) in THF (0.5 mL) at 0°C was 
added HClO4 in H2O (0.65 mL of 0.1 M solution) dropwise. The resulting 
mixture was stirred at room temperature for 3 hours. Water and EtOAc were 
added. The layers were separated and the aqueous phase was extracted with 
EtOAc (5x). The organic phases were combined, washed with brine, dried 
over MgSO4 filtered and concentrated under reduced pressure to afford the 
crude mixture.  
The crude product was dissolved in DCM (0.9 mL) along with benzoyl 
chloride (0.04 g, 0.183 mL). To this solution were added Et3N (0.024 mL, 
0.2 mmol) and a catalytic amount of DMAP at 0°C. The resulting mixture 
was stirred overnight at room temperature. It was quenched with a saturated 
aqueous solution of NH4Cl and extracted with DCM (3x). The organic 
phases were combined, dried over Na2SO4, filtered and concentrated under 
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reduced pressure. The crude product was purified by silica gel column 
chromatography (eluent: PE/Et2O 20:15:1) to afford the desired product as 
a white solid. Yield: 0.01 g (44 %). 
 (S)-1-((2R,4S,5R,6R)-6-ethyl-4,5-dihydroxy-5-methyltetrahydro-2H-
pyran-2-yl)ethyl 4-bromobenzoate 5.015 
 
1H NMR (300MHz, MeOH-d4): δ 7.92 (d, 2H, H13, J= 6.6 Hz), 7.66 (d, 2H, 
H12, J=6.7 Hz), 5.04 (quint, 1H, H2, J=6.4 Hz), 3.79 (ddd, 1H, H3, J= 11.9 
Hz, J=6.6 Hz, J=2.0 Hz), 3.58 (t, 1H, H8, J= 2.8 Hz), 3.45 (dd, 1H, H4, J=8.2 
Hz, J=4.9 Hz), 2.00 (ddd, 1H, H7, J=13.8 Hz, J=11.9 Hz, J=2.9 Hz), 1.68 (dt, 
1H, H7, J=13.7 Hz, 2.6 Hz),1.61-1.51 (d, 2H, H5), 1.38 (d, 3H, H1, J=6.4 
Hz), 1.12 (s, 3H, H10), 1.00 (t, 3H, H6, J=7.3 Hz). 
13C NMR (75MHz, MeOH-d4): δ 166.5 (C11), 132.9-132.6 (C12 and 13), 130.9-
129.0 (Car), 81.4 (C4), 75.3 (C3), 74.9 (C2), 73.4 (C8), 71.7 (C9), 32.6 (C7), 
22.4 (C5), 22.1 (C10), 16.9 (C1), 11.3 (C6). 
MS (ESI) m/z (%): 123.09 (87), 296.22 (26), 301.17 (72), 352.32 (15), 
387.08, 389.08 (62, 60) [M+1]+, 409.06, 411.06 (100, 98) [M+Na]+. 
HRMS m/z: calculated for C17H24O5 Br: 387.08016. Found: 387.08016. 
IR (film, cm-1): 758, 850, 1012, 1055, 1103, 1240, 1375, 1456, 1589, 1759, 
1770, 2926, 2955, 2993. 
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III.3. Benzoylation 
III.3.1. General procedure 
To a solution of epoxide (1 eq) and benzoyl chloride (1.1 eq) in DCM 
(0.2M) at 0°C was added Et3N (1.2 eq) and DMAP (0.1 eq). The resulting 
reaction mixture was stirred at room temperature overnight. Solution was 
quenched with a saturated aqueous solution of NH4Cl and extracted with 
DCM (3x). The organic phases were combined, dried over Na2SO4, filtered 
and concentrated under reduced pressure. 
III.3.2. Synthesis of 5.011 
 
 (S)-1-((1R,2R,4R,6R)-2-ethyl-1-methyl-3,7-
dioxabicyclo[4.1.0]heptan-4-yl)ethyl 4-bromobenzoate 5.011 
 
The reaction was carried out on 0.16 mmol (0.3 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O 20:15:1) to afford the desired product as a white solid. 
Yield: 0.03 g (50 %). 
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1H NMR (300MHz, CDCl3): δ 7.87 (d, 2H, H13, J=8.6 Hz), 7.57 (d, 2H, H12, 
J=8.6 Hz), 5.02 (q, 1H, H2, J=6.3 Hz), 3.50 (dd, 1H, H4, J=9.7 Hz, J=2.9 Hz), 
3.40-3.32 (m, 1H, H3), 3.09 (d, 1H, H8, J=5.6 Hz), 1.99-1.56 (m, 4H, H5 and 
7), 1.35 (d, 3H, H1, J=6.3 Hz), 1.28 (s, 3H, H10), 1.03 (t, 3H, H6, J=7.4 Hz). 
13C NMR (75MHz, CDCl3): δ 165.2 (C11), 131.8 (C13), 131.2 (C12), 129.5 
(Car), 128.2 (Car), 78.7 (C4), 75.4 (C3), 73.5 (C2), 57.6 (C9), 56.1 (C8), 26.7 
(C7), 23.7 (C5), 18.7 (C10), 16.1 (C1), 10.4 (C6). 
MS (ESI) m/z (%): 369.07, 371.07 (100,96)  [M+H]+, 391.05, 393.05 (53,52) 
[M+Na]+ 
HRMS m/z: calculated for C17H22O4Br: 369.06988. Found: 369.06960 
IR (film, cm-1): 683, 719, 756, 849, 858, 1012, 1068, 1101, 1117, 1173, 
1230, 1270, 1377, 1397, 1454, 1483, 1589, 1718, 2851, 2874, 2924, 2962, 
2976. 
X-ray: Crystal data and structure refinement 
Identification code  hxg_09_020_01 
Empirical formula  C17 H21 Br O4 
Formula weight  369.25 
Temperature  293(2) K 
Wavelength  0.7107 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 11.6441(6) Å 
 b = 5.8019(2) Å 
 c = 13.7278(8) Å 
 α= 90°. 
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 β= 111.601(6)°. 
 γ = 90°. 
Volume 862.28(7) Å3 
Z 2 
Density (calculated) 1.422 g/cm3 
Absorption coefficient 2.398 mm-1 
F(000) 380 
Crystal size 0.9 x 0.14 x 0.09 mm3 
Theta range for data collection 3.51 to 28.68°. 
Reflections collected 6361 
Independent reflections 3609 [R(int) = 0.0478] 
Completeness to theta = 25.24° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.30917 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3609 / 1 / 202 
Goodness-of-fit on F2 1.018 
Final R indices [I>2sigma(I)] R1 = 0.0532, wR2 = 0.0801 
R indices (all data) R1 = 0.1273, wR2 = 0.0988 
Absolute structure parameter 0.006(13) 
Largest diff. peak and hole 0.303 and -0.290 e.Å-3 
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III.3.3. Synthesis of 5.018 
 
 (1S)-1-(2R,4R)-2-ethyl-3,7-dioxabicyclo[4.1.0]heptan-4-yl)ethyl 4-
bromobenzoate 5.018a and 5.018b 
O
1 2
3 4
5
6
7
8
9
O H
O
O
Br
13
12
11 H O
1 2
3 4
5
6
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8
9
O H
O
O
Br
13
12
11 H
5.018a 5.018b
 
The reaction was carried out on 0.14 mmol (0.025 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/Et2O 20:15:1) to afford the desired product and the 2 
diastereomers were separated. Yield: 0.02 g (39 %). 
5.018a 
1H NMR (300MHz, CDCl3): δ 7.87 (d, 2H, H13, J= 8.6 Hz), 7.57 (d, 2H, H12, 
J=8.6 Hz), 5.04 (q, 1H, H2, J=6.3 Hz), 3.74 (t, 1H, H4, J=6.4 Hz), 3.53-3.47 
(m, 1H, H3), 3.38-3.36 (m, 1H, H8), 3.01 (d, 1H, H9, J=4.3 Hz), 2.17-2.12 
(m, 1H, H7), 1.83-1.79 (m, 1H, H7), 1.77-1.63 (m, 2H, H5), 1.32 (d, 3H, H1, 
J= 6.4 Hz), 1.00 (t, 3H, H6, J=7.4 Hz). 
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13C NMR (75MHz, CDCl3): δ 165.2 (C11), 131.8 (C13), 131.2 (C12), 129.5 
(Car), 128.2 (Car), 76.4 (C4), 73.2 (C2), 71.9 (C3), 54.8 (C9), 51.6 (C8), 27.4 
(C7 or 5), 27.1 (C7 or 5), 16.4 (C1), 9.7 (C6). 
  = +16 (c=0.6 M, CHCl3). 
5.018b 
1H NMR (300MHz, CDCl3): δ 7.87 (d, 2H, H13, J=8.6 Hz), 7.57 (d, 2H, H12, 
J=8.6 Hz), 5.01 (q, 1H, H2, J=6.2 Hz), 3.64 (t, 1H, H4, J=6.7 Hz), 3.39-3.34 
(m, 2H, H3 and 8), 3.00 (d, 1H, H9, J=4.1 Hz), 1.97-1.80 (m, 2H, H7), 1.75-
1.68 (m, 2H, H5), 1.34 (d, 3H, H1, J=6.4 Hz), 1.04 (t, 3H, H3, J=7.4 Hz). 
13C NMR (75MHz, CDCl3): δ165.2 (C11), 131.8 (C13), 131.2 (C12), 129.4 
(Car), 128.2 (Car), 75.8 (C4), 75.4 (C3), 73.4 (C2), 51.6 (C9), 50.07 (C8), 25.8 
(C7 or 5), 25.7 (C7 or 5), 16.0 (C1), 10.1 (C6). 
MS (ESI) m/z (%): 137.09 (4), 155.01 (10), 337.0, 339.04 (6, 5), 335.05, 
357.05 (100, 97) [M+H]+ 
HRMS m/z: calculated for C16H20O4Br: 355.05393. Found: 355.05395. 
IR (film, cm-1): 719, 734, 756, 756, 787, 848, 864, 880, 939, 1010, 1066, 
1103, 1116, 1222, 1371, 1396, 1454, 1483, 1589, 1716, 2852, 2923, 2962. 
III.3.4. Synthesis of 5.013 
 
 (S)-1-(2R,5R,6R)-6-ethyl-5-hydroxy-5-methyltetrahydro-2H-pyran-
2-yl)ethyl 4-bromobenzoate 5.013 
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The reaction was carried out on 0.053 mmol (0.01 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/EtOAc 10:1) to afford the desired product; Yield: 0.008 g (40 
%). 
1H NMR (300MHz, CDCl3): δ 7.89 (d, 2H, H13, J=8.6 Hz), 7.58 (d, 2H, H12, 
J=8.6 Hz), 5.09 (q, 1H, H2, 6.3 Hz), 3.47-3.40 (m, 1H, H3), 3.07 (dd, 1H, H4, 
J=10.1 Hz, J=2.9 Hz), 2.20 (bs, 1H, -OH), 1.82-1.76 (m, 1H, H8), 1.65-1.57 
(m, 5H, H5,7,8), 1.53 (d, 3H, H1, J=7.4 Hz), 1.11 (s, 3H, H10), 0.97 (t, 3H, H6, 
J=7.3Hz). 
13C NMR (75MHz, CDCl3): δ 165.2 (C11), 131.8 (C13), 131.2 (C12), 129.5 
(Car), 128.2 (Car), 85.9 (C4), 79.8 (C3), 73.5 (C2), 68.5 (C9), 37.3 (C8), 24.3 
(C5), 23.9 (C10), 21.5 (C7), 16.3 (C1), 10.7 (C6). 
MS (ESI) m/z (%): 218.08 (14), 353.07, 355.07 (8) [M-OH]+, 371.08, 373.08 
(18) [M+H]+, 395.05 (100) [M+Na]+ 
Ms2:81.07 (19), 95.08 (55), 109.10 (37), 135.12 (41), 153.13 (75), 182.94 
(100), 371.28 (5). 
HRMS m/z: calculated for C17H24O4Br: 371.08543. Found: 371.08525. 
IR (film, cm-1): 734.8, 757.9, 777.3, 1012.6, 1062.7, 1103.2, 1116.7, 1269.1, 
1284.5, 1452.3, 1589.2, 1718.4, 2927.7, 3493.2. 
  = +16 (c=0.4M, CHCl3). 
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III.4. Hydrogenation 
O O
HOHO H H H HH2, Pd/C
EtOAc
4.099b 5.019
2 dias
39%
 
 (1S)-1-((2R,6R)-6-ethyl-5-methyltetrahydro-2H-pyran-2-yl)ethanol 
5.019 
 
To a solution of substrate (0.223 mmol, 0.038 g) in EtOAc (1.1 mL) was 
added Pd/C 10% w/w (0.033 mmol, 0.036 g). The reaction vessel was 
saturated with hydrogen and stirred overnight. The resulting mixture was 
filtered over a pad of silica/celite and rinsed with EtOAc. The crude product 
was purified by silica gel column chromatography to afford the desired 
product as a colorless oil and a mixture of two diastereomers (1:1). Yield: 
0.015 g (39 %). 
 1H NMR (300MHz, CDCl3): δ 3.85-3.77 (m, 2H, H2 and 2’), 3.32-3.18 (m, 
3H, H3,3’ and 4’), 2.88 (td, 1H, H4, J=9 Hz, J=3 Hz), 1.82-1.24 (m, 14H, H5, 7, 8, 
9, 5’, 7’, 8’, 9’), 1.15-1.12 (m, 6H, H1 and 1’), 0.95-0.86 (m, 9H, H6, 6’ and 10’), 0.80 (d, 
3H, H10, J=6.4 Hz). 
13C NMR (75MHz, CDCl3): δ 84.6 (C4), 81.9 (C4’), 81.4 (C3’), 80.6 (C3), 
69.8 (C2 and 2’), 34.9-32.6-30.8-30.2-26.3-26.0-25.5 (C5, 7, 8, 9, 5’, 7’, 8’ and 9’), 19.6 
(C1 or 1’), 17.9 (C10), 17.8 (C1 or 1’), 11.5 (C10’), 10.5 (C6’), 9.7 (C6). 
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MS (ESI) m/z (%): 137.13 (57), 155.14 (28) [M-H2O]+ 173.15 (6) [M+1]+, 
195.14 (100) [M+Na]+ 
HRMS m/z: calculated for C10H21O2: 173.15367. Found: 173.15361. 
IR (film, cm-1): 652, 958, 976, 1053, 1086, 1120, 1381, 1456, 2501, 2854.4, 
2876, 2928, 2964, 3331. 
III.5. Esterification 
III.5.1. General procedure13 
To a solution of substrate (1 eq), DCC (1.1 eq) and DMAP (0.1 eq) in DCM 
(0.2 M), was added the acid (1.1 eq). The resulting solution was stirred at 
room temperature for 20 hours. Mixture was then filtered and washed with 
DCM (3x). The organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure.  
III.5.2. Synthesis of ester 5.029 
 
 (2E,4E)-(S)-1-((2S,6S)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-
yl)ethyl hexa-2,4-dienoate 5.029 
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The reaction was carried out on 0.85 mmol (0.14 g). 
The crude product was purified twice by silica gel column chromatography 
(eluent: PE/AcOEt 50:1) to afford the desired product as a clear oil. Yield: 
0.04 g (18 %). 
1H NMR (300MHz, CDCl3): δ 7.23-7.20 (m, 1H, H13), 6.24-6.08 (m, 2H, 
H14 and 15), 5.80 (d, 1H, H12, J=15.3 Hz), 5.52 (d, 1H, H8, J=5.7 Hz), 5.05 
(quint, 1H, H2, J=5.7 Hz), 3.99-3.97 (m, 1H, H4), 3.56-3.50 (m, 1H, H3), 
2.10-2.05 (m, 1H, H7), 1.85 (d, 3H, H16, J=5.7Hz), 1.79-1.70 (m, 2H, H7 and 
5), 1.58 (s, 3H, H10), 1.49-1.41 (m, 1H, H5), 1.25 (d, 3H, H1, J=6.6 Hz), 0.90 
(t, 3H, H6, J=6.8 Hz) 
13C NMR (75MHz, CDCl3): δ 166.2 (C11), 144.9 (C13), 139.1 (C15), 135.8 
(C9), 130.0 (C14), 120.1 (C12), 119.6 (C8), 78.5 (C4), 74.9 (C3), 71.7 (C2), 
26.7 (C7 or 5), 25.7 (C7 or 5), 19.0 (C16 or 10), 18.8 (C16 or 10), 15.7 (C1), 9.8 (C6). 
MS (CI) m/z (%):95 (13), 153 (24), 247 (17), 265 (100) [M+H]+ 
HRMS m/z: calculated for C16H25O3 : 265.18037. Found: 265.17979. 
III.5.3. Synthesis of esters 5.027 and 5.028 
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 (S)-1-((2S,6S)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-yl)ethyl 
cinnamate 5.027 
 
The reaction was carried out on 0.59 mmol (0.1 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/AcOEt 50:1) to afford the desired product as a clear oil. Yield: 
0.076 g (43 %). 
1H NMR (300MHz, CDCl3): δ 7.68 (d, 1H, H12, J=15.9 Hz), 7.54-7.51 (m, 
2H, Har), 7.39-7.37 (m, 3H, Har), 6.46 (d, 1h, H13, J=15.9 Hz), 5.55-5.54 (m, 
1H, H8), 5.03 (quint, 1H, H2, J=6.6 Hz), 4.06-4.03 (m, 1H, H4), 3.58-3.52 
(m, 1H, H3), 2.05-2.00 (m, 2H, H7), 1.79-1.70 (m, 1H, H5), 1.59 (s, 3H, H10), 
1.56-1.50 (m, 1H, H5), 1.34 (d, 3H, H1 , J=6.6 Hz), 0.88 (t, 3H, H6, J=7.5 Hz) 
13C NMR (75MHz, CDCl3): δ 166.3 (C11), 144.7 (C12), 135.6 (C9 or ar), 134.6 
(C9 or ar), 130.3-129.0-128.2 (Car), 120.2 (C8), 118.7 (C13), 78.3 (C4), 75.3 
(C3), 72.9 (C2), 29.5 (C5), 27.4 (C7), 19.0 (C10), 16.0 (C1), 8.5 (C6). 
 
 (S)-1-((2R,6R)-6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-yl)ethyl 
cinnamate 5.028 
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The reaction was carried out on 0.59 mmol (0.1 g). 
The crude product was purified by silica gel column chromatography 
(eluent: PE/AcOEt 50:1) to afford the desired product as a clear oil. Yield: 
0.085 g (49 %). 
1H NMR (300MHz, CDCl3): δ 7.7 (d, 1H, H12, J=15.9 Hz), 7.53-7.50 (m, 
2H, Har), 7.39-7.37 (m, 3H, Har), 6.43 (d, 1H, H13, J= 15.9 Hz), 5.49-5.47 (m, 
1H, H8), 5.02 (quint, 1H, H2, J=6 Hz), 3.90 (t, 1H, H4, J=6.3 Hz), 3.74-3.67 
(m, 1H, H3), 2.08-2.03 (m, 2H, H7), 1.64-1.61(m, 5H, H5 and 10), 1.36 (d, 3H, 
H1, J=6.3 Hz), 1.03 (t, 3H, H6, J=7.5 Hz). 
13C NMR (75MHz, CDCl3): δ 166.5 (C11), 144.8 (C12), 136.2 (C9 or ar), 134.6 
(C9 or ar), 130.3-129.0-128.2 (Car), 118.6 (C13 or 8), 118.5 (C13 or 8), 78.0 (C4), 
72.6 (C2), 69.0 (C3), 27.2 (C7), 24.5 (C5), 20.0 (C10), 16.2 (C1), 10.7 (C6). 
MS (CI) m/z (%): 153 (19), 283 (15), 301 (100) [M+H]+. 
HRMS m/z: calculated for C19H25O3 : 301.18037. Found: 301.18074. 
III.5.4. Synthesis of ester 5.026 
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 (E)-(1S)-1-(6-ethyl-5-methyl-3,6-dihydro-2H-pyran-2-yl)ethyl but-
2-enoate 5.026 
 
The reaction was carried out on 0.59 mmol (0.1 g). 
The crude product was purified by silica gel column chromatography 
(eluent:PE/Et2O 30:1) to afford the desired product as a clear oil and a 
mixture of two diastereomers. Yield: 0.079 g (71 %). 
1H NMR (300MHz, CDCl3): δ 7.02-6.90 (m, 2H, H13,13'), 5.84 (d, 2H, 
H12,12'), 5.52-5.50 (m, 2H, H8,8'), 5.03 (q, 1H, H2’, J=6 Hz), 4.93 (q, 1H, H2, 
J= 6 Hz), 4.02-3.97 (m, 2H, H4,4'), 3.52-3.44 (m, 2H, H3,3'), 2.03-1.90 (m, 4H, 
H7,7'), 1.85 (d, 6H, H14,14', J=9 Hz), 1.78-1.67 (m, 2H, H5,5'), 1.56 (s, 6H, 
H10,10'), 1.49-1.41 (m, 2H, H5,5'), 1.26 (d, 3H, H1, J=6 Hz), 1.22 (d, 3H, H1’, 
J=6 Hz), 0.85 (t, 6H, H6,6'). 
13C NMR (75MHz, CDCl3): δ 166.3 (C11), 166.1 (C11’), 144.6 (C13), 144.4 
(C13’), 135.8 (C9’), 135.5 (C9), 123.2 (C12 and 12’), 120.1 (C8), 120.0 (C8’), 78.5 
(C4’), 78.2 (C4), 75.3 (C3), 74.9 (C3’), 72.4 (C2), 71.6 (C2’), 27.4 (C7), 26.6 
(C7’), 25.7 (C5), 25.6 (C5’), 19.0 (C10 and 10’), 18.1 (C14 and 14’), 16.1 (C1), 15.6 
(C1’), 8.8 (C6’), 8.5 (C6). 
MS (CI) m/z (%): 102(22), 135 (43), 153 (12), 239 (58) [M+H]+, 261 (100) 
[M+Na]+. 
HRMS m/z: calculated for C14H23O3:239.16410. Found: 239.16417 
IR (film, cm-1): 688, 737, 839, 918, 925, 968, 997, 1026, 1060, 1101, 1122, 
1184, 1263, 1292, 1377, 1444, 1656, 1716, 2854, 2923, 2964. 
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IV. Chapter 6: lactone synthesis 
IV.1. Substrates synthesis 
IV.1.1. Glycidol protection 
IV.1.1.1. With a benzyl group 
 
To a solution of glycidol (2.0 ml, 30.0 mmol) in DMF (55 ml) was added 
NaH 60 % (1.8 g, 45.0 mmol) at 0°C. Benzyl bromide (14.4 ml, 120.0 
mmol) and TBAI (1.11 g, 3.0 mmol) were then added. The solution was 
warmed up to room temperature and stirred for 72 hours. The reaction was 
quenched with water and the solution was diluted with EtOAc. The aqueous 
phase was extracted with EtOAc. The combined organic layers were washed 
with water, dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude mixture was purified by silica gel column 
chromatography (PE/EtOAc 8:2) to afford the desired compound as a yellow 
oil; yield: 2.95 g (62 %). 
 (±)-2-((benzyloxy)methyl)oxirane 6.00214 
 
CAS number : [2930-05-4] 
                                                     
14 Master thesis, Sophie Moreau, UCL 2012 
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1H NMR (300MHz, CDCl3): δ 2.64 (dd, J=5.0 Hz, J=2.7 Hz, 1H, H1), 2.81 
(dd, J=5.0 Hz,  J=4.2 Hz, 1H, H1), 3.20 (m, 1H, H2), 3.46 (dd, J=11.4 Hz 
,J=5.8 Hz, 1H, H3), 3.78 (dd, J=11.4 Hz, J=3.1 Hz, 1H, H3), 4.58 (d, J=11.9 
Hz, 1H, H4), 4.63 (d, J=11.9 Hz, 1H, H4), 7.28-7.37 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 44.4 (C1), 50.9 (C2), 70.9 (C3), 73.4 (C4), 
127.8-128.5-137.9 (Car). 
Data are in agreement with literature values. 
IV.1.1.2. With a TBS group 
O
OH
TBSCl, Im, DMF (1.7 M)
0 °C to r.t., 2 h
O
OTBS
6.001 6.005quant.  
A solution of glycidol (1.33 ml, 20 mmol) and imidazole (2.18 g, 32 mmol) 
in DMF (12 ml) was stirred for 10 minutes at 0°C. TBSCl (3.92 g, 26.00 
mmol) was then added at 0°C and the resulting mixture was stirred for 30 
minutes. The reaction was then warmed up to room temperature and stirred 
for 2 hours. It was quenched with saturated brine and the mixture was stirred 
for 30 minutes. The solution was extracted with Et2O. The combined organic 
layers were washed with brine and concentrated under redued pressure to 
afford the desired compound as a colorless oil; yield: 3.87 g (quant.). 
 (±)-Tert-butyldimethyl(oxiran-2-ylmethoxy)silane 6.00515 
 
CAS number : [114413-26-2] 
                                                     
15 Donohoe, T. J.; Ironmonger, A.; Kershaw, N. M. Angew. Chem. Int. Ed. 2008, 47, 
7314.  
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1H NMR (300MHz, CDCl3): δ 0.07 (s, 3H, HTBS), 0.08 (s, 3H, HTBS), 0.90 (s, 
9H, HTBS), 2.64 (dd, 1H, H1, J=5.1 Hz, J=2.7 Hz), 2.77 (dd, 1H, H1, J=5.1 
Hz, J=4.1 Hz), 3.09 (m, 1H, H2), 3.66 (dd, 1H, H3, J=11.9 Hz, J=4.8 Hz), 
3.85 (dd, 1H, H3, J=11.9 Hz, J=3.2 Hz). 
13C NMR (75MHz, CDCl3): δ -5.2 (CTBS), -5.2 (CTBS), 18.5 (CTBS), 26.0 
(CTBS), 44.6 (C1), 52.57 (C2), 63.9 (C3). 
Data are in agreement with literature values. 
IV.1.2. Opening of epoxides 
IV.1.2.1. Synthesis of nitrile 6.006 
 
To a solution of  substrate (2 g, 12.2 mmol) in a mixture of EtOH/H2O (5:1, 
80 ml) was added KCN (1.6 g, 24.4  mmol). The reaction was stirred 
overnight at room temperature. Water was added and the aqueous phase was 
extracted with EtOAc. The combined organic layers were dried over  
MgSO4, filtered and concentrated under reduced pressure. The crude product 
was purified by silica gel column chromatography (PE/EtOAc 8:2) to afford 
the desired compound as a colorless oil; yield: 2.14 g (92 %). 
 4-(benzyloxy)-3-hydroxybutanenitrile 6.006 
 
CAS number : [137618-52-1] 
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1H NMR (300MHz, CDCl3): δ 2.57 (dd, 1H, H2, J=16.8 Hz, J=6.3 Hz), 3.01-
3.03 (m, 1H, H2), 3.53 (m, 2H, H4), 4.07 (quint., 1H, H3, J=5.4 Hz), 4.56 (s, 
2H, H5), 7.29-7.40 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 22.5 (C2), 66.5 (C3), 72.2 (C4), 73.7 (C5), 
117.4 (C1), 127.9-128.1-128.6-127.3 (Car). 
MS (EI) m/z (%): 84.0 (93), 91.1 (100), 191.1 (11) [M]+ 
IR (film, cm-1): 698, 738, 1091, 1454, 1496, 2250, 2860, 3440, 3745. 
IV.1.2.2. Synthesis of nitrile 6.007 
 
To a solution of substrate (1.3 g, 6.9 mmol) in a mixture of EtOH/H2O (5:1, 
18 ml) was added KCN (0.9 g, 13.8 mmol) at room temperature. The 
mixture was stirred for 6 hours. Then, water was added. The aqueous layer 
was extracted with EtOAc and the combined organic layers were directly 
concentrated under reduced pressure. The crude mixture was purified by 
silica gel column chromatography (PE/EtOAc 9:1) to afford the desired 
compound as a colorless oil; yield: 0.370 g (26 %). 
 4-((tert-butyldimethylsilyl)oxy)-3-hydroxybutanenitrile 6.00714 
 
CAS number : [141096-18-6] 
1H NMR (300MHz, CDCl3): δ 0.10 (s, 6H, HTBS), 0.91 (s, 9H, HTBS), 2.57 
(dd, 2H, H2,  J=6.2 Hz, J=1.8 Hz), 3.65 (dd, 1H, H4, J=10.2 Hz, J=5.2 Hz), 
3.73 (dd, 1H, H4, J=10.2 Hz, J=4.2 Hz), 3.99 (m, 1H, H3). 
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13C NMR (75MHz, CDCl3): δ -4.7 and -4.7 (CTBS), 18.1 (CTBS), 23.0 (C2), 
25.8 (CTBS), 65.6 (C4), 68.9 (C3), 117.7 (C1). 
Data are in agreement with literature values. 
IV.1.2.3. Synthesis of homopropargylic alcohol 6.030 
 
To a solution of methyl propiolate (2.50 ml, 28.1 mmol) in THF (100 ml) at 
-78°C was added n-BuLi ((2.5M solution in THF), 11.20 ml, 28.1 mmol). 
The mixture was stirred for 20 minutes, then, BF3OEt2 (3.50 ml, 28.1 mmol) 
was added at -78°C. The resulting solution was stirred for another 20 
minutes. Finally, tert-butyldimethyl(oxiran-2-ylmethoxy)silane (1.53 g, 8.1 
mmol) was added at -78°C. The mixture was warmed up to room 
temperature and stirred overnight. The solution was quenched with NH4Cl, 
extracted with EtOAc, washed with brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude product was purified by 
silica gel column chromatography (PE/EtOAc 95:5) to afford the desired 
compound as a yellow oil; yield: 2.0 g (91 %) 
 Methyl 6-(benzyloxy)-5-hydroxyhex-2-ynoate 6.03016 
 
                                                     
16 J. Maguire, R.; P. Munt, S.; J. Thomas, E. J. Chem. Soc., Perkin Trans. 1 1998, 
2853.  
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CAS number : [124067-07-8] 
1H NMR (300MHz, CDCl3): δ 0.08 (s, 6H, HTBS), 0.90 (s, 9H, HTBS), 2.57 
(d, 2H, H5, J=6.4 Hz), 3.61 (dd, 1H, H7, J=5.4 Hz, J=10.1 Hz), 3.72 (dd, 1H, 
H7, J=3.7 Hz, J=6.4 Hz),  3.76 (s, 3H, H1), 3.87 (m, 1H, H6). 
13C NMR (75MHz, CDCl3): δ -4.8 (CTBS), 18.4 (CTBS), 24.0 (C5), 26.3 
(CTBS), 52.9 (C1), 65.5 (C7), 70.0 (C6), 74.8 (C3), 86.3 (C4), 154.2 (C2). 
Data are in agreement with literature values. 
IV.1.2.4. Synthesis of homoallylic alcohol 6.019 
 
To a solution of vinyl magnesium bromide ((0.7 M solution in THF) 30.90 
ml, 21.6 mmol) in THF (40 ml) was added CuI (0.343 g, 1.8 mmol) at 0°C. 
The solution was stirred for 15 minutes then, cooled to -15°C and 2-
((benzyloxy)methyl)oxirane (2.955 g, 18.0 mmol) in THF (10 ml) was added 
dropwise. The reaction was warmed up to room temperature and stirred for 
20 minutes. The mixture was quenched with NH4Cl and extracted with Et2O. 
The combined organic phases were washed with NH4Cl and brine, dried 
over MgSO4 and concentrated under reduced pressure. The crude mixture 
was purified by silica gel column chromatography (PE/EtOAc 9:1) to afford 
the desired compound as a yellow oil; yield: 3.24 g (95 %). 
 1-(benzyloxy)pent-4-en-2-ol 6.0191 
 
CAS number : [58931-16-1] 
300                                    EXPERIMENTAL PART 
1H NMR (300MHz, CDCl3): δ 2.12 (bs, 1H, H5), 2.27 (m, 2H, H3),  3.38 
(dd, 1H, H5,  J=9.5 Hz, J=7.4 Hz), 3.52 (dd, 1H, H5, J=9.5 Hz, J=3.4 Hz), 
3.89 (m, 1H, H4), 4.56 (s, 2H, H6), 5.12 (m, 2H, H1), 5.83 (ddt, 1H, H2, 
J=17.1 Hz, J=10.1 Hz, J=7.0 Hz), 7.30-7.37 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 38.0 (C3), 69.9 (C4), 73.5 (C2), 74.0 (C6), 
117.9 (C1), 127.9-127.9-128.6-134.3-138.1 (Car). 
Data are in agreement with literature values. 
IV.1.2.5. Synthesis of homopropargylic alcohol 6.020 
O
OTBS
MgCl
CuI, THF
0°C to r.t.
OTBS
OH
90 %
6.005 6.020
 
To a solution of vinyl magnesium chloride ((1.9 M solution in THF) 13.2 ml, 
25.1 mmol) in THF (40 ml) was added CuI (0.398 g, 2.1 mmol) at 0°C. The 
solution was stirred for 30 minutes and tert-butyldimethyl(oxiran-2-
ylmethoxy)silane (3.932 g, 20.9 mmol) was added to the solution at -15°C. 
The solution was warmed up to room temperature and stirred for 1 hour. It 
was quenched with NH4Cl and extracted with EtOAc. The combined organic 
layers were washed with NH4Cl and brine, dried over MgSO4, filtered and 
concentrated under reduced pressure. The desired product was obtained as a 
brown oil; yield: 4.1 g (90 %). 
 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-ol 6.02017 
                                                     
17 D. Amans, V. Bellosta, C. Dacquet, A. Ktorza, N. Hennuyer, B. Staels, D.  
Caignard,  J. Cossy,  Org. Biomol. Chem. 2012, 10, 6169.  
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CAS number: [127793-63-9] 
1H NMR (300MHz, CDCl3): δ 0.07 (s, 6H, HTBS), 0.90 (s, 9H, HTBS), 2.24 
(m, 2H, H3), 3.45 (dd, 1H, H5, J=9.9 Hz, J=6.9 Hz), 3.63 (dd, 1H, H5, J=9.9 
Hz, J=3.7 Hz), 3.71 (m, 1H, H4), 5.11 (m, 2H, H1), 5.84 (m, 1H, H2). 
13C NMR (75MHz, CDCl3): δ -5.2 and -5.2 (CTBS), 18.3 (CTBS), 26.0 (CTBS), 
37.7 (C3), 66.7 (C5), 71.2 (C4), 117.5 (C1), 134.6 (C2). 
Data are in agreement with literature values. 
IV.1.3. Protection with TMSCl 
IV.1.3.1. Synthesis of 6.011 
 
To a solution of 4-(benzyloxy)-3-hydroxybutanenitrile (0.86 g, 4.5 mmol) in 
DCM (10 mL) were added HMDS (0.57 mL, 2.7 mmol) and TMSCl (0.02 
mL, 0.2 mmol) at 0°C. The solution was warmed up to room temperature 
and stirred overnight. It was quenched by adding saturated NH4Cl, extracted 
with DCM and concentrated under reduced pressure to afford the desired 
compound as a colorless oil; yield: 1.139 g (96 %). 
 4-(benzyloxy)-3-((trimethylsilyl)oxybutanenitrile 6.011 
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1H NMR (300MHz, CDCl3): δ 0.15 (s, 9H, HTMS), 2.52 (dd, 1H, H2, J=16.6 
Hz, J=6.8 Hz,), 2.64 (dd, 1H, H2, J=16.6 Hz, J=4.4 Hz), 3.39 (dd, 1H, H4, 
J=9.6 Hz, J=6.9 Hz), 3.50 (dd, 1H, H4, J=9.6 Hz, J=4.8 Hz), 4.07 (m, 1H, 
H3), 4.54 (s, 2H, H5), 7.30-7.39 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 0.2 (CTMS), 24.0 (C2), 67.6 (C3), 72.9 (C4), 
73.7 (C5), 117.9 (C1), 127.9-128.1-128.6-137.7 (Car). 
MS (APCI) m/z (%): 91.09 (59), 174.05 (100), 264.12 (100) [M+1]. 
HRMS m/z: calculated for C14H21O2NNaSi: 286.12353. Found: 286.12338. 
IR (film, cm-1): 698, 736, 840, 1251, 1454, 2250, 2908. 
IV.1.4. Esterifications 
IV.1.4.1. Synthesis of 6.021 
 
To a solution of 1-(benzyloxy)pent-4-en-2-ol (0.476 g, 2.5 mmol) in Et2O 
(10 mL) was added Et3N (0.28 mL, 3.5 mmol). The solution was cooled to 
0°C and acryloyl chloride (0.28 mL, 3.5 mmol) was added dropwise. The 
solution was stirred for 1 hour, filtered, the solution was washed with 
PE/EtOAc (8:2) and the combined solutions were concentrated under 
reduced pressure. The product was purified by elution through a short silica 
gel column (PE/EtOAc 9:1) to afford the desired compound as a yellow oil; 
yield: 0.42 g (70 %). 
 1-(benzyloxy-pent-4-en-2-yl acrylate 6.0211 
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CAS number : [640298-47-1] 
1H NMR (300MHz, CDCl3): δ 2.44 (m, 2H, H3), 3.57 (d, 2H, H5, J=4.9 Hz), 
4.52 (d, 1H, H9, J=12.1 Hz), 4.58 (d, 1H, H9, J=12.1 Hz), 5.09 (m, 2H, H1), 
5.17 (m, 1H, H4), 5.74 (m, 1H, H2), 5.83 (dd, 1H, H8,  J=10.4 Hz, J=1.6 Hz), 
6.14 (dd, 1H, H7, J=17.3 Hz, J=10.3 Hz), 6.42 (dd, 1H, H8, J=17.3 Hz, J=1.5 
Hz), 7.28-7.36 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 35.5 (C3), 70.6 (C5), 72.3 (C4), 73.3 (C9), 
118.2 (C1), 127.8-127.8-128.5 (Car), 128.7 (C7), 131.0 (C8), 133.3 (C2), 138.1 
(Car), 165.9 (C6). 
Data are in agreement with literature values. 
IV.1.4.2. Synthesis of 6.022 
OTBS
OH
Cl
O
Et3N, DCM
OTBS
O
O
6.020 6.02285 %  
To a solution of 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-ol (0.769 g, 4.0 
mmol) and Et3N (0.83 mL, 6.0 mmol) in DCM (10 mL) was added dropwise 
acryloyl chloride (0.45 mL, 5.6 mmol) at 0°C. The solution was warmed up 
to room temperature and stirred for 15 minutes. The mixture was diluted 
with water and extracted with DCM. The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated under 
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reduced pressure to afford the desired compound as a yellow oil; yield: 0.92 
g (85 %). 
 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-yl acrylate 6.022 
 
1H NMR (300MHz, CDCl3): δ 0.05 (s, 6H, HTBS), 0.88 (s, 9H, HTBS), 2.40 
(m, 2H, H3), 3.69 (d, 2H, H5, J=5.0 Hz,), 5.07 (m, 3H, H1 and H4), 5.80 (m, 
2H, H8 and H2), 6.11 (dd, 1H, H7, J=17.3 Hz, J=10.3 Hz), 6.40 (dd, 1H, H8, 
J=17.3 Hz, J=1.1 Hz). 
13C NMR (75MHz, CDCl3): δ -5.3 (CTBS), 18.4 (CTBS), 25.9 (CTBS), 35.1 
(C3), 63.7 (C5), 74.0 (C4), 118.0 (C1), 128.8 (C7), 130.7 (C8), 133.6 (C2), 
165.9 (C6). 
IR (film, cm-1): 810, 833, 1103, 1191, 1253, 1406, 1471, 1637, 1726, 2856, 
2927, 2952. 
MS (ESI) m/z (%): 271.17 (25) [M+H]+, 293.15 (100) [M+Na]+ 
HRMS m/z: calculated for C14H27O3Si: 271.17229. Found: 271.17240. 
IV.1.4.3. Synthesis of 6.036 
 
To a solution of 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-ol (1.961 g, 9.1 
mmol) and Et3N (1.89 mL, 13.6 mmol) in DCM (20 mL) was added 
methacryloyl chloride (1.24 mL, 12.7 mmol) at 0°C. The solution was 
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warmed up to room temperature and stirred for 15 minutes. Mixture was 
quenched with water and extracted with DCM. The combined organic layers 
were dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude product was purified by silica gel column chromatography 
(PE/EtOAc 95:5) to afford the desired compound as a yellow oil; yield: 
1.116 g (43 %). 
 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-yl methacrylate 6.036 
 
1H NMR (300MHz, CDCl3): δ 0.05 (s, 6H, HTBS), 0.89 (s, 9H, HTBS), 1.94 
(dd, 3H, H8, J=1.5 Hz, J=0.9 Hz), 2.42 (m, 2H, H3), 3.69 (dd, 2H, H5, J=5.0 
Hz, J=1.1 Hz), 4.99 (m, 1H, H4) 5.10 (m, 2H, H1), 5.55 (m, 1H, H9), 5.79 (m, 
1H, H2), 6.11 (dd, 1H, H9, J=1.7 Hz, J=0.9 Hz). 
13C NMR (75MHz, CDCl3): δ -5.2 (CTBS), 18.7 (CTBS and C8), 26.0 (CTBS), 
35.3 (C3), 63.9 (C5), 74.3 (C4), 118.0 (C1), 125.6 (C9), 133.9 (C2), 137.0 (C7), 
167.1 (C6). 
MS (ESI) m/z (%): 285.19 (43) [M+H]+, 307.17 (100) [M+Na]+  
HRMS m/z: calculated for C15H29O3Si: 285.18754. Found: 285.18805. 
IR (film, cm-1): 734, 775, 835, 1109, 1165, 1252, 1471, 1639, 1720, 2856, 
2927. 
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IV.2. Synthesis of lactones 6.016 and 6.017 
IV.2.1. Blaise reaction 
IV.2.1.1. Synthesis of 6.010 
Powdered zinc was activated with 3M HCl, rinsed with water, EtOH and 
Et2O then dried under reduced pressure.  
To a suspension of activated zinc dust (0.89 g, 13.7 mmol) in THF (6.8 mL) 
was added TMSCl (0.26 mL, 2.0 mmol). The solution was stirred for 20 
minutes, treated with substrate 6.011 (1.8 g, 6.8 mmol) and the mixture was 
heated to reflux. Methyl bromoacetate (1.03 mL, 10.9 mmol) was then added 
dropwise over 90 minutes and the mixture was refluxed for 60 more minutes. 
The mixture was cooled to 0°C and 3M HCl (4 mL) was added dropwise. 
After 2 hours, the organic volatiles were removed under reduced pressure 
and the remaining mixture was extracted with EtOAc. The organic layer was 
washed with water, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The residue was purified by silica gel column 
chromatography (eluent: PE/EtOAC 85:15 70:30) to afford the title 
product as a yellow oil; yield: 1.28 g (70 %). 
 Methyl 6-(benzyloxy)-5-hydroxy-3-oxohexanoate 6.010 
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1H NMR (300MHz, CDCl3): δ 2.76 (m, 2H, H4), 3.50 (m, 2H, H6), 3.51 (s, 
2H, H2), 3.74 (s, 3H, H8), 4.29 (m, 1H, H5), 4.56 (s, 2H, H7), 7.27-7.33 (m, 
5H, Har) 
13C NMR (75MHz, CDCl3): δ 46.3 (C4), 49.5 (C8), 52.2 (C2), 66.5 (C5), 73.1 
(C6), 73.2 (C7), 127.6-128.3-137.7 (Car), 167.4 (C1), 202.2 (C3). 
MS (ESI) m/z (%): 91.13 (21), 249.04 (85), 266.83 (100) [M]+, 283.94 (65). 
HRMS m/z: calculated for C14H19O5: 267.12278. Found: 267.12270. 
IR (film, cm-1): 736, 1078, 1454, 1712, 1745, 2918, 3420. 
IV.2.1.2. Synthesis of 6.013 
Powdered zinc was activated with 3M HCl, rinsed with water, EtOH and 
Et2O then dried under reduced pressure.  
To a suspension of activated zinc dust (0.26 g, 4.0 mmol) in THF (2 mL) 
was added TMSCl (0.04 mL, 0.3 mmol). The solution was stirred for 20 
minutes, treated with substrate 6.011 (1.8 g, 6.8 mmol) and the mixture was 
heated to reflux. Methyl bromoacetate (0.45 mL, 4 mmol) in THF (3 mL) 
was then added dropwise over 90 minutes and the mixture was refluxed for 2 
more hours. The mixture was cooled to 0°c and added onto a solution of 
APTS (3 eqs)/H2O (5 mL)/THF (5 mL) at 0°C and it was stirred for 1 hour. 
The solvent was then removed under reduced pressure. The residue was 
dissolved in EtOAc, washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by silica gel 
column chromatography (eluent: PE/EtOAC 1:1, 5 % Et3N) to afford the 
title product as a clear oil; yield: 0.157 g (57 %). 
 Methyl 6-(benzyloxy)-5-hydroxy-2-methyl-3-oxohexanoate 6.013 
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1H NMR (300MHz, CDCl3): δ 1.34 (d, 3H, H9, J=7.1Hz), 2.78 (m, 2H, H4), 
3.52 (m, 3H, H2 and 6), 3.72 (s, 3H, H8), 4.29 (m, 1H, H5), 4.56 (s, 2H, H7), 
7.27-7.39 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 12.7 (C9), 44.8 (C4), 52.6 (C8), 53.3 (C2), 66.8 
(C5), 73.2 (C6), 73.5 (C7), 127.8-127.9-128.6-137.9 (Car), 170.8 (C1), 205.6 
(C3). 
MS (ESI) m/z (%): 303.12 (100) [M+Na]+, 319.09 (14), 583.25 (11) 
[2M+Na]+ 
HRMS m/z: calculated for C15H21O5: 281.13862. Found: 281.13835. 
IR (film, cm-1): 700, 734, 1114, 1454, 1714, 1737, 3380. 
IV.2.1.3. Synthesis of 2.033 
 To a suspension of activated Zn (10 mmol, 0.65 g) in THF (5 mL) was 
added TMSCl (0.75 mmol, 0.1 mL) dropwise and the resulting mixture was 
stirred for 20 minutes. Nitrile (0.66 g, 2.5 mmol) was added and the solution 
was heated to reflux (76°C). A solution of methyl-bromo acetate (10 mmol, 
1.12 mL) in THF (7.5 mL) was added dropwise over 90 minutes and stirred 
for 2 more hours at reflux. The reaction mixture was cooled down to 0°C 
and poured on a solution of APTS (3eq)/H2O(5 mL)/THF (5 mL) at 0°C and 
stirred for 1 hour. The solvent was evaporated under reduced pressure and 
the residue was taken in EtOAc. It was washed with brine, dried over 
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Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was purified by silica gel column chromatography (eluent: PE/EtOAc 1:1, 5 
% Et3N) to afford the pure product as a clear oil and a mixture of two 
compounds (1:1); yield: 0.41 g (58 %). 
 (R)-Methyl 6-(benzyloxy)-5-hydroxy-2-methyl-3-oxohexanoate 
2.0331 
 
CAS number : [934623-82-2] 
1H NMR (300MHz, CDCl3): δ 7.35-7.29 (m, 5H, Har), 4.54 (s, 2H, H9), 4.28 
(quint., 1H, H7, J=6Hz), 3.71 (s, 3H, H1), 3.50-3.43 (m, 3H, H3 and 8), 2.76-
2.73 (m, 2H, H6), 1.32 (d, 3H, H4, J=9Hz). 
13C NMR (75MHz, CDCl3): δ 205.6 (C5,5'), 170.9 (C2,2'), 137.9-128.6-127.9 
(Car), 73.5-73.2-73.1 (C8,8', 9,9'), 66.9-66.8 (C7 and 7’), 53.4-53.3-52.7 (C1,1',3,3'), 
44.8-44.9 (C6 and 6’), 12.6-12.7 (C4 and 4’). 
Data are in agreement with literature values. 
IV.2.2. Lactonization 
IV.2.2.1. General procedure 
To a solution of substrate (1 eq) in DCM (0.1 M) was added MeOH (30 eqs). 
The resulting solution was cooled to -78°C and TMSCl (4 eqs) was added 
dropwise. The solution was allowed to warm up to 0°C and stirred 8 hours at 
0°C. The mixture was placed in a refrigerator overnight. Saturated NaHCO3 
was added and the aqueous phase was extracted with DCM. The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. 
310                                    EXPERIMENTAL PART 
IV.2.2.2. Synthesis of 6.014 
MeO OBn
O O OH
6.010
TMSCl, MeOH
DCM, -78 to 0 °C, 24 h
O
MeO
O
OBn
6.01486 %  
 6-((benzyloxy)methyl)-4-methoxy-5,6-dihydro-2H-pyran-2-one 
6.014 
 
The reaction was carried out on 4.67 mmol (1.2 g). 
The crude mixture was purified by silica gel column chromatography 
(PE/EtOAc 85:15) to afford the title product as a yellow oil; yield: 1 g (86 
%). 
1H NMR (300MHz, CDCl3): δ 2.39 (dd, 1H, H4, J=17.2 Hz, J=4.1 Hz), 2.73 
(ddd, 1H, H4, J=17.2 Hz, J=11.8 Hz, J=1.2 Hz), 3.70 (dd, 2H, H6, J=4.8 Hz, 
J=1.8 Hz), 3.74 (s, 3H, H8), 4.57 (m, 1H, H5), 4.60 (s, 2H, H7), 5.14 (d, 1H, 
H2, J=1.2 Hz), 7.29-7.39 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 29.8 (C4), 56.1 (C8), 70.6 (C6), 73.6 (C5), 74.6 
(C7), 90.2 (C2), 127.7-127.9-128.5-137.7 (Car), 166.7 (C3), 172.8 (C1). 
MS (ESI) m/z (%): 249.11 (31) [M+1]+, 271.09 (69) [M+Na]+, 519 (100) 
[2M+Na]+ 
HRMS m/z: calculated for C14H17O4: 249.11217. Found: 249.11214. 
IR (film, cm-1): 698, 736, 1051, 1224, 1390, 1454, 1622, 1697. 
 
 
EXPERIMENTAL PART  311 
 
IV.2.2.3. Synthesis of 6.015 
MeO OBn
O O OH
6.010
TMSCl, MeOH
DCM, -78 to 0 °C, 24 h
O
MeO
O
OBn
6.01550 %  
 6-((benzyloxy)methyl)-4-methoxy-3-methyl-5,6-dihydro-2H-pyran-
2-one 6.015 
 
The reaction was carried out on 2.79 mmol (0.78 g). 
The crude mixture was purified by silica gel column chromatography 
(PE/EtOAc 85:15) to afford the title product as a yellow oil; yield: 0.37 g (50 
%). 
1H NMR (300MHz, CDCl3): δ 1.79 (s, 3H, H9), 2.68 (m, 2H, H4), 3.72 (m, 
2H, H6), 3.79 (s, 3H, H8), 4.48 (m, 1H, H5), 4.61 (s, 2H, H7), 7.28-7.40 (m, 
5H, Har). 
13C NMR (75MHz, CDCl3): δ 8.7 (C9), 25.9 (C4), 55.4 (C8), 70.7 (C6), 73.3 
(C5), 74.7 (C7) 102.7 (C2), 127.7-127.8-128.3-137.6 (Car), 165.6 (C3), 171.1 
(C1). 
MS (ESI) m/z (%): 263.13 (82) [M+1]+, 285.11 (93) [M+Na]+, 301.08 (48), 
547.23 (100) [2M+Na]+ 
HRMS m/z: calculated for C15H19O4: 263.12779. Found: 263.12779. 
IR (film, cm-1): 700, 736, 1099, 1238, 1454, 1643, 1693. 
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IV.2.2.4. Synthesis of 2.034 
 
To a solution of βketoester (0.1 g, 0.36 mmol) in THF (4 mL) was added 
aqueous NaOH (1 M) (1.4 mL, 1.43 mmol). The mixture was stirred for 30 
minutes and then quenched with saturated NH4Cl followed by diluted HClaq. 
The aqueous phase was extracted with EtOAc. The organic phase was 
washed with brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was diluted in acetone (3.4 mL). 
Me2SO4 (0.05 mL, 0.51 mmol) was added followed by K2CO3. The resulting 
mixture was stirred for 2 days.  Mixture was quenched with water and 
extracted with Et2O. The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure.  The crude product was purified by 
silica gel column chromatography (eluent PE/EtOAc 5:1  1:1) to afford 
the desired product as a clear oil; yield: 0.037 g (41 %). 
 (R)-6-((benzyloxy)methyl)-4-methoxy-3-methyl-5,6-dihydro-2H-
pyran-2-one 2.0341 
 
1H NMR (300MHz, CDCl3): δ 1.77 (s, 3H, H9), 2.69-2.63 (m, 2H, H4), 3.71 
(dd, 2H, H6, J=4.5 Hz, J=2.7 Hz), 3.78 (s, 3H, H8), 4.50-4.45 (m, 1H, H5), 
4.59 (d, 2H, H7, J=3.6 Hz), 7.29-7.39 (m, 5H, Har). 
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13C NMR (75MHz, CDCl3): δ 168.1 (C1), 165.5 (C3), 137.7-128.6-128.1-
127.9 (Car), 103.3 (C2), 73.9 (C7), 73.4 (C5), 70.9 (C6), 55.6 (C8), 26.3 (C4), 
9.0 (C9). 
Data are in agreement with literature values. 
IV.2.3. Deprotection 
IV.2.3.1. General procedure 
To a solution of substrate (1 eq) in DCM (0.1 M) was added FeCl3 (3 eqs). 
The resulting suspension was stirred at room temperature for 1 hour. Water 
was added and the phases were separated. The aqueous layer was extracted 
with DCM. The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. 
IV.2.3.2. Synthesis of 6.016 
 
 6-(hydroxymethyl)-4-5,6-dihydro-2H-pyran-2-one 6.016 
 
The reaction was carried out on 1.54 mmol (0.38 g). 
The crude mixture was purified by silica gel column chromatography 
(PE/EtOAc 1:1  0:1) to afford the title product as a white solid; yield: 0.17 
g (69 %). 
314                                    EXPERIMENTAL PART 
1H NMR (300MHz, CDCl3): δ 2.27 (dd, 1H, H4, J=17.1 Hz, J=3.9 Hz), 2.79 
(ddd, 1H, H4, J=17.2 Hz, J=12.6 Hz, J=1.6 Hz), 3.72 (dd, 1H, H6, J=12.3 Hz, 
J=4.7 Hz), 3.77 (s, 3H, H8), 3.91 (dd, 1H, H6, J=12.3 Hz, J=3.9 Hz), 4.50 (m, 
1h, H5), 5.15 (d, 1H, H2, J=1.6 Hz). 
13C NMR (75MHz, CDCl3): δ 29.0 (C4), 56.3 (C8), 63.8 (C6), 76.4 (C5), 90.0 
(C2), 167.0 (C3), 173.17 (C1). 
MS (ESI) m/z (%): 159.07 (57) [M+1]+, 181.07 (100) [M+Na]+ 
HRMS m/z: calculated for C7H11O4: 159.06519. Found: 159.06569. 
IR (film, cm-1): 854, 997, 1033, 1226, 1382, 1620, 1681, 2918, 3377. 
Mp (°C): 126-127°C. 
IV.2.3.3. Synthesis of 6.017 
 
 6-(hydroxymethyl)-4-methoxy-3-methyl-5,6-dihydo-2H-pyran-2-one 
6.017 
 
The reaction was carried out on 0.51 mmol (0.27 g). 
The crude mixture was purified by silica gel column chromatography 
(PE/EtOAc 1:1  0:1) to afford the title product as a white solid; yield: 
0.052 g (60 %). 
1H NMR (300MHz, CDCl3): δ 1.75 (s, 3H, H9), 2.54 (dd, 1H, H4, J=17.1 Hz, 
J=3.7 Hz), 2.76 (t, 1H, H4, J=17.2 Hz), 3.72 (dd, 1H, H6, J=12.2 Hz, J=4.4 
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Hz), 3.79 (s, 3H, H8), 3.89 (dd, 1H, H6, J=12.2 Hz, J=3.5 Hz), 4.4 (m, 1H, 
H5). 
13C NMR (75MHz, CDCl3): 8.9 (C9), 25.3 (C4), 55.7 (C8), 63.7 (C6), 75.1 
(C5), 102.8 (C2), 166.1 (C3), 168.6 (C1). 
MS (ESI) m/z (%): 173.08 (100) [M+1]+, 195.06 (69) [M+Na]+, 367.13 (52) 
[2M+Na]+ 
HRMS m/z: calculated for C8H13O4: 173.08084. Found: 173.08114. 
IR (film, cm-1): 761, 997, 1132, 1236, 1326, 1386, 1463, 1639, 1672, 2921, 
3346. 
IV.3. Synthesis of lactone 6.028 
IV.3.1. Via ring-closing metathesis 
IV.3.1.1. Synthesis of 6.026 
 
A solution of 1-(benzyloxy)pent-4-en-2-yl acrylate (0.250 g, 1.0 mmol) in 
DCM (35 mL) was heated to reflux. Grubb’s II catalyst (0.02 g, 0.03 mmol) 
was added to the solution and the mixture was stirred for 1 hour. Then, a 
second portion of 10 mg (1.5 mol %) of Grubb’s II catalyst was added to the 
solution which was stirred for another hour. The solution was concentrated 
and the crude mixture was purified by silica gel column chromatography 
(PE/EtOAc 8:2 0:1) to afford the desired compound as a brown oil; yield: 
0.222 g (56 %). 
 6-((benzyloxy)methyl)-5,6-dihydro-2H-pyran-2-one 6.0261 
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1H NMR (300MHz, CDCl3): δ 2.37 (dddd, 1H, H4, J=18.5 Hz, J=5.8 Hz,  
J=4.4 Hz, J=1.2 Hz), 2.55 (ddt, 1H, H4, J=18.6 Hz, J=11.5 Hz, J=2.6 Hz), 
3.68 (d, 2H, H6, J=4.7 Hz), 4.58 (m, 1H, H5), 4.59 (d, 2H, H7, J=1.4 Hz), 
6.00 (ddd, 1H, H2, J=9.7 Hz,  J=2.7 Hz, J=1.1 Hz), 6.89 (ddd, 1H, H3, J=9.7 
Hz, J=5.91 Hz, J=2.6 Hz), 7.28-7.34 (m, 5H, Har). 
13C NMR (75MHz, CDCl3): δ 31.8 (C4), 70.9 (C6), 73.7 (C7), 76.8 (C5), 
121.2 (C2), 127.9 (Car), 128.0-128.6-137.8 (Car), 145.3 (C3), 163.9 (C1). 
Data are in agreement with literature values 
IV.3.1.2. Synthesis of 6.027 
 
A solution of ((tert-butyldimethylsilyl)oxy)pent-4-en-2-yl acrylate (0.139 g, 
0.51 mmol) in DCM (17 mL) was heated to reflux. Then, Grubbs II catalyst 
(0.017 g, 0.02 mmol) was added and the mixture was stirred under reflux for 
1 hour. The solution was cooled to room temperature and concentrated under 
reduced pressure. The crude mixture was purified by silica gel column 
chromatography (PE/EtOAc 9:1) to afford the desired compound as an 
orange oil; yield: 0.098 g (78 %). 
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 6-((benzyloxy)methyl)-5,6-dihydro-2H-pyran-2-one 6.02718 
 
1H NMR (300MHz, CDCl3): δ 0.06 (s, 6H, HTBS), 0.88 (s, 9H, HTBS), 2.40 
(m, 1H, H4), 2.53 (m, 1H, H4), 3.81 (dd, 2H, H6, J=4.9 Hz,  J=1.3 Hz), 4.47 
(dq, 1H, H5,  J=10.5 Hz, J=5.2 Hz), 6.01 (d, 1H, H2, J=9.7 Hz), 6.90 (ddd, 
1H, H3, J=9.7 Hz, J=5.7 Hz, J=2.8 Hz). 
13C NMR (75MHz, CDCl3): δ -5.2 (CTBS), 18.4 (CTBS), 26.0 (CTBS), 26.1 
(C4), 64.3 (C6), 77.9 (C5), 121.3 (C2), 145.1 (C3), 164.1 (C1).  
IV.3.2. Via intramolecular esterification 
IV.3.2.1. Synthesis of 6.029 
 
Hydrogen was bubbled into a solution of Lindlar catalyst (0.118 g, 1.11 
mmol) and quinoline (0.26 mL, 2.21 mmol) in EtOH (6 mL) for 10 minutes 
and the mixture was stirred for 30 minutes. Then, methyl-6-((tert-
butyldimethylsilyl)oxy)-5-hydroxyhex-2-ynoate (1.006 g, 3.69 mmol) was 
added to the heterogeneous mixture and the mixture was stirred overnight. 
                                                     
18 A. Ahmed, E. K. Hoegenauer, V. S. Enev, M. Hanbauer, H. Kaehlig, E. Öhler,  J. 
Mulzer, J. Org. Chem. 2003, 68, 3026.  
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EtOAc was added to the mixture which was filtered and the solid residue 
extracted several times with EtOAc. After concentration of the solution 
under reduced pressure, the crude mixture was purified by silica gel column 
chromatography (PE/EtOAc 9:1) to afford the desired compound as a yellow 
oil; yield: 0.597 g (59 %). 
 (Z)-methyl 6-((tert-butyldimethylsilyl)oxy)-5-hydroxyhex-2-enoate 
6.029 
 
1H NMR (300MHz, CDCl3): δ 0.08 (s, 6H, HTBS), 0.91 (s, 9H, HTBS), 2.68 
(d, 1H, -OH, J=4.2 Hz), 2.82 (m, 2H, H5), 3.50 (dd, 1H, H7, J=6.9 Hz,  
J=10.0 Hz) , 3.65 (dd, 1H, H7, J=10.0 Hz, J=4.0 Hz), 3.71 (s, 3H, H1), 3.78 
(m, 1H, H6), 5.92 (dt, 1H, H3, J=11.5 Hz, J=1.7 Hz), 6.43 (dt, 1H, H4,  
J=11.5 Hz, J=7.5 Hz). 
13C NMR (75MHz, CDCl3): δ -5.1 (CTBS), 18.8 (CTBS), 26.3 (CTBS), 33.0 
(C5), 51.5 (C1), 67.3 (C8), 71.6 (C6), 121.5 (C3), 146.9 (C4), 167.3 (C2). 
MS (ESI) m/z (%): 275.16 (18) [M+H]+, 297.16 (75) [M+Na]+ 
HRMS m/z: calculated for C13H27O3: 275.16728. Found: 275.16731. 
IR (film, cm-1): 777, 835, 119, 1173, 1254, 1440, 1464, 1647, 1724, 2856.4, 
2928, 2953. 
IV.3.2.2. Synthesis of 6.027 
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To a solution of (Z)-methyl 6-((tert-butyldimethylsilyl)oxy)-5-hydroxyhex-
2-enoate (1.7 g, 4.19 mmol) in iPrOH (10 mL) was added NaOH ((1M 
aqueous solution) 8.39 mL, 8.39 mmol). The solution was stirred at room 
temperature for 1 hour then it was quenched with 1M HCl and extracted with 
EtOAc. The combined organic layers were washed with brine, dried over 
MgSO4 and concentrated under reduced pressure. Pyridine (10 mL) was 
added to the resulting product and the solution was cooled to 0°C. 
Yamaguchi’s reagent (1.42 g, 5.83 mmol) was then added and the reaction 
was stirred for 1 hour. The mixture was diluted with Et2O, the organic layer 
was washed with 1M NaOH, dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude mixture was purified by silica gel column 
chromatography (PE/EtOAc 9:1) to afford the desired compound as an 
orange oil; yield: 0.52 g (46 %). 
 6-(((tert-butyldimethylsilyl)oxy)methyl)-5,6-dihydro-2H-pyran-2-
one 6.027 
Cfr IV.3.1.2 for analyses. 
IV.3.3. Deprotection 
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To a solution of 6-(((tert-butyldimethylsilyl)oxy)methyl)-5,6-dihydro-2H-
pyran-2-one (0.11 g, 0.46 mmol) in THF (2 mL) was added TBAF.3H2O 
(0.29 g, 0.92 mmol). The mixture was stirred overnight and quenched by 
adding saturated NaHCO3. The mixture was extracted with EtOAc and the 
combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure. The crude mixture was purified by 
silica gel column chromatography (PE/EtOAc 9:1) to afford the desired 
product as a colorless oil; yield: 0.02 g (39 %). 
 6-(hydroxymethyl)5,6-dihydro-2H-pyran-2-one 6.02819 
 
CAS number : [124918-95-2] 
1H NMR (300MHz, CDCl3): δ 1.81 (bs, 1H, -OH), 2.32 (dddd, 1H, H4,  
J=18.5 Hz, J=6.2 Hz, J=4.0 Hz, J=0.9 Hz), 2.63 (ddt, 1H, H4, J=18.4 Hz, 
J=12.5 Hz, J=2.7 Hz), 3.76 (dd, 1H, H6, J=12.4 Hz, J=4.9 Hz), 3.91 (dd, 1H, 
H6, J=12.4 Hz,  J=3.2 Hz),  4.53-4.61 (m, 1H, H5), 6.05 (ddd, 1H, H2, J=9.8 
Hz,  J=2.8 Hz, J=0.9 Hz), 6.95 (ddd,  1H, H3, J=9.7 Hz, J=6.2 Hz, J=2.3 Hz). 
13C NMR (75MHz, CDCl3): δ 25.4 (C4), 64.1 (C6), 78.4 (C5), 121.2 (C2), 
145.4 (C3), 163.8 (C1). 
IV.4. Synthesis of lactone 6.038 
IV.4.1. Via Grubbs metathesis 
IV.4.1.1. Synthesis of 6.037 
                                                     
19 K.S. Kumar,  C. S. Reddy, Org. Biomol. Chem. 2012, 10, 2647.  
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To a solution of 1-((tert-butyldimethylsilyl)oxy)pent-4-en-2-yl methacrylate 
(0.515 g, 1.81 mmol) in DCM (60 mL) was added Grubb’s II catalyst (0.031 
g, 0.04 mmol) under  reflux. The mixture was stirred for 1 hour. Then, a 
second amount (2 mol %) of Grubbs II catalyst was added. The reaction was 
stirred overnight before adding another 2 mol % of catalyst. The mixture was 
stirred for 6 more hours. Finally, a last addition of 2 mol% of Grubb’s 
catalyst was done and the mixture stirred for another hour. The solution was 
concentrated under reduced pressure and the crude mixture was purified by 
silica gel column chromatography (PE/EtOAc 95:5) to afford the desired 
compound as a brown oil; yield: 0.155 g (33 %). 
 6-(((tert-butyldimethylsilyl)oxy)methyl)-3-methyl-5,6-dihydro-2H-
pyran-2-one 6.037 
 
1H NMR (300MHz, CDCl3): δ 0.09 (s, 6H, HTBS), 0.90 (s, 9H, HTBS), 1.93 (s, 
3H, H3), 2.42 (m, 2H, H5), 3.80 (m, 2H, H7), 4.42 (ddt, 1H, H6, J=11.0 Hz, 
J=5.7 Hz, J=4.5 Hz),  6.60 (dd, 1H, H4, J=5.9 Hz, J=2.8 Hz). 
13C NMR (75MHz, CDCl3): δ -5.2 (CTBS), 17.3 (C3), 18.4 (CTBS), 26.0 
(CTBS), 64.4 (C7), 78.0 (C6), 128.3 (C2), 139.0 (C4), 165.6 (C1). 
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IV.4.1.2. Synthesis of 6.038 
 
To a solution of 6-(((tert-butyldimethylsilyl)oxy)methyl)-3-methyl-5,6-
dihydro-2H-pyran-2-one (0.15 g, 0.59 mmol) in THF (2 mL) was added 
TBAF.3H2O (0.369 g, 1.17 mmol). The mixture was stirred overnight, 
quenched with saturated NaHCO3 and extracted with EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude mixture was purified by 
silica gel column chromatography (PE/EtOAc 9:1) to afford the desired 
compound as a colorless oil; yield: 0.036 g (49 %). 
 6-(((tert-butyldimethylsilyl)oxy)methyl)-3-methyl-5,6-dihydro-2H-
pyran-2-one 6.038 
 
1H NMR (300MHz, CDCl3): δ 1.90 (s, 3H, H3), 2.26 (m, 1H, H5), 2.54 (ddd, 
1H, H5, J=18.1 Hz, J=12.6 Hz, J=2.6 Hz), 2.70 (bs, 1H, -OH), 3.71 (dd, 1H, 
H7,  J=12.3 Hz, J=5.0 Hz), 3.82 (dd, 1H, H7, J=12.3 Hz, J=3.3 Hz), 4.45 (dq, 
1H, H6, J=12.4 Hz, J=4.3 Hz), 6.60 (m, 1H, H4). 
13C NMR (75MHz, CDCl3): δ 17.1 (C3), 25.7 (C5), 64.0 (C7), 78.6 (C6), 
128.1 (C2), 139.3 (C4), 165.7 (C1). 
MS (ESI) m/z (%): 143.07 (33) [M+H]+, 165.05 (100) [M+Na]+  
HRMS m/z: calculated for C7H11O3: 143.07027. Found: 143.07027. 
IR (film, cm-1): 731, 1230, 1375, 1452, 1654, 1708, 2854, 2926, 3400. 
